



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continued Prosecution Application

Under 37 C.F.R. § 1.53(d) Based On:

Application of: LeCluyse, Edward L., et al.

Group Art Unit: 1651

Serial No.: 09/527,352

Examiner: Afremova, V.

Filed: March 17, 2000

Docket No.: 421/17/2

For: METHOD OF SCREENING CANDIDATE COMPOUNDS FOR
SUSCEPTIBILITY TO BILIARY EXCRETION

DECLARATION OF XINGRONG LIU PURSUANT TO 37 C.F.R. §1.132

Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. I, Xingrong Liu, am a co-inventor of the invention disclosed and claimed in the subject above captioned U.S. Patent Application Serial No. 09/527,352 and the sole author of the dissertation entitled, "Sandwich-Cultured Rat Hepatocytes: A Novel In Vitro Model To Study Hepatobiliary Disposition Of Substrates", filed with the U.S. Patent and Trademark Office in a supplemental filing dated May 28, 2003 and marked therein as "Exhibit B" (hereinafter the "Dissertation").


2. The Dissertation was written and submitted by me to the University of North Carolina at Chapel Hill in partial fulfillment of criteria for my Ph.D. degree. As such, I am listed as the sole author of the Dissertation.

3. My co-inventors on the present U.S. Patent Application Serial No. 09/527,352, Drs. Kim Brouwer and Edward LeCluyse, provided input, support and guidance to the underlying research set forth in the Dissertation, and also provided editorial assistance in drafting and organizing the Dissertation. However, given that the Dissertation was prepared in partial fulfillment of criteria for my Ph.D. degree, Drs. Brouwer and LeCluyse were not identified as co-authors of the Dissertation.


4. Co-inventors, Liu, Brouwer, and LeCluyse, are the sole co-inventors of the subject matter disclosed in the Dissertation and which is also part of the subject matter disclosed in the subject U.S. Patent Application Serial No. 09/527,352.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Xingrong Liu, Ph.D.



Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continued Prosecution Application

Under 37 C.F.R. § 1.53(d) Based On:

Application of: LeCluyse, Edward L., et al.

Group Art Unit: 1651

Serial No.: 09/527,352

Examiner: Afremova, V.

Filed: March 17, 2000

Docket No.: 421/17/2

For: METHOD OF SCREENING CANDIDATE COMPOUNDS FOR
SUSCEPTIBILITY TO BILIARY EXCRETION

DECLARATION OF RONALD T. BORCHARDT, PH.D.
PURSUANT TO 37 C.F.R. §§1.132

Commissioner of Patents
Washington, D.C. 20231

Sir:

1. My name is Ronald T. Borchardt, Ph.D., and I am currently Solon E. Summerfield Distinguished Professor in the Department of Pharmaceutical Chemistry at the University of Kansas. I am also on the Scientific Advisory Board and Board of Directors of Qualyst, Inc.

2. A true and accurate copy of my *curriculum vitae*, which evidences my expertise and credentials, is attached herewith and labeled **Exhibit A**.

3. I have had an opportunity to review pending claims 105-118 in the subject above captioned U.S. Patent Application Serial No. 09/527,352.

4. I have also reviewed the following documents: the Official Action issued January 2, 2004 on the above captioned U.S. Patent Application Serial No. 09/527,352 by the U.S. Patent and Trademark Office; and Liu et al. (1997) Pharm. Res. 24:S-459 (hereinafter referred to as Liu et al. [EE]) cited in the Official Action.

5. Liu et al. [EE] describes calculating a biliary excretion index based on the difference in retention of substrate in standard buffer compared to calcium-free buffer at 10 minutes in Day 5 sandwich-cultured hepatocytes.
6. A biliary clearance value, as described in the present U.S. patent application, is calculated from fundamentally different data than those required for calculating the biliary excretion index. In order to collect these data, a different experimental design is required. The biliary excretion index is calculated from the difference in substrate accumulation between standard and calcium-free buffer. This difference (i.e., the mass of substrate that appears in the bile) comprises the numerator in both the biliary excretion index and the biliary clearance value calculation. However, the denominator differs for these two parameters. For the biliary excretion index, the denominator is simply substrate uptake in standard buffer. In contrast, for determination of a biliary clearance value, the area under the curve (AUC), wherein the AUC represents the integral of xenobiotic concentration in the medium from time 0 to time T, serves as the denominator in the biliary clearance calculation.
7. There is no disclosure in the Liu et al. [EE] abstract of any experimental design in which the calculation of AUC could be accomplished. Without this requisite information, biliary clearance cannot be calculated.
8. The biliary excretion index only reflects the fraction of the substrate accumulated in the hepatocyte that ultimately is excreted into bile. In essence, this parameter indicates the disposition of a compound only after it has been taken up into the cell. In contrast, the biliary clearance value determines the rate at which a compound will move from outside the cell into bile, without respect to which step (net uptake by the cell or movement from the cell interior into bile) might be the rate-limiting process. The distinction between the utility of the biliary excretion index and the biliary clearance value is important. A compound may have a high biliary excretion index even if biliary excretion is not an important route of elimination from the body. For some compounds, net uptake by the hepatocyte may be low (due to low uptake or significant efflux from the cell into the media), so that the liver does not contribute significantly to overall removal of the compound from the body. However, excretion of the compound from the cell into bile may be efficient. In this case, the

biliary excretion index would be high, even though biliary excretion, from a biologic standpoint, would be unimportant. In contrast, the biliary clearance value would accurately characterize the behavior of the compound: a low degree of uptake into the hepatocyte will yield a low measure of biliary clearance regardless of how efficiently the compound is removed from the cell into bile.


9. Physiological processes, such as clearance values, are additive and typically scale across species. This is not necessarily true for fractional excretion values. Compounds usually are categorized as low, intermediate or high clearance. Total body clearance is the sum of hepatic clearance and clearance by all non-hepatic routes; in turn, hepatic clearance is the sum of metabolic clearance and biliary clearance. Total body clearance is a determinant of compound concentrations in blood that are produced by a given administration regimen for that compound. Hepatic clearance is a further determinant of systemic concentrations for compounds that are administered orally (as are most therapeutic agents) in that hepatic clearance can mediate loss of the compound before it appears in the systemic circulation (so-called "first-pass extraction" by the liver). It is critically important to identify compounds (potential drugs) that have a high hepatic clearance, as these will suffer a high degree of first-pass loss (and therefore may be undesirable as therapeutic agents). Compounds that have a high biliary clearance will have a high hepatic clearance and therefore, a large first-pass extraction; compounds with a high biliary excretion index may or may not have a high hepatic clearance.

10. The utility of the *in vitro* biliary clearance value, but inability of biliary excretion index, to predict *in vivo* biliary clearance is evident in the data submitted in the subject U.S. Patent Application Serial No. 09/527,352. See for example, Figures 6A and 6B. In Figure 6A, the biliary excretion index of methotrexate (open circle) is relatively high. However, the low *in vivo* biliary clearance value of methotrexate, as shown in Figure 6B of the subject U.S. Patent Application Serial No. 09/527,352, indicates that as methotrexate moves through the liver on any single pass, it is not rapidly or extensively excreted into bile. This can be the case if methotrexate is cleared predominantly by another route of elimination *in vivo* (e.g., non-hepatic

routes). Biliary clearance also can be low if methotrexate is not taken up efficiently by the hepatocyte. Thus, the susceptibility of methotrexate to biliary excretion is low, but this would not be predicted by the biliary excretion index. In contrast, the low *in vitro* biliary clearance of methotrexate determined in the sandwich-cultured hepatocytes is predictive of the *in vivo* biliary clearance value.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Ronald T. Borchardt, Ph.D

3/26/04

Date

Attachment: Exhibit A



Curriculum Vita
Ronald T. Borchardt

Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry, The University of Kansas,
Lawrence, KS

Address:Business

Department of Pharmaceutical Chemistry
School of Pharmacy - 2095 Constant Avenue
The University of Kansas
Lawrence, Kansas 66047
(785) 864-3427 or 864-4820 (Telephone)
(785) 864-5736 (FAX)
E-Mail Address: rborchardt@ku.edu

Home

3100 Campfire Drive
Lawrence, Kansas 66049
(785) 842-5075

Personal Information: Born: February 18, 1944

Marital Status: Married

Wife: Pamela K.

Children: Scott R., Paul M., Kelly C.

Education:

<u>Institution and Location</u>	<u>Degree</u>	<u>Conferred</u>	<u>Field</u>	<u>Year</u>	<u>Scientific</u>
School of Pharmacy, University of Wisconsin, Madison, Wisconsin			B.S.	1967	Pharmacy
School of Pharmacy, University of Kansas, Lawrence, Kansas	Ph.D.	1970	Medicinal Chemistry		
NIH, NIAMD, Bethesda, Maryland			Postdoc.	1971	Physical Organic Chemistry

Research and Professional Experience:

1983-present:	Solon E. Summerfield Distinguished Professor, Department of Pharmaceutical Chemistry, The University of Kansas
1983-1998:	Victorian Professor, Victorian College of Pharmacy, Melbourne, Australia
1983-1998:	Chairman, Department of Pharmaceutical Chemistry, The University of Kansas
1981-1999:	Solon E. Summerfield Distinguished Professor, Department of Molecular Biosciences, The University of Kansas
1981-1994:	Solon E. Summerfield Distinguished Professor, Department of Medicinal Chemistry, The University of Kansas
1991-1993:	Acting Dean, School of Pharmacy, The University of Kansas
1981-1988:	Director, The Center for Biomedical Research, The University of Kansas
1979-1981:	Professor, Department of Biochemistry, The University of Kansas
1974-1979:	Established Investigator of the American Heart Association
1975-1979:	Associate Professor, Department of Biochemistry, The University of Kansas
1971-1975:	Assistant Professor, Department of Biochemistry, The University of Kansas
1969-1971:	Senior Assistant Scientist, Laboratory of Chemistry, National Institute of Arthritis and Metabolic Diseases
1967-1969:	NSF Graduate Fellow, Department of Medicinal Chemistry, School of Pharmacy, The University of Kansas

Membership on Scientific and Educational Advisory Committees:

1976-1979: American Heart Association, Kansas Affiliate Research Review Committee, member

1979-1981: American Heart Association, Kansas Affiliate, Research Review Committee, Chairman

1977-1981: American Heart Association, Midwest Regional Research Review Committee, member

1980-1984: Pharmacological Sciences Review Committee, National Institute of General Medical Sciences, member

1986-1988: Cancer Therapeutics Program Project Review Committee, National Cancer Institute, member

1987-1993: Advisory Committee, George Herbert Hitchings Award for Innovative Methods in Drug Design, The Burroughs Wellcome Fund, member

1992-1994: Scientific Advisory Board, Oread Laboratories, Chairman

1996-1999: Scientific and Technical Advisory Board, Oread Inc., Chairman

1996-2001: Scientific Advisory Board, NaviCyte, Inc.

1999-2001: Scientific Advisory Board, Coelacanth Corporation

1996-2002: Scientific Advisory Board, AvMax Corporation

2000-2003: Research Committee, American Heart Association, Heart Land Affiliate

1987-present: Advisory Committee, International Sato Memorial Award-The Foundation for Advanced Education in the Sciences, Inc., Chairman

1996-present: Scientific Advisory Board, West Pharmaceutical Services

1996-present: Board of Directors, Globalization of Pharmaceuticals Education Network

1996-present: Executive Committee, Globalization of Pharmaceuticals Education Network

1997-present: Scientific Advisory Board, Arizeke Pharmaceuticals, Inc.

1997-present: Scientific Advisory Board, ProQuest Pharmaceuticals, Inc.

1999-present: Scientific Advisory Board, Guilford Pharmaceuticals, Inc.

2000-present: Scientific Advisory Board, Diazyme Laboratories

2000-present: Drug Development Advisory Board, Scios, Inc.

2000-present: Scientific Advisory Board, Pointilliste, Inc.

2001-present: Scientific Advisory Board, Ricerca, LLC

2001-present: Scientific Advisory Board, Lexicon Pharmaceuticals, Inc.

2001-present: Scientific Advisory Board, Argolyn Bioscience, Inc.

2002-present: Scientific Advisory Board, Roche Palo Alto

2002-present: Scientific Advisory Board, Eiffel Technologies

2003-present: Scientific Advisory Board, Absorption Systems

2003-present: Scientific Advisory Board, Enzon Corporation

2003-present: Pharmaceutical R&D Advisory Board, Abbott Laboratories

2003-present: Board of Directors and Scientific Advisory Board, Qualyst, Inc.

Membership in Professional Organizations (Present):

American Chemical Society, Medicinal Chemistry Section
American Society for Pharmacology and Experimental Therapeutics
American Society for Biochemistry and Molecular Biology
American Association for the Advancement of Science
American Association of Pharmaceutical Scientists
American Society for Cell Biology
The Protein Society
International Society for Antiviral Research
American Peptide Society
American Pharmaceutical Association
American Association of Colleges of Pharmacy
European Federation for Pharmaceutical Sciences

Editorships

Series Editor, Pharmaceutical Biotechnology (Kluwer/Plenum), 1989-2001
Associate Editor, Journal of Pharmaceutical Sciences, 1996-2001
Associate Editor, Journal of Peptide Research, 1998-2001
Editor (Biotechnology), AAPSPHarmSci, 1999-2001
Series Editor, Biotechnology: Pharmaceutical Aspects (AAPSPress), 2001-present
Editor, Journal of Pharmaceutical Sciences, 2001-present

Editorial Boards:

Journal of Medicinal Chemistry - 1988-1993
Antiviral Research - 1988-2000
AAPSPHarmSci - 1999-2001
Journal of Peptide Research - 1997-2001
European Journal of Pharmaceutical Sciences - 1998-2003
Pharmaceutical Research - 1986-present
Journal of Drug Targeting - 1992-present
Advanced Drug Delivery Reviews - 1992-present
Perspective in Drug Discovery and Design - 1992-present
Journal of Pharmaceutical Sciences - 1994-present
Molecular Interventions - 2000-present

Editorial Activities (Present):

Ad Hoc Reviewer for the Journal of Medicinal Chemistry, Journal of Organic Chemistry, Biochemistry, Molecular Pharmacology, Biochemical Pharmacology, Journal of Biological Chemistry, Biochimica et Biophysica Acta, Journal of the American Chemical Society, Analytical Biochemistry, Life Sciences, Science, Journal of Pharmacology and Experimental Therapeutics, Journal of Bacteriology, Archives of Biochemistry and Biophysics, Proceedings of the National Academy of Science, Journal Neurochemistry, International Journal of Pharmaceutics, Journal of Pharmaceutical Sciences, Nucleosides and Nucleotides, Pharmaceutical Research, Cancer Research, Bioorganic and Medicinal Chemistry Letters, AAPSPHarmSci

Committee Activities (Present):

1. University or Departmental
 - (a) Biochemical Service Research Laboratory - Steering Committee - University
 - (b) NCI Bioanalytical Training Grant Steering Committee - University
 - (c) NIGMS Biotechnology Grant Steering Committee, Chairman - University
2. Outside Research and Public Service
 - (a) Ad Hoc Reviewer for National Science Foundation and National Institutes of Health

Consultantships:

INTERx Corporation, Lawrence, KS, 1971-1981
Merck, Sharp & Dohme, Rahway, NJ, 1981-1986
Glaxo, Inc., Research Triangle Park, NC, 1986-1995
Oread Laboratories, Lawrence, KS, 1992-1994
Wyeth-Ayerst Pharmaceuticals, 1994
Whitehall-Robins Pharmaceuticals, 1995
Affymax Corporation, Palo Alto, CA, 1995-1998
Tanabe Research Laboratories, San Diego, CA, 1997-1999
Oread Inc., Lawrence, KS, 1996-1999 (Chairman of the Scientific and Technical Advisory Board)
Rhone-Poulenc Rorer, Collegeville, PA, 1993-1999
Hoechst Marion Roussel, Kansas City, MO, 1994-1999
Alza Corporation, Palo Alto, CA, 1993-1999
Astra-Zeneca Pharmaceuticals, Inc., Wilmington, DE, 1995-2001
NaviCyte, Inc., San Diego, CA, 1996-2001 (Member of the Scientific Advisory Board)
Biogen Corporation, Cambridge, MA, 1997-2001
COR Therapeutics, Inc., South San Francisco, CA, 2000-2002
Wyeth-Ayerst Research, Cambridge, MA, 2000-2002
Vertex Pharmaceuticals, Inc., Cambridge, MA, 1997-2002
AvMax, Inc., Belvedere, CA, 1995-2002 (Member of the Scientific Advisory Board)
ARIAD Pharmaceuticals, Cambridge, MA, 1998-2002
Inhale Therapeutic Systems, San Carlos, CA, 2001-2002
Pharmacia, Inc., Kalamazoo, MI, Skokie, IL, and Chesterfield, MO, 1983-2003
GlaxoSmithKline Pharmaceuticals, Upper Merion, PA, 1993-present
Genentech Corporation, South San Francisco, CA, 1993-present
West Pharmaceutical Services, Lionville, PA, 1996-present (Consultant and Member of the Scientific Advisory Board)
Arizeke Pharmaceuticals, Inc., Del Mar, CA, 1997-present (Consultant and Member of Scientific Advisory Board)
ProQuest Pharmaceuticals, Inc., Lawrence, KS, 1997-present (Founder, Consultant and Member of Scientific Advisory Board)
Hoffmann-LaRoche, Inc., Nutley, NJ, 1998-present
Millennium Pharmaceuticals, Inc., Cambridge, MA, 1998-present
Guilford Pharmaceuticals, Inc., Baltimore, MD, 1999-present (Consultant and Member of the Scientific Advisory Board)
Serono Reproductive Biology Institute, Inc., Randolph, MA and Geneva, Switzerland, 1999-present
Aventis Corp., Bridgewater, NJ and Frankfurt, Germany, 1999-present
Diazyme Laboratories, San Diego, CA, 2000-present (Consultant and Member of Scientific Advisory Board)
Pointilliste, Inc., Mountain View, CA, 2000-present (Consultant and Member of Scientific Advisory Board)
Ricerca, LLC, Painesville, OH, 2001-present (Consultant and Member of Scientific Advisory Board)
Lexicon Pharmaceuticals, Inc., East Windsor, NJ, 2001-present (Consultant and Member of Scientific Advisory Board)
Roche-Palo Alto, Palo Alto, CA, 2001-present (Consultant and Member of Scientific Advisory Board)
Sepracor, Inc., Marlborough, MA, 2001-present
Argolyn Bioscience, Inc., Charleston, SC, 2001-present (Consultant and Member of Scientific Advisory Board)
3D Pharmaceuticals, Exton, PA, 2002-present
Synaptic Corporation, Parnas, NJ, 2002-present
Metaphore Pharmaceuticals, Inc., St. Louis, MO, 2002-present
Eiffel Technologies, Melbourne, Australia (Consultant and Member of Scientific Advisory Board), 2002-present
Infinity Pharmaceuticals, Inc., Cambridge, MA, 2002-present
AstraZeneca, Waltham, MA, 2003-present
Concurrent Pharmaceuticals, Fort Washington, PA, 2003-present
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, 2003-present
Genomics Institute of the Novartis Research Foundation, San Diego, CA, 2003-present
Artesian Therapeutics, Gaithersburg, MD, 2003-present
Rib-X Pharmaceuticals, New Haven, CT, 2003-present
Abbott Laboratories, Abbott Park, IL (Consultant and member of the Pharmaceutical R&D Advisory Board), 2003-present
Enzon Corporation, Bridgewater, NJ (Member of Scientific Advisory Board), 2003-present
Qualyst, Inc., Raleigh, NC (Consultant and Member of Scientific Advisory Board), 2003-present
Absorption Systems, Exton, PA (Consultant and Member of Scientific Advisory Board), 2003-present
Neurocrine Biosciences, Inc., San Diego, CA (), 2003-present

Honors:

- Established Investigator of the American Heart Association, 1974-1979
- Elected to Membership in the American Society of Pharmacology and Experimental Therapeutics, 1974
- Elected to Membership in the American Society of Biochemistry and Molecular Biology, 1977
- Mortar Board Outstanding Educator, The University of Kansas, 1980
- E. C. Franklin Lecturer - University of Kansas, 1980
- Mid-America State Universities Association (MASUA) Honor Lecturer, 1980-1981
- Sato Memorial International Award - Pharmaceutical Society of Japan and the Foundation for Advanced Education in the Sciences, 1981
- Named Solon E. Summerfield Distinguished Professor of Biochemistry - University of Kansas, 1981
- Dolph C. Simons, Sr. Research Award in the Biomedical Sciences - University of Kansas, 1983
- Elected to Membership in the American Society for Cell Biology, 1985
- J. Clarence Karcher Lecturer, University of Oklahoma, 1988
- Parke-Davis Distinguished Lecturer, Rutgers University, 1988
- Fellow, American Association of Pharmaceutical Scientists, 1988
- Minnetonka Lecturer, University of Minnesota, 1989
- Citation of Merit, University of Wisconsin-Madison, 1989
- Percy L. Julian - Sigma Xi Lecturer, Howard University, 1991
- Meritorious Manuscript Award, American Association of Pharmaceutical Scientists, 1991
- Watkins Visiting Professorship in the Life Sciences, Wichita State University, 1992
- Kenneth E. Avis Distinguished Visiting Professor, The University of Tennessee-Memphis, 1993
- Takeru and Aya Higuchi Memorial Award, Academy of Pharmaceutical Sciences and Technology, Japan, 1993
- Research Achievement Award in Biotechnology, American Association of Pharmaceutical Scientists, 1993
- 14th Annual Graduate Student Symposium for the Pharmacological Sciences Keynote Speaker, University of Michigan, 1994
- Distinguished Lecturer, University of Kentucky, 1994
- Research Achievement Award in Medicinal Chemistry and Natural Products Chemistry, American Association of Pharmaceutical Scientists, 1994
- Fellow, American Association for the Advancement of Science, 1995
- David Guttman Lecturer, University of Kentucky, 1997
- Paul Dawson Biotechnology Award, American Association of Colleges of Pharmacy, 1997
- Louis Byrd Graduate Educator Award, The University of Kansas, 1997
- Distinguished Pharmaceutical Scientist Award, American Association of Pharmaceutical Scientists, 1997
- Wellcome Visiting Professor in the Basic Medical Sciences, Washington State University, 1998
- Volwiler Research Achievement Award, American Association of Colleges of Pharmacy, 1998
- Meritorious Manuscript Award, American Association of Pharmaceutical Scientists, 1998
- Host-Madsen Medal, Federation Internationale Pharmaceutique, 1999
- Distinguished Service Award – FASEB Research Conference on Biological Methylation, 1999
- Millennial Pharmaceutical Scientist Award, The Millennial World Congress of Pharmaceutical Sciences, April, 2000
- Leiden/Amsterdam Center for Drug Research – Distinguished Lecturer, November, 2000
- President, American Association for Pharmaceutical Scientists, 2001
- Research Achievement Award in the Pharmaceutical Sciences, American Pharmaceutical Association, 2001
- University of Southern California, School of Pharmacy, Distinguished Lecturer, 2001
- Medieval Distinguished Lecturer in the Pharmaceutical Sciences, 2001
- Honorary Doctorate Degree – Royal Danish School of Pharmacy, 2002
- Takeru Higuchi Research Prize, American Pharmaceutical Association, 2003
- Smitsman-Bristol-Myers Squibb Award, American Chemical Society, Division of Medicinal Chemistry, 2003
- University of Pittsburgh, School of Pharmacy, Distinguished Lecturer, 2003
- Doctor Honoris Causa (Honorary Doctorate Degree) – Catholic University of Leuven, 2004
- Bristol-Myers Squibb Distinguished Lecturer – University of Buffalo, State University of New York, 2004

**Predoctoral and Postdoctoral Students and Visiting Scientists
Trained by Ronald T. Borchardt**

Trainee	Predoc/ Postdoc	Period	Present Employment
Pharmaceutical Chemistry Department			
Aikawa, K.	Visiting Sci.	1991-92	Scientist, Taisho Pharmaceutical Co.
Akimoto, Katsuya	Visiting Sci.	1996-97	Scientist, Daiichi Pharmaceuticals
Ali, Mashood	Postdoc	1989-91	Assist. Prof., Aligarh Univ., India
Amsberry, Kent	Predoc	1984-89	Sr. Scientist, Quintile's, Inc.
Andersen, Rikke	Visiting Sci.	2001	Student, Royal Danish School of Pharmacy
Audus, Ken	Postdoc	1984-86	Professor & Chair, Univ. of Kansas
Augustijns, Patrick	Visiting Sci.	1992-93	Professor, Univ. of Leuven, Belgium
Bak, Annette	Visiting Sci.	1996-97, 1998-99	Scientist, Amgen Corp.
Bartel, Ronnda	Postdoc	1986-89	Sr. Director, SRS Capital Research Assoc., Covance
Beck-Westermeyer, Melissa	Predoc	1996-00	Student, Royal Danish School of Pharmacy
Berglund, Petter	Visiting Sci.	1998	Sr. Scientist, Aventis
Borcharding, D.	Postdoc	1986-88	Sr. Scientist, GlaxoSmithKline, England
Brazell, Celia	Postdoc	1984-86	Present student
Bross, Becky	Predoc	2003-	Administrator, FDA
Brunt, Elsbeth	Predoc	1991-94	Sr. Scientist, Novartis, Switzerland
Camenisch, Gian	Postdoc	1997-98	Director, Alcon Labs
Chastain, Jim	Postdoc	1986-88	Scientist, Pharmacopeia
Chen, Wei Qing	Postdoc	1999-02	Assist. Prof., Univ. of Maryland
Chikhale, P.	Postdoc	1991-94	Scientist, Jansen Pharm. Co., Belgium
Cools, Marina	Visiting Sci.	1988	Student, Royal Danish School of Pharmacy
Eriksson, Andre	Visiting Sci.	2000	Sr. Lecturer, University of Kelaniya, Sri Lanka
Fernando, A.	Postdoc	1991-92	Scientist, Leo Pharmaceuticals, Denmark
Friedrichson, Gerda	Visiting Sci.	1999-00	Present student
Fuchs, Tarra	Postdoc	2003-	Assoc. Res. Head, Takeda Pharm. Corp., Japan
Fukuta, M.	Visiting Sci.	1990	Sr. Scientist, Corixa Pharmaceuticals
Gangwar, S.	Postdoc	1992-96	Scientist, Bristol-Myers Squibb
Gao, Jinnian	Predoc	1995-00	Sr. Scientist, Abbott Laboratories
Garren, Julie	Predoc	1983-88	Research Associate, Univ. of Kansas
Ghezze, Elena	Visiting Sci.	1991	Asst. Director, Indian Inst. of Chemical Biol., India
Ghosh, Anil	Postdoc	1983-86	Scientist, Regeneron Inc.
Goolcharan, Charlie	Predoc	1994-99	Sr. Scientist, Johnson & Johnson Pharm. Co.
Gray, Ronda	Predoc	1988-92	Assoc. Prof., Univ. of South Dakota
Guan, Xiangming	Postdoc	1991-92	Scientist, Bristol-Myers Squibb
Gudmundsson, Olafur	Predoc	1994-98	Assoc. Prof., Tokyo Univ., Japan
Hasobe, Masa.	Postdoc	1986-89	Present student
Head, Kevin	Predoc	2001-	Scientific Director, Absorption Systems
Hidalgo, Ismael	Postdoc	1986-90	Scientist, Eli Lilly
Hillgren, Kathy	Predoc	1988-94	Scientist, Shionogi & Co., Japan
Hori, Kazutoshi	Visiting Sci.	2000-01	Assoc. Prof., Washington State Univ.
Hu, Ming	Postdoc	1988-90	Scientist, Wyeth Laboratories
Hu, Yongbo	Postdoc	1999-02	Director, Abrika Pharmaceuticals
Huang, He	Postdoc	1995-96	Scientist, GlaxoSmithKline
Hugger, Erin	Predoc	1997-01	Postdoctoral Fellow
Hui, Ouyang	Postdoc	1999-01, 2002-	Sr. Scientist, Merck, Sharp and Dohme
Huskey, S.-E.	Postdoc	1983-85	Professor, Kumamoto University
Imai, Teruko	Visiting Sci.	1998	Director, Pharmacia, Inc., Japan
Ishii, Hiroaki	Visiting Sci.	1987-88	Sr. Res. Invest., Bristol-Myers Squibb
Kakarla, Ramesh	Postdoc	1988-91	Sr. Scientist, Orion Pharma, Finland
Kanerva, Harri	Visiting Sci.	1995	Sr. Scientist, Eisai Co., Japan
Kato, Akira	Visiting Sci.	1988, 1992-93	Scientist, Dojin Iyaku Kako Co., Japan
Kawamura, Y.	Visiting Sci.	1992-94	Assoc. Prof., Josai Univ., Japan
Kawase, M.	Postdoc	1985-87	Sr. Res. Scientist, Pfizer
Keller, Brad	Postdoc	1983-85	Scientist, Centecor
Khossravi, Mehnaz	Predoc	1994-99	Assoc. Professor, Chungnam Natl. Univ., Korea
Kim, Dong Chool	Postdoc	1991-93	Research Associate, Akorn, Inc.
Kolli, Sudha	M.S.	1993-94	Assist. Professor, Rutgers University
Knipp, Greg	Predoc	1992-97	Consultant
Kupczyk-Subotkowska, Lidia	Postdoc	1996-98	Scientist, Bristol-Myers Squibb
Lai, Mei	Predoc	1993-98	
Li, Bei	Predoc	1999-2004	Scientist, Eli Lilly & Co.
Li, Qing-Shen	Postdoc	2003-	Present student

Li, Rong	Predoc	1997-01	Scientist, Pharmacia
Li, Shihong	Predoc	1991-95	Sr. Scientist, Pfizer
Liederer, Bianca	Predoc	2000-	Present student
Liu, Siming	Postdoc	1991-94	Postdoctoral Fellow, North Carolina State Univ.
Matuszewska, B.	Postdoc	1981-85	Sr. Res. Fellow, Merck, Sharp and Dohme
Miller, Donald	Postdoc	1991-93	Assoc. Professor, Univ. of Nebraska
Murase, Osamu	Visiting Sci.	1999	Scientist, Organon Pharmaceuticals, Japan
Nakagami, Hiroaki	Visiting Sci.	1992	Sr. Scientist, Daiichi Pharm. Co., Japan
Narayanan, Su.	Postdoc	1986-88	Sr. Scientist, Aventis
Nerurkar, Manoj	Predoc	1992-96	Sr. Scientist, Bristol-Myers Squibb
Ng, Lawrence	Postdoc	1991-94	Assist. Prof., University of Colorado
Nicolaou, Mike	Predoc	1990-96	Assoc. Director, Epimune
Nielsen, Lisbeth	Visiting Sci.	2001	Scientist, Lundbeck Pharmaceuticals, Denmark
Nigam, S. C.	Postdoc	1988-91	Scientist, ISP Fine Chemicals
Nimkar, Kalpana	Postdoc	1996-97	Consultant
Nonomura, M.	Postdoc	1990-91	Assoc. Res. Head, Takeda Pharm. Corp., Japan
Okumu, Franklin	Predoc	1992-96	Scientist, Optimer Pharmaceuticals
Oliyai, Cecilia	Predoc	1988-93	Sr. Scientist, Corixa Pharmaceuticals
Ostergaard, Jesper	Visiting Sci.	1999	Graduate Student, Royal Danish School of Pharm.
Owens, Heather	M.S.	2000-02	Pharmacy Residency
Paisley, Steven	Postdoc	1986-88	Principal Investigator, Pharmacia
Patel, Kamlesh	Predoc	1985-89	Sr. Scientist, GlaxoSmithKline
Pauletti, Giovanni	Postdoc	1993-97	Asst. Professor, Univ. of Cincinnati
Pryor, Celestia	Postdoc	1987-90	Assoc. Prof., Univ. of the Pacific
Raeissi, Shamsi	MS	1988-92	Scientist, Pfizer
Ranta, Veli Pekka	Visiting Sci.	1997-98	Graduate Student, Univ. of Kuopio, Finland
Salfer, Dorothee	Visiting Sci.	1999	Student, Marburg Univ., Germany
Schoneich, C.	Postdoc	1991-92	Assoc. Professor, Univ. of Kansas
Scriba, Gerhard	Postdoc	1985-88	Professor, University of Jena, GDR
Shah, Mandar	Predoc	1985-91	Sr. Scientist, Alcon Labs
Shah, Praful	Predoc	1985-90	Director, NaPro
Simmons, J.	Postdoc	1983-85	Administrator, FDA
Sinhababu, A.	Postdoc	1980-88	Director, Genentech
Smith, Kevin	Postdoc	1986-89	Manager, Cephalon Corp.
Sonderkaer, Susanne	Visiting Sci.	1999	Graduate Student, Royal Danish School of Pharm.
Song, Yuan	Postdoc	1998-2001	Scientist, Inhale Corp.
Sorensen, Mette	Visiting Sci.	1996	Graduate Student, Royal Danish School of Pharmacy
Steenberg, Betina	Visiting Sci.	1996	Graduate Student, Royal Danish School of Pharmacy
Stevenson, C.	Predoc	1988-92	Sr. Scientist, Inhale Corp.
Sudoh, Masao	Visiting Sci.	1995-96	Scientist, Ono Pharm. Co., Japan
Takakura, Yoshi	Visiting Sci.	1989-90	Professor, Kyoto Univ., Japan
Tamura, Kiyoshi	Visiting Sci.	1994-96	Sr. Scientist, Banyu Pharmaceuticals
Tang, Fuxing	Postdoc	2000-02	Scientist, Forest Laboratory
Thombre-Patel, U.	Postdoc	1982-84	Consultant
Toddywalla, V.S.	Visiting Sci.	1988-89	Sr. Scientist, Inst. Res. Reproduction, India
Trammel, Andy	Predoc	1985-90	Sr. Scientist, Quintile's Inc.
Turner, Greg	Postdoc	1987-88	Group Leader, Midwest Research Institute
vanBree, Joost	Visiting Sci.	1988	Sr. Scientist, Novartis, Switzerland
Votruba, I.	Visiting Sci.	1987-88	Sr. Scientist, Czech. Academy of Science
Wakankar, Aditya	Predoc	2001-	Present student
Wang, Binghe	Postdoc	1992-93	Professor, Georgia State Univ.
Wang, Wen	Postdoc	1993-97	Physician
Wilson, Ashley	Predoc	1994-00	Scientist, Eli Lilly
Wolfe, Janet	Predoc	1985-92	Consultant
Xie, Minli	Predoc	1993-97	Sr. Scientist, DuPont Pharmaceuticals
Yang, Jerry	Predoc	1997-2002	Scientist, Pfizer
Yang, Xiaoda	Postdoc	1997-00	Professor, Peking Univ. Med. Ctr., China
Yeh, Jerry	Postdoc	1986-92	Sr. Scientist, Alza Corp.
Yike, Iwona	Postdoc	1983-85	Res. Asst. Prof., Case Western Res. Univ.
Yin, Daniel	Postdoc	1997-01	Scientist, Merck Sharp & Dohme
Yu, Qiang	Postdoc	1999-2002	Scientist, SynChem
Yuan, Chong-Sheng	Postdoc	1991-97	Managing Director, Diazyme Laboratories
Zhang, Jinsong	Postdoc	2001-2003	Res. Asst. Prof., Univ. of Kansas Medical Center

Molecular Sciences Department (formerly Biochemistry Department)

Ault-Riche, Dana	Predoc	1989-94	Founder and CEO, Pointilliste
Baranczyk-Kuzma, A.	Visiting Sci.	1980-81	Prof., Warsaw Medical School, Poland

Bartel, Ronnda	Predoc	1979-84
Bhatia, Pramila	MS	1974-76
Cai, Sumin	Predoc	2004-
Chen, Hu	Predoc	2004-
Chen, Shiang Y.	Postdoc	1979-80
Cheng, Chao Fu	Predoc	1971-75
Elrod, Philip	MS	1998-00
Huber, Joan	Postdoc	1974-84
Huskey, Su-Er W.	Predoc	1975-79
Lee, Younha	Predoc	1988-93
Liang, Nina	Postdoc	1980-83
Liang, Sherrie	MS	1988-92
Olsen, Julie	Postdoc	1976-78
Patel-Thombre, U.	Predoc	1978-82
Pugh, Charles	Predoc	1976-79
Ramakrishnan, V.	Predoc	1981-86
Scharnhorst, D.	Postdoc	1979-80
Schasteen, C.	Predoc	1975-80
Thakker, D.	Predoc	1972-75
Thomas, P.	MS	1979-81
Varia, Smita T.	Predoc	1978-83
Wang, Meng Meng	Predoc	2001-
Wu, Yih Shiong	Predoc	1972-76
Yu, Xiao Hong	Predoc	1993-96

Sr. Director, SRS Capital
Research Associate, Abbott Laboratories
Present student
Present student
Sr. Scientist, Glaxo-Wellcome
Research Associate, Cornell University
Research Associate, Pharmacia, Inc.
Consultant
Sr. Res. Fellow, Merck, Sharp and Dohme
Postdoctoral Fellow, Glaxo-Wellcome
Sr. Scientist, IBM
Research Assistant, Univ. of Calgary, Canada
Professor, Wabush College
Consultant
Scientific Writer, Consultant
Sr. Scientist, Core Therapeutics
Physician, Private practice
Director, Novus Corp.
Ferguson Distinguished Prof., Univ. of North Carolina
Professor, Univ. of Kansas
Res. Asst. Professor, Rutgers University
Present student
Retired
Patent Attorney, University of California-San Diego

Medicinal Chemistry Department

Bartlett, Bill	MS	1986-89
Borcherding, D.	Predoc	1981-86
Houston, Mike	Predoc	1978-83
Moorman, Allan	Predoc	1978-83
Sheley, John	MS	1990-94
Wolfe, Mike	Predoc	1984-90

Pharmacist
Sr. Scientist, Aventis
Sr. Scientist, Quintile's
Executive Director, King Pharma
Chemist, Ricerca, Inc.
Assoc. Professor, Harvard University

Current and Pending Support

Ronald T. Borchardt
The University of Kansas, Lawrence, KS

ACTIVE

•GM-29332 (PI, R.T. Borchardt) 02/01/03 to 01/31/07 15% (PI)
NIH \$220,000 (Year 30)
AdoHcy Hydrolase: Inhibitors as Antiparasitic Agents

This grant supports research aimed at elucidating the structure and mechanism of catalysis of S-adenosylhomocysteine hydrolase and designing and synthesizing potential inhibitors of the human and parasitic (*Trypanosoma* and *Leishmania*) forms of this enzyme.

•GM-51633 (PI, R.T. Borchardt) 07/01/99 to 06/30/04 15% (PI)
NIH \$170,576 (Year 8)
Transport Characteristics of Peptide Mimetics

This grant supports research aimed at elucidating how bioisosteres of the peptide bond affect the permeability of peptide mimetics through the intestinal mucosa and the blood-brain barrier and their clearance by the liver.

•DA-09315 (PI, R.T. Borchardt) 07/01/03 to 06/30/08 15% (PI)
NIDA \$175,000 (Year 8)
Cyclic Prodrugs of Opioid Peptide

This grant supports research aimed at preparing cyclic prodrugs of opioid peptides which could improve their permeability through the intestinal mucosa and the blood-brain barrier.

•GM-54195 (PI, E. Topp) 08/01/00 to 07/31/04 15% (Co-Invest)
NIH \$170,000 (Year 5)
Peptide Degradation in Polymer Matrices

This grant supports research aimed at elucidating the pathways by which peptide and protein drugs chemically degrade in polymeric delivery systems.

•GM-08359 (PI, C. R. Middaugh) 07/01/02 to 06/30/07 5% (Preceptor)
NIH \$244,864 (Year 14)
Pharmaceutical Aspects of Biotechnology Training

This grant supports the training of pharmaceutical scientists to handle the development of products arising from biotechnology.

•CA-09242 (PI, J.F. Stobaugh)	04/01/00 to 03/31/05	2.5% (Preceptor)
NIH	\$265,000 (Year 25)	
Clinical Analysis of Anticancer Drugs-Pre and Postdoctoral Training Grant		

This grant supports predoctoral and postdoctoral trainees in the Departments of Pharmaceutical Chemistry and Chemistry in the area of clinical analysis of anticancer drugs.

•GM069663 (PI, J. Aube)	09/15/03-09/14/08	4% (Collaborator)
NIH	\$2,430,741 (Year 1)	
Center of Excellence in Chemical Methodologies and Library Development.		

This P50 grant is focused on the development of innovative combinatorial chemistry.

PENDING

•EB000253 (PI, E. Topp)	08/01/04-07/31/09	10% (Co-PI)
NIH	\$250,000 (Year 6)	
Peptide and Protein Degradation in Amorphous Solids		

This competitive renewal application would support the investigation of the kinetics and mechanisms of peptide and protein degradation in amorphous solids.

Publications:

1. S. M. Kupchan, T. H. Yang, M. L. King and R. T. Borchardt, "Thalictrum Alkaloids, VIII. The Isolation, Structural Elucidation and Synthesis of Dehydrothalcarpine", *J. Org. Chem.*, **33**, 1052-1055 (1968).
2. Ronald T. Borchardt, "A Stereochemical Approach to the Adrenergic System", Ph.D. Thesis, University of Kansas, 1970.
3. E. E. Smismman and R. T. Borchardt, "A Conformational Study of Catecholamine Receptor Sites. V. The Synthesis of dl-3-Amino-2-(3', 4'-dihydroxyphenyl)-trans-decalol Hydrochlorides", *J. Med. Chem.*, **14**, 377-382 (1971).
4. E. E. Smismman and R. T. Borchardt, "A Conformational Study of Catecholamine Receptor Sites. VI. The Synthesis of dl-3-Amino-2-(3', 4'-dihydroxyphenyl)-trans-decalin Hydrochlorides", *J. Med. Chem.*, **14**, 383-387 (1971).
5. E. E. Smismman and R. T. Borchardt, "Conformational Study of Catecholamine Receptor Sites. VII. Syntheses of erythro- and threo-2-Amino-3-(3', 4'-dihydroxyphenyl)-butane Hydrochlorides", *J. Med. Chem.*, **14**, 701-707 (1971).
6. E. E. Smismman, R. T. Borchardt and K. B. Schowen, "Conformational Aspects of Systems Related to Acetylcholine. IV. The Syntheses of the dl-2-Dimethylamino-trans-decalin Methiodides", *J. Med. Chem.*, **15**, 545-548 (1972).
7. R. T. Borchardt and L. A. Cohen, "Stereopopulation Control. II. Rate Enhancement of Intramolecular Nucleophilic Displacement", *J. Amer. Chem. Soc.*, **94**, 9166-9174 (1972).
8. R. T. Borchardt and L. A. Cohen, "Stereopopulation Control. III. Facilitation of Intramolecular Conjugate Addition of the Carboxyl Group", *J. Amer. Chem. Soc.*, **94**, 9175-9182 (1972).
9. R. T. Borchardt, "Catechol-O-Methyltransferase. I. Kinetics of Tropolone Inhibition", *J. Med. Chem.*, **16**, 377-382 (1973).
10. R. T. Borchardt, "Catechol-O-Methyltransferase. II. In Vitro Inhibition by Substituted 8-Hydroxyquinolines", *J. Med. Chem.*, **16**, 382-387 (1973).
11. R. T. Borchardt, "Catechol-O-Methyltransferase. III. Mechanism of Pyridoxal 5'-Phosphate Inhibition", *J. Med. Chem.*, **16**, 387-391 (1973).
12. R. T. Borchardt, "Catechol-O-Methyltransferase. IV. In Vitro Inhibition by 3-Hydroxy-4-Pyridones and 3-Hydroxy-2-Pyridones", *J. Med. Chem.*, **16**, 581-583 (1973).
13. R. T. Borchardt and D. Thakker, "Affinity Labeling of Catechol-O-Methyltransferase", *Biochem. Biophys. Res. Commun.*, **54**, 1233-1239 (1973).
14. R. T. Borchardt and L. A. Cohen, "Stereopopulation Control. IV. Facilitation of Intramolecular Conjugate Addition of Solvated Hydroxyl Groups", *J. Amer. Chem. Soc.*, **95**, 8303-8313 (1973).
15. R. T. Borchardt and L. A. Cohen, "Stereopopulation Control. V. Facilitation of Intramolecular Conjugate Addition of an Aldehyde Hydrate and Hemiacetal", *J. Amer. Chem. Soc.*, **95**, 8313-8319 (1973).
16. R. T. Borchardt and L. A. Cohen, "Stereopopulation Control. VI. Conformational Selection of Alternative Oxidative Pathways", *J. Amer. Chem. Soc.*, **95**, 8319-8326 (1973).
17. C. R. Creveling, R. T. Borchardt, and C. Isersky, "Immunological Characterization of Catechol-O-Methyltransferase", in Frontiers in Catecholamine Research (E. Usdin and S. H. Snyder, Eds.), Pergamon Press, New York, p. 117-119 (1973).
18. R. T. Borchardt, "A Rapid Spectrophotometric Assay for Liver Catechol-O-Methyltransferase", *Anal. Biochem.*, **58**, 382-389 (1974).
19. R. T. Borchardt, C. F. Cheng, P. H. Cooke and C. R. Creveling, "Purification and Properties of Microsomal Catechol-O-Methyltransferase", *Life Sciences*, **14**, 1089-1100 (1974).
20. R. T. Borchardt and P. E. Hanna, "Histamine-N-Methyltransferase: Inhibition and Potentiation by trans and cis-1, 5-Diphenyl-3-dimethyl-aminopyrrolidine", *J. Med. Chem.*, **17**, 471-473 (1974).
21. R. T. Borchardt and Y. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. I. Modification of the Amino Acid Portion of S-Adenosyl-homocysteine", *J. Med. Chem.*, **17**, 862-868 (1974).
22. R. T. Borchardt, J. A. Huber and Y. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent

- Methyltransferases. II. Modification of the Base Portion of S-Adenosylhomocysteine", *J. Med. Chem.*, **17**, 868-873 (1974).
23. R. T. Borchardt, "Synthesis and Biological Activity of Analogs of S-Adenosylhomocysteine and Inhibitors of Methyltransferases", in *The Biochemistry of S-Adenosylmethionine*, (F. Solvatore, E. Borck, V. Zappia, H. G. Williams-Ashman, F. Schlenk, Eds.), Columbia University Press, New York, p. 151-170, 1977.
 24. R. T. Borchardt, C. R. Creveling and C. Isersky, "Immunological Characterization of Catechol-O-Methyltransferase", *Biochem. Pharmacol. Suppl.*, **23**, 72 (1974).
 25. R. T. Borchardt and J. A. Huber, "Catechol-O-Methyltransferase. V. Structure-Activity Relationships for Inhibition by Flavonoids", *J. Med. Chem.*, **18**, 120-122 (1975).
 26. R. T. Borchardt and D. R. Thakker, "Catechol-O-Methyltransferase. VI. Affinity Labeling with N-Haloacetyl-3,5-Dimethoxy-4-Hydroxyphenylalkylamines", *J. Med. Chem.*, **18**, 152-158 (1975).
 27. R. T. Borchardt and Y. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. III. Modifications of the Sugar Portion of S-Adenosylmethionine", *J. Med. Chem.*, **18**, 300-304 (1975).
 28. R. T. Borchardt, C. F. Cheng and D. R. Thakker, "Purification of Catechol-O-Methyltransferases by Affinity Chromatography", *Biochem. Biophys. Res. Commun.*, **63**, 69-77 (1975).
 29. R. T. Borchardt, "Affinity Labeling of Catechol-O-Methyltransferase by the Oxidation Products of 6-Hydroxydopamine", *Mol. Pharmacol.*, **11**, 436-449 (1975).
 30. R. T. Borchardt, "Inhibition of Indolethylamine-N-Methyltransferase by Analogs of S-Adenosylhomocysteine", *Biochem. Pharmacol.*, **24**, 1542-1544 (1975).
 31. R. T. Borchardt, G. L. Grunewald, J. M. Grindel and W. C. Vincek, "Importance of the Aromatic Ring in Adrenergic Amines. Non-Aromatic Analogs of Phenylethanolamine as Substrates for Phenylethanolamine-N-Methyltransferase", *Mol. Pharmacol.*, **11**, 694-699 (1975).
 32. R. T. Borchardt and D. R. Thakker, "Affinity Labeling of Catechol-O-Methyltransferase by N-Haloacetyl Derivatives of 3, 5-Dimethoxy-4-Hydroxyphenylethylamine and 3, 4-Dimethoxy-5-Hydroxyphenylethylamine. Kinetics of Inactivation", *Biochemistry*, **14**, 4543-4551 (1975).
 33. E. E. Smismman, J. R. Reid, D. A. Walsh and R. T. Borchardt, "Synthesis and Biological Activity of 2- and 4-Substituted-6,7-Dihydroxy-1,2,3,4-Tetrahydroisoquinoline", *J. Med. Chem.*, **19**, 127-131 (1976).
 34. R. T. Borchardt, E. E. Smismman, D. Nerland and J. R. Reid, "Catechol-O-Methyltransferase. 7. Affinity Labeling with the Oxidation Products of 6-Aminodopamine", *J. Med. Chem.*, **19**, 30-37 (1976).
 35. R. T. Borchardt and Y. S. Wu, "S-Aristeromycinyl-L-Homocysteine—A Potent Inhibitor of S-Adenosylmethionine-Dependent Transmethylations", *J. Med. Chem.*, **19**, 197-198 (1976).
 36. R. T. Borchardt, "Catechol-O-Methyltransferase: A Model to Study the Mechanism of 6-Hydroxydopamine Interaction with Proteins", in *Chemical Tools in Catecholamine Research* (G. Jonsson, T. Malmfors and C. Sachs, Eds.), North Holland Publishing Company, Amsterdam, p. 33-40, 1975.
 37. R. T. Borchardt, J. A. Huber and Y. S. Wu, "A Convenient Preparation of S-Adenosylhomocysteine and Related Compounds", *J. Org. Chem.*, **41**, 565-567 (1976).
 38. R. T. Borchardt, D. R. Thakker, W. D. Warner, D. M. Mirth and J. N. Sane, "Catechol-O-Methyltransferase. 8. Structure-Activity Relationship for Inhibition by 8-Hydroxyquinoline", *J. Med. Chem.*, **19**, 558-560 (1976).
 39. R. T. Borchardt, "New Approaches to Controlling the Activity of Phenylethanolamine-N-Methyltransferase in Stress", in *Catecholamines and Stress* (E. Usdin, R. Kvetnansky and I. J. Kopin, Eds.), Pergamon Press, Oxford, p. 313-319, 1976.
 40. M. R. Hegazi, R. T. Borchardt and R. L. Schowen, "An S_N2 -Like Transition State for Methyl Transfer Catalyzed by Catechol-O-Methyltransferase", *J. Amer. Chem. Soc.*, **98**, 3048-3049 (1976).
 41. R. T. Borchardt, Y. S. Wu and J. A. Huber, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. IV. Further Modifications of the Amino Acid and Base Portions of S-Adenosylhomocysteine", *J. Med. Chem.*, **19**, 1094-1099 (1976).
 42. R. T. Borchardt and Y. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. V. The Role of the Asymmetric Sulfonium Pole in Enzymatic Binding of S-Adenosylmethionine", *J. Med. Chem.*, **19**, 1099-1103 (1976).

43. R. T. Borchardt, J. A. Huber, A. F. Wycpalek and Y. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. VI. Structural Modifications of S-Adenosylmethionine", *J. Med. Chem.*, **19**, 1104-1110 (1976).
44. R. T. Borchardt, D. R. Thakker and J. R. Reid, "Catechol-O-Methyltransferase. 9. Mechanism of Inactivation by 6-Hydroxydopamine", *J. Med. Chem.*, **19**, 1201-1209 (1976).
45. R. T. Borchardt and D. R. Thakker, "Evidence for Sulfhydryl Groups at the Active Site of Catechol-O-Methyltransferase", *Biochim. Biophys. Acta*, **445**, 598-609 (1976).
46. R. T. Borchardt and D. R. Thakker, "Affinity Labeling of Catechol-O-Methyltransferase Using N-Haloacetyl Derivatives of 3,5-Dimethoxy-4-Hydroxyphenylethylamine and 3,4-Dimethoxy-5-Hydroxyphenylethylamine", in Methods in Enzymology-Affinity Labeling (W. B. Jacoby and M. Wilcheck, Eds.), Academic Press, New York, Vol. **46**, p. 554-561, 1977.
47. R. T. Borchardt, W. C. Vincek and G. L. Grunewald, "A Liquid Chromatographic Assay for Phenylethanolamine N-Methyltransferase", *Anal. Biochem.*, **82**, 149-151 (1977).
48. R. T. Borchardt, S. K. Burgess, J. R. Reid, Y. O. Liang and R. N. Adams, "Effects of 2- and/or 5-Methylated Analogs of 6-Hydroxydopamine of Noradrenergic and Dopaminergic Neurons", *Mol. Pharmacol.*, **13**, 805-818 (1977).
49. R. T. Borchardt, C. Pugh and H. O. Stone, "Inhibition of Newcastle Disease Virion m-RNA (guanine 7-methyltransferase by Analogs of S-Adenosylhomocysteine", *Biochemistry*, **16**, 3928-3932 (1977).
50. R. T. Borchardt, "Chemical Probes of the Active Site of Catechol-O-Methyltransferase", in Biochemistry and Function of Monoamine Enzymes (E. Usdin and N. Weiner, Eds.), Marcel Dekker, New York, p. 707-726, 1977.
51. R. T. Borchardt and C. S. Schasteen, "Phenol-Sulfotransferase Inactivation by 2,3-Butanedione and Phenylglyoxal: Evidence for an Active Site Arginyl Residue", *Biochem. Biophys. Res. Commun.*, **78**, 1067-1073 (1977).
52. R. T. Borchardt, Y. S. Wu and B. S. Wu, "S-Adenosyl-L-Homocysteine Dialdehyde: An Affinity Labeling Reagent for Histamine-N-Methyltransferase", *Biochem. Biophys. Res. Commun.*, **78**, 1025-1033 (1977).
53. R. T. Borchardt and C. F. Cheng, "Purification and Characterization of Rat Heart and Brain Catechol-O-Methyltransferase", *Biochim. Biophys. Acta*, **522**, 49-62 (1978).
54. R. T. Borchardt, M. F. Hegazi and R. L. Schowen, "The Determination of the O-Methylated Metabolites of Catecholamines Using High Performance Liquid Chromatography and Electrochemical Detection", *J. Chromatography*, **152**, 25-259 (1978).
55. R. T. Borchardt, S. E. Wu and C. S. Schasteen, "Adenosine 5'-Diphosphate Dialdehyde: An Affinity Labeling Reagent for Phenol-sulfotransferase", *Biochem. Biophys. Res. Commun.*, **81**, 841-849 (1978).
56. R. T. Borchardt and C. F. Cheng, "Purification and Characterization of Rat Liver Thiol-S-Methyltransferase", *Biochim. Biophys. Acta*, **522**, 340-353 (1978).
57. R. T. Borchardt, Y. S. Wu and B. S. Wu, "Mechanism of Inhibition of Pineal Hydroxyindole-O-Methyltransferase by Pyridoxal 5'-Phosphate", *Biochem. Pharmacol.*, **27**, 120-122 (1978).
58. R. T. Borchardt, C. Pugh and H. O. Stone, "Simultaneous Assays for m-RNA(Guanine-7-) Methyltransferase and m-RNA(Nucleoside-2'-)Methyltransferase", *Anal. Biochem.*, **88**, 502-512 (1978).
59. P. S. Leboy, F. Steiner, S. Henry, J. M. Glick and R. T. Borchardt, "S-Adenosylhomocysteine Analogues as Inhibitors of Specific t-RNA Methylations", *Biochim. Biophys. Acta*, **520**, 153-163 (1978).
60. R. T. Borchardt, C. Pugh and H. O. Stone, "Sinefungin: A Potent Inhibitor of Virion m-RNA(Guanine-7-)Methyltransferase and m-RNA(Nucleoside-2'-)Methyltransferase and Viral Multiplication", *J. Biol. Chem.*, **253**, 4075-4077 (1978).
61. R. T. Borchardt, J. Olsen, L. Eiden, R. L. Schowen and C. O. Rutledge, "The Isolation and Characterization of the Methyl Acceptor Proteins from Adrenal Chromaffin Granules", *Biochem. Biophys. Res. Commun.*, **83**, 970-976 (1978).
62. R. T. Borchardt, J. A. Huber and Y. S. Wu, "An Improved Synthesis of S-Adenosylhomocysteine", in Nucleic Acid Chemistry; Improved and New Synthetic Procedures: Methods and Techniques (L. B. Townsend and R. S. Tipson, Eds.), Wiley-Interscience, New York, Part II, p. 541-545, 1978.
63. R. T. Borchardt, M. F. Hegazi, S. Osaki and R. L. Schowen, "S-Adenosyl-L-Methionine-CD₃ and S-Adenosyl-L-

- Methionine- $^{13}\text{CH}_3$ ", in Nucleic Acid Chemistry: Improved and New Synthetic Procedures: Methods and Techniques (L. B. Townsend and R. S. Tipson, Eds.), Wiley-Interscience, New York, Part II, p. 889-894, 1978.
64. R. T. Borchardt, "The Mechanism of Alkaline Hydrolysis of S-Adenosyl-L-Methionine and Related Sulfonium Nucleosides", *J. Amer. Chem. Soc.*, **101**, 458-463 (1979).
 65. R. T. Borchardt, Y. S. Wu and B. S. Wu, "Affinity Labeling of Histamine-N-Methyltransferase by 2',3'-Dialdehyde Derivatives of S-Adenosylhomocysteine and S-Adenosylmethionine. Kinetics of Inactivation", *Biochemistry*, **17**, 4145-4153 (1978).
 66. R. T. Borchardt, Y. S. Wu and B. S. Wu, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 7. Role of the Ribosyl Moiety in Enzymatic Binding of S-Adenosylhomocysteine and S-Adenosylmethionine", *J. Med. Chem.*, **21**, 1307-1310 (1978).
 67. R. E. Tessel, L. E. Kennedy, S. K. Burgess and R. T. Borchardt, "Epinephrine in Rat Hypothalamus: Antagonism of Desmethylinipramine of 6-Hydroxydopamine-Induced Depletion", *Brain Research*, **153**, 615-617 (1978).
 68. M. F. Hegazi, R. T. Borchardt and R. L. Schowen, "alpha-Deuterium and Carbon-13 Isotope Effects for Methyl Transfer Catalyzed by Catechol-O-Methyltransferase: SN_2 -like Transition State", *J. Amer. Chem. Soc.*, **101**, 4359-4365 (1979).
 69. G. L. Grunewald, W. C. Vincek, D. P. Davis and R. T. Borchardt, "Some New Inhibitors of Epinephrine Biosynthesis", in Catecholamines: Basic and Clinical Frontiers (E. Usdin, I. J. Kopin and J. Barchas, Eds.), Pergamon Press, New York, Vol. 1, p. 189-191, 1979.
 70. R. T. Borchardt, J. Olsen, J. Eiden, R. L. Schowen and C. O. Rutledge, "Isolation and Characterization of Methyl Acceptor Protein from Adrenal Chromaffin Granules", in Catecholamines: Basic and Clinical Frontiers (E. Usdin, I. J. Kopin and J. Barchas, Eds.), Pergamon Press, New York, Vol. 1, p. 250-252, 1979.
 71. R. T. Borchardt and C. S. G. Pugh, "Analogues of S-Adenosyl-L-Homocysteine as Inhibitors of Viral mRNA Methyltransferases", in Transmethylation (E. Usdin, R. T. Borchardt and C. R. Creveling, Eds.), Elsevier North-Holland, New York, p. 197-206, 1979.
 72. L. Eiden, R. T. Borchardt and C. O. Rutledge, "Protein Carboxymethylation in Neurosecretory Process", in Transmethylation (E. Usdin, R. T. Borchardt and C. R. Creveling, Eds.), Elsevier North-Holland, New York, p. 539-546, 1979.
 73. J. Olsen, Y. S. Wu, R. T. Borchardt, and R. L. Schowen, "Transition-State Structure and Catalytic Power in Methyl Transfer," in Transmethylation (E. Usdin, R. T. Borchardt and C. R. Creveling, Eds.), Elsevier-North Holland, New York, p. 127-133, 1979.
 74. R. T. Borchardt, L. E. Eiden, B. S. Wu and C. O. Rutledge, "Sinefungin, a Potent Inhibitor of S-Adenosylmethionine: Protein O-Methyltransferase", *Biochem. Biophys. Res. Commun.*, **89**, 919-924 (1979).
 75. R. T. Borchardt, "S-Adenosyl-L-Methionine-Dependent Macromolecule Methyltransferases: Potential Targets for the Design of Chemotherapeutic Agents", *J. Med. Chem.*, **23**, 347-357 (1980).
 76. R. T. Borchardt, "N- and O-Methylation" in Enzymatic Basis of Detoxification (W. B. Jakoby, Ed.), Academic Press, New York, Vol. II, p. 43-62, 1980.
 77. H. Hibasami, R. T. Borchardt, S. Y. Chen, J. K. Coward and A. E. Pegg, "Studies of Inhibition of Rat Spermidine and Spermine Synthesis", *Biochem. J.*, **187**, 419-428 (1980).
 78. A. W. Wertheimer, S. Y. Chen, R. T. Borchardt and Y. Furuichi, "S-Adenosylmethionine and its Analogs: Structural Features Correlated with Synthesis and Methylation of mRNA's of Cytoplasmic Polyhedrosis Virus", *J. Biol. Chem.*, **255**, 5924-5930 (1980).
 79. W. C. Vincek, C. Aldrich, R. T. Borchardt and G. L. Grunewald, "Non-Aromatic Analogs of Phenylethanolamine as Inhibitors of Phenylethanolamine-N-Methyltransferase: The Role of Hydrophobic Interaction. Importance of the Aromatic Ring in Adrenergic Amines," *J. Med. Chem.*, **24**, 7-12 (1981).
 80. D. Davis, R. T. Borchardt, and G. L. Grunewald, "Non-Aromatic Analogs of Phenylethanolamine and Inhibitors of Phenylethanolamine-N-Methyltransferase: The Role of π Electronic Interactions. Importance of Aromatic Ring in Adrenergic Amines", *J. Med. Chem.*, **24**, 12-16 (1981).
 81. A. E. Pegg, R. T. Borchardt and J. K. Coward, "Effects of Inhibitors of Spermidine and Spermine Synthesis on Polyamine Levels and Growth of Transformed Mouse Fibroblasts", *Biochem. J.*, **194**, 79-89 (1981).

82. R. T. Borchardt, "Catechol-O-Methyltransferase: Assay, Purification and Properties", in Methods in Enzymology, Detoxification and Drug Metabolism: Conjugation and Related Systems (W. B. Jakoby, Ed.), Academic Press, New York, Vol. 77, 267-272, 1981.
83. A. Baranczyk-Kuzma, R. T. Borchardt, C. S. Schasteen and C. Pinnick, "Phenol Sulfotransferase: Purification and Characterization of the Rat Enzyme", in Phenol Sulfotransferase in Mental Health Research (E. Usdin and M. Sandler, Eds.), Macmillan Publishers, London, p. 55-73, 1981.
84. A. Baranczyk-Kuzma, R. T. Borchardt, C. S. Schasteen and C. Pinnick, "Phenol Sulfotransferase: Purification and Characterization of the Rat Liver, Kidney and Brain Enzymes", *Psychopharmacology Bulletin*, 17, 50-52 (1981).
85. R. T. Borchardt and J. A. Huber, "3-Substituted-4-Methoxy-5-Hydroxybenzaldehydes and Benzoic Acids as Inhibitors of Catechol-O-Methyltransferase", in Function and Regulation of Monoamine Enzymes - Basic and Clinical Aspects (E. Usdin, N. Weiner, M. B. H. Youdin, Eds.), Macmillan, London, p. 657-664, 1981.
86. G. L. Grunewald, R. T. Borchardt, M. F. Rafferty and P. Krass, "Conformational Preferences of Amphetamine Analogues for Inhibition of Phenylethanolamine N-Methyltransferase. Conformationally Defined Adrenergic Agents 5", *Mol. Pharmacol.*, 20, 377-381 (1981).
87. L. E. Eiden, R. T. Borchardt and C. O. Rutledge, "Protein Carboxymethylation in the Rat Hypothalamus", *J. Neurochem.*, 38, 631-637 (1982).
88. R. T. Borchardt and A. K. Sinhababu, "An Efficient Synthesis of 3,5-Dihydroxy-4-Methylbenzoic Acid", *J. Org. Chem.*, 24, 5021-5022 (1981).
89. R. T. Borchardt and J. A. Huber, "Catechol-O-Methyltransferase 10. 3-Substituted-4-Methoxy-5-Hydroxybenzaldehydes and Benzoic Acids as Inhibitors", *J. Med. Chem.*, 25, 258-263 (1982).
90. R. T. Borchardt and J. A. Huber, "Catechol-O-Methyltransferase 11. Affinity Labeling with 3-Mercapto-4-Methoxy-5-Hydroxybenzoic Acid", *J. Med. Chem.*, 25, 321-323 (1982).
91. R. T. Borchardt and P. Bhatia, "Catechol-O-Methyltransferase 12. Affinity Labeling with the Oxidation Products of 5,6-Dihydroxyindole", *J. Med. Chem.*, 25, 263-271 (1982).
92. J. A. Yoffe and R. T. Borchardt, "Characterization of Serotonin Uptake in Cultured Pheochromocytoma Cells. Comparison with Norepinephrine Uptake", *Mol. Pharmacol.*, 21, 362-367 (1982).
93. J. A. Yoffe and R. T. Borchardt, "Characterization of Serotonin Uptake in Cultured Neuroblastoma Cells. Difference Between Differentiated and Nondifferentiated Cells", *Mol. Pharmacol.*, 21, 368-373 (1982).
94. R. T. Borchardt, D. Kuonen, J. A. Huber and A. Moorman, "Inhibition of Calf Thymus and Rat Hypothalamic Synaptosomal Protein Carboxymethyltransferase by analogues of S-Adenosylhomocysteine", *Mol. Pharmacol.*, 21, 181-186 (1982).
95. C. S. G. Pugh and R. T. Borchardt, "Effects of S-Adenosylhomocysteine Analogues on Vaccinia Virion RNA Synthesis and Posttranscriptional Modification", *Biochemistry*, 21, 1535-1541 (1982).
96. R. T. Borchardt, A. Baranczyk-Kuzma, C. S. Schasteen, Su-Er Wu, and C. Pinnick, "Purification and Characterization of a Rat Liver Isozyme", in Sulfate Metabolism and Sulfate Conjugation, (G. J. Mulder, F. Caldwell, G. M. VanKemperal, R. J. Vork, Eds.), Taylor and Francis, London, p. 29-35 (1982).
97. N. Y. Liang, R. E. Tessel, G. L. Grunewald and R. T. Borchardt, "The Use of Phenylethanolamine N-Methyltransferase Inhibitors in Elucidating the Role of Brain Epinephrine in the Control of Cardiovascular Function", in The Biochemistry of S-Adenosylmethionine and Related Compounds (R. T. Borchardt, C. R. Creveling and E. Usdin, Eds.), Macmillan, London, p. 457-460 (1982).
98. R. T. Borchardt, U. G. Patel and Ronnda Bartel, "2'-O-[(R)-Formyl-(adenin 9yl)methyl]-(S)-glyceraldehyde: A Potent Inhibitor of S-Adenosylhomocysteine Hydrolase", in The Biochemistry of S-Adenosylmethionine and Related Compounds (R. T. Borchardt, C. R. Creveling and E. Usdin, Eds.), Macmillan, London, p. 645-652 (1982).
99. M. Frana, R. T. Borchardt and H. O. Stone, "Inhibition of Rous Sarcoma Virus Mediated Cellular Transformation by Analogues of S-Adenosyl-L-Homocysteine", in The Biochemistry of S-Adenosylmethionine and Related Compounds (R. T. Borchardt, C. R. Creveling and E. Usdin, Eds.), Macmillan, London, p. 657-666 (1982).
100. R. T. Borchardt and J. E. Simmons, "General Method for the Preparation of α and/or β Deuterium-Labelled 6-Hydroxydopamine Derivatives", *J. Labelled Compds. Radiopharm.*, 19, 433-445 (1982).
101. J. R. Yoffe and R. T. Borchardt, "Effects of Ascorbic Acid on the Uptake of Serotonin into Differentiated Neuroblastoma

- Cells", *Life Sciences*, **31**, 489-493 (1982).
102. R. T. Borchardt and C. S. Schasteen, "Phenol Sulfotransferase: I. Purification of the Rat Liver Enzyme by Affinity Chromatography", *Biochim. Biophys. Acta*, **708**, 272-279 (1982).
 103. R. T. Borchardt, C. S. Schasteen and Su-Er Wu, "Phenol Sulfotransferase: II. Inactivation by 2,3-Butanedione, Phenylglyoxal, N-Ethylmaleimide and Nucleotide Dialdehydes", *Biochim. Biophys. Acta*, **708**, 280-293 (1982).
 104. N. Y. Liang, R. E. Tessel, G. L. Grunewald and R. T. Borchardt, "Inhibitors of Phenethanolamine N-Methyltransferase. 1. Effects of 2-Cyclooctyl-2-Hydroxyethylamine on Rat Brain Catecholamine Content and Blood Pressure", *J. Pharmacol. Exptl. Therap.*, **223**, 375-381 (1982).
 105. N. Y. Liang, R. E. Tessel, G. L. Grunewald and R. T. Borchardt, "Inhibitors of Phenethanolamine N-Methyltransferase. 2. Effects on Rat Brain and Adrenal Catecholamine Content and Blood Pressure. Comparison of Nonaromatic Analogues of Phenylethanolamine, SKF64139 and 3,4-Dichlorobenzylamine", *J. Pharmacol. Exptl. Therap.*, **223**, 382-387 (1982).
 106. M. F. Rafferty, D. S. Wilson, J. A. Monn, P. Krass, R. T. Borchardt and G. L. Grunewald, "Comparisons of Norepinephrine N-Methyltransferase for Aromatic Versus Nonaromatic Substrate and Inhibitors. The Importance of the Aromatic Ring in Adrenergic Amines. 7.", *J. Med. Chem.*, **25**, 1198-1204 (1982).
 107. M. F. Rafferty, P. Krass, R. T. Borchardt and G. L. Grunewald, "2-(Aminomethyl)-trans-2-decalols as Inhibitors of Norepinephrine N-Methyltransferase. Importance of the Aromatic Ring in Adrenergic Amines. 8.", *J. Med. Chem.*, **25**, 1250-1252 (1982).
 108. G. L. Grunewald, J. Monn, M. F. Rafferty, P. Krass and R. T. Borchardt, "Probes of the Active Site of Norepinephrine N-Methyltransferase: The Effect of Hydrophobic and Hydrophilic Interactions on Side Chain Binding of Amphetamine and α -Methylbenzylamine", *J. Med. Chem.*, **25**, 1248-1250 (1982).
 109. M. F. Rafferty, G. L. Grunewald and R. T. Borchardt, "Probes of the Active Site of Norepinephrine N-Methyltransferase: Directional Probes of the Hydrophobic Component of the Aromatic Ring Binding Site", *J. Med. Chem.*, **25**, 1204-1208 (1982).
 110. N. Y. Liang, G. L. Grunewald and R. T. Borchardt, "Effect of Inhibitors of Phenylethanolamine N-Methyltransferase on Rat Brain Epinephrine Levels and Body Temperature", *Res. Commun. Chem. Pathol. Pharmacol.*, **37**, 445-452 (1982).
 111. A. R. Moorman and R. T. Borchardt, "Synthesis of Methyl 5-O-Acetyl-7-Deoxy-2,3-O-Isopropylidene Heptofuranoside-6-ulose", *Carbohydrate Res.*, **119**, 269-272 (1983).
 112. A. R. Moorman, R. T. Borchardt and T. Martin, "Addition of 1-Nitroalkanes to 2,3-O-Isopropylidene- β -D-Ribopentodialdo-1,4-Furanoside and N⁶-Benzoyl-2',3'-O-Isopropylideneadenosine 5'-Aldehyde", *Carbohydrate Res.*, **113**, 233-239 (1983).
 113. A. Baranczyk-Kuzma, R. T. Borchardt and C. Pinnick, "An Ecteola-Cellulose Chromatography Assay for 3'-Phosphoadenosine 5'-Phosphosulfate: Phenol Sulfotransferase (EC 2.8.2.1)", *Anal. Biochem.*, **130**, 334-338 (1983).
 114. C. W. Bradberry, R. T. Borchardt and C. J. Decedue, "Immobilization of Ascorbic Acid Oxidase", *FEBS Letters*, **146**, 348-352 (1982).
 115. B. Matuszewska and R. T. Borchardt, "Guinea Pig Brain Histamine N-Methyltransferase: Purification and Partial Characterization", *J. Neurochem.*, **41**, 113-118 (1983).
 116. J. Simmons and R. T. Borchardt, "Regioselective Synthesis of Deuterium Labelled 6-Hydroxydopamines", *J. Labelled Compds. Radiopharm.*, **20**, 325-338 (1983).
 117. A. Sinhababu and R. T. Borchardt, "Silica Gel-Assisted Reductive Cyclization of Dinitrostyrenes to Indoles", *J. Org. Chem.*, **48**, 3347-3349 (1983).
 118. A. Sinhababu and R. T. Borchardt, "A General Method for the Synthesis of Phthalaldehydic Acids and Phthalides from ortho-Bromobenzaldehydes via ortho-Lithiated Aminoalkoxides", *J. Org. Chem.*, **48**, 2356-2360 (1983).
 119. A. Sinhababu and R. T. Borchardt, "An Efficient Method for Conversion of Phenolic Mannich Bases to C-Methylated Phenols: Synthesis of 3,6-Dimethylcatechol", *Synth. Commun.*, **12**, 983-988 (1982).
 120. A. Sinhababu and R. T. Borchardt, "Selective Ring C-Methylation of Hydroxybenzaldehydes via Their Mannich Bases", *Synth. Commun.*, **13**, 677-683 (1983).
 121. A. Sinhababu and R. T. Borchardt, "Silica Gel-Assisted Reduction of Nitrostyrenes to Nitroalkanes with Sodium

- Borohydride", *Tetrahedron Letters*, **24**, 227-230 (1983).
122. A. Sinhababu and R. T. Borchardt, "Silica Gel-Assisted Reduction of Nitrostyrenes to 2-Aryl-2-[³H]-Nitroethanes with Sodium Borodeuteride", *J. Labelled Compds. Radiopharm.*, **20**, 1027-1033 (1983).
 123. Su-Er Wu, W. P. Huskey, R. T. Borchardt and R. L. Schowen, "The Chiral Instability at Sulfur of S-Adenosylmethionine", *Biochemistry*, **22**, 2828-2832 (1983).
 124. A. Sinhababu and R. T. Borchardt, "Aromatic Hydroxylation. Hydroxybenzaldehydes from Bromobenzaldehydes via Reaction of *in situ* Generated, Lithiated α -Morpholinobenzyl Alkoxides with Nitrobenzene", *J. Org. Chem.*, **48**, 1941-1944 (1983).
 125. R. Bartel and R. T. Borchardt, "Effects of Adenosine Dialdehyde on S-Adenosylhomocysteine Hydrolase and S-Adenosylmethionine-Dependent Transmethylations in Mouse L-Cells", *Mol. Pharmacol.*, **25**, 418-424 (1984).
 126. R. T. Borchardt, B. T. Keller and U. Patel-Thombre, "Neplanocin A. A Potent Inhibitor of Cell S-Adenosylhomocysteine Hydrolase and Vaccinia Virus Multiplication in Mouse L-929 Cells", *J. Biol. Chem.*, **259**, 4353-4358 (1984).
 127. A. M. Trammel, J. E. Simmons and R. T. Borchardt, "An Efficient *In Vitro* Assay for Acetylcholinesterase Regenerators Using Immobilized Enzyme", *Pharmaceutical Res.*, **1**, 115-120 (1984).
 128. B. T. Keller and R. T. Borchardt, "Metabolic Conversion of Neplanocin A to S-Neplanocylmethionine by Mouse L-929 Cells", *Biochem. Biophys. Res. Commun.*, **120**, 131-137 (1984).
 129. N.Y. Liang, C. A. Burrichter and R. T. Borchardt, "The Role of Central Epinephrine Neurons in Regulation of Serum Corticosterone Levels. In *Stress: The Role of Catecholamines and Other Neurotransmitters* (E. Usdin, R. Kvetnansky and J. Axelrod, Eds.), Gordon and Breach Science Publishers, New York, p. 243-248, 1984.
 130. Su-Er Wu, W. P. Huskey, R. T. Borchardt and R. L. Schowen, "Different Isotope Effects of Parallel Pathways of Enzyme-Catalyzed Transmethylation", *J. Amer. Chem. Soc.*, **106**, 5762-5763 (1984).
 131. N. Y. Liang, A. Chandra, R. E. Tessel, G. Grunewald and R. T. Borchardt, "Effects of Phenylethanolamine-N-Methyltransferase (PNMT) Inhibitors on Blood Pressure in DOCA Salt Hypertensive Rats", *Res. Commun. Chem., Pathol. Pharmacol.*, **46**, 319-330 (1984).
 132. U. G. Patel and R. T. Borchardt, "Adenine Nucleoside 2',3'-Dialdehydes: Potent Inhibitors of Bovine Liver S-Adenosylhomocysteine Hydrolase", *Biochemistry*, **24**, 1130-1136 (1985).
 133. D. M. Houston, E. K. Dolence, B. T. Keller, U. Patel-Thombre and R. T. Borchardt, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 8. Molecular Dissections of Carbocyclic 3-Deaza-adenosine as Inhibitors of S-Adenosylhomocysteine Hydrolase", *J. Med. Chem.*, **28**, 467-471 (1985).
 134. D. M. Houston, E. K. Dolence, B. Keller, U. Patel-Thombre and R. T. Borchardt, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 9. 2',3'-Dialdehyde Derivatives of Carbocyclic Purine Nucleosides as Inhibitors of S-Adenosylhomocysteine Hydrolase", *J. Med. Chem.*, **28**, 471-477 (1985).
 135. D. M. Houston, B. Matuszewski and R. T. Borchardt, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 10. Base and Sugar Modified Analogs of S-Arisotermycinyllhomocysteine", *J. Med. Chem.*, **28**, 478-482 (1985).
 136. R. T. Borchardt and B. Matuszewska, "S-Adenosylmethionine-Dependent Transmethylation of Histamine: Purification and Partial Characterization of Guinea Pig and Rat Kidney Histamine N-Methyltransferase" in *Frontiers in Histamine Research* (C. R. Ganellin and J. C. Schwartz, Eds.), Pergamon Press, New York, p. 163-172, 1985.
 137. N. Y. Liang, J. A. Hower and R. T. Borchardt, "Release of Endogenous Brain Epinephrine by the Calcium-Ionophores X537A and A23187", *Brain Res.*, **341**, 297-302 (1985).
 138. A. K. Sinhababu and R. T. Borchardt, "Efficient Synthesis of Deuterium Labelled Epinines", *J. Labelled Compds. Radiopharm.*, **22**, 767-774 (1985).
 139. A. K. Sinhababu, A. K. Ghosh and R. T. Borchardt, "Molecular Mechanism of Action of 5,6-Dihydroxytryptamine. Synthesis and Biological Evaluation of 4-Methyl-, 7-Methyl- and 4,7-Dimethyl-5,6-Dihydroxytryptamines", *J. Med. Chem.*, **28**, 1273-1279 (1985).
 140. A. K. Sinhababu and R. T. Borchardt, "Mechanism and Products of Autoxidation of 5,7-Dihydroxytryptamine", *J. Amer. Chem. Soc.*, **107**, 7618-7627 (1985).

141. R. Bartel and R. T. Borchardt, "Quantitation of S-Adenosylhomocysteine Hydrolase in Mouse L-929 Cells Using the Inhibitor Neplanocin A", *Anal. Biochem.*, **149**, 191-196 (1985).
142. B. T. Keller, R. S. Clark, A. E. Pegg and R. T. Borchardt, "Purification and Characterization of Some Metabolic Effects of S-Neplanocylmethionine", *Mol. Pharmacol.*, **28**, 364-370 (1985).
143. I. Osiecka, R. T. Borchardt, J. A. Fix, C. A. Gardner and P. A. Porter, "In Vitro Drug Absorption Models. I. Brush Border Membrane Vesicles, Isolated Mucosal Cells and Everted Intestinal Rings: Characterization and Salicylate Accumulation", *Pharmaceutical Res.*, **2**, 284-293 (1985).
144. P. A. Porter, I. Osiecka, R. T. Borchardt, J. A. Fix, L. Frost and C. A. Gardner, "In Vitro Drug Absorption Models. II. Salicylate, Cefoxitin, α -Methyldopa and Theophylline Uptake in Cells and Rings: Correlation with In Vivo Bioavailability", *Pharmaceutical Res.*, **2**, 293-298 (1985).
145. A. Sinhababu, R. L. Bartel, N. Pochopin and R. T. Borchardt, "Mechanism of Action of S-Adenosyl-L-homocysteine Hydrolase. Measurement of Kinetic Isotope Effects Using Adenosine 3'-d and S-Adenosyl-L-homocysteine 3'-d as Substrates", *J. Amer. Chem. Soc.*, **107**, 7628-7632 (1985).
146. A. Baranczyk-Kuzma, R. T. Borchardt and C. L. Pinnick, "Phenol Sulfotransferase: Purification and Characterization of the Rat Kidney and Stomach Enzymes", *Acta Biochimica Polonica*, **32**, 335-45 (1985).
147. N. Y. Liang, C. A. Burrichter, J. L. Vooght and R. T. Borchardt, "The Role of Central Epinephrine Neurons in the Regulation of Serum Prolactin and Leuteinizing Hormone Release in Female Rats", *Res. Commun. Chem. Pathol. Pharmacol.*, **48**, 459-462 (1985).
148. N. Y. Liang, J. A. Hower and R. T. Borchardt, "Effects of Phenylethanolamine-N-Methyltransferase Inhibitors on Uptake and Release of Norepinephrine and Dopamine from Rat Brain", *Res. Commun. Chem. Pathol. Pharmacol.*, **49**, 467-470 (1985).
149. B. Matuszewska and R. T. Borchardt, "Rat Kidney Histamine N-Methyltransferase: Purification and Characterization", *Preparative Biochem.*, **14**, 145-157 (1985).
150. K. L. Audus and R. T. Borchardt, "Characterization of an In Vitro Blood Brain Barrier Model System for Studying Drug Transport and Metabolism", *Pharmaceutical Res.*, **3**, 81-88 (1986).
151. A. R. Moorman and R. T. Borchardt, "Synthesis of Methyl 7-Alkyl-6,7-Tetrahydro-6,7-talo-dideoxy-2,3-O-Isopropylidene- α -L- and β -D-allo-Hepto-Furanosides", in Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques in Nucleic Acid Chemistry, (L.B. Townsend and R. S. Tipson, Eds.), John Wiley & Sons, Inc., New York, Vol. 3, p. 38-42, 1986.
152. B. T. Keller and R. T. Borchardt, "Metabolism and Mechanism of Action of Neplanocin A: A Potent Inhibitor of S-Adenosylhomocysteine Hydrolase" in Biological Methylation and Drug Design - Experimental and Clinical Roles of S-Adenosylmethionine (R. T. Borchardt, C. R. Creveling and P. M. Ueland, Eds.), Humana Press, Clifton, NJ, p. 385-396, 1986.
153. A. Baranczyk-Kuzma, K. L. Audus and R. T. Borchardt, "Catecholamine-Metabolizing Enzymes of Bovine Brain Microvessel Endothelial Cell Monolayers", *J. Neurochem.*, **46**, 1956-1960 (1986).
154. K. L. Audus and R. T. Borchardt, "Characteristics of the Large Neutral Amino Acid Transport System of Bovine Brain Microvessel Endothelial Cell Monolayers", *J. Neurochem.*, **47**, 484-488 (1986).
155. S. Rim, K. L. Audus and R. T. Borchardt, "Relationship of Octanol/Buffer and Octanol/Water Partition Coefficients to Transcellular Diffusion Across Brain Microvessel Endothelial Cell Monolayers", *Int. J. Pharmaceutics*, **32**, 79-84 (1986).
156. K. L. Audus and R. T. Borchardt, "Carrier-Mediated and Receptor-Mediated Transport Across the Endothelial Cells of the Vasculature" in Bioreversible Carriers in Drug Design: Theory and Applications (E. B. Roche, Ed.), Pergamon Press, New York, p. 226-242, 1987.
157. R. T. Borchardt, "Endothelial Cells of the Vasculature: A Significant Barrier to Effective Drug Delivery", Proceedings of the International Symposium for Controlled Release of Bioactive Material, **14**, 4-5 (1987).
158. B. T. Keller and R. T. Borchardt, "Adenosine Dialdehyde: A Potent Inhibitor of Vaccinia Virus Multiplication in Mouse L-929 Cells", *Mol. Pharmacol.*, **31**, 485-492 (1987).
159. I. Osiecka, M. Cortese, P. A. Porter, R. T. Borchardt, J. A. Fix and C. R. Gardner, "Intestinal Absorption of α -Methyldopa: In Vitro Mechanistic Studies in Rat Small Intestinal Segments", *J. Pharmacol. Exptl. Therap.*, **242**, 443-449 (1987).

160. E. W. Fisher, C. J. Decedue, B. T. Keller and R. T. Borchardt, "Neplanocin A Inhibition of S-Adenosylhomocysteine Hydrolase in Alcaligenes Faecalis Has No Effect on Growth of the Microorganism", *J. Antibiotics*, **40**, 873-881 (1987).
161. V. Ramakrishnan and R. T. Borchardt, "Adenosine Dialdehyde and Neplanocin A: Potent Inhibitors of S-Adenosylhomocysteine Hydrolase in Neuroblastoma N-2a Cells", *Neurochemistry International*, **10**, 423-431 (1987).
162. B. Matuszewska and R. T. Borchardt, "Inhibition of S-Adenosylhomocysteine Hydrolase from Alcaligenes faecalis by Neplanocin A", *Arch. Biochem. Biophys.*, **256**, 50-55 (1987).
163. B. Matuszewska and R. T. Borchardt, "The Role of NAD⁺ in the Inhibition of S-Adenosylhomocysteine Hydrolase by Neplanocin A", *J. Biol. Chem.*, **262**, 265-268 (1987).
164. M. Kawase, A. K. Sinhababu and R. T. Borchardt, "Tert-Butyldimethylsilyl Ethers of Phenols: Their One-Step Conversion to Benzyl or Methyl Esters and Utility in Regioselective ortho-Lithiation", *Tetrahedron Letters*, **28**, 4139-4142 (1987).
165. D. R. Borcharding, S. A. Scholtz and R. T. Borchardt, "The Synthesis of Analogs of Neplanocin A: Utilization of Optically Active Dihydroxycyclopentenones Derived from Carbohydrates", *J. Org. Chem.*, **52**, 5457-5461 (1987).
166. M. Hasobe, J. G. McKee, D. R. Borcharding and R. T. Borchardt, "9-(Trans-2',Trans-3'-dihydroxycyclopent-4'-enyl)-Adenine and -3-Deazaadenine: Analogs of Neplanocin A Which Retain Potent Antiviral Activity But Exhibit Reduced Cytotoxicity", *Antimicro. Agents Chemotherap.*, **31**, 1849-1851 (1987).
167. R. G. Rosenfeld, H. Pham, B. Keller, R. T. Borchardt and W. M. Pardridge, "Structural Comparison of Receptors for Insulin, Insulin-Like Growth Factor I- and II- (IGF-I and IGF-II) in Brain and Blood Brain Barrier", *Biochem. Biophys. Res. Commun.*, **149**, 159-166 (1987).
168. M. Kawase, A. K. Sinhababu and R. T. Borchardt, "Silica Gel-Assisted Reductive Cyclization of 2-Nitro- β -piperidinostyrenes, Derived from 2-Nitrotoluenes, to Indoles", *J. Heterocyclic Chem.*, **24**, 1499-1501 (1987).
169. K. L. Audus and R. T. Borchardt, "Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood Brain Barrier" in Biological Approaches to the Controlled Delivery of Drugs (R. L. Juliano, Ed.), New York Academy of Science, New York, NY, Vol. 507, p. 9-18, 1987.
170. K. L. Audus, I. Hidalgo and R. T. Borchardt, "Biological Barriers to the Efficient Delivery of Peptide Drugs" in Topics in Pharmaceutical Sciences (D. D. Breimer and P. Speiser, Eds.), Elsevier Science Publishers, Amsterdam, p. 325-337, 1987.
171. K. L. Audus and R. T. Borchardt, "The Use of Isolated Epithelial and Cultured Endothelial Cells to Elucidate Drug Transport Mechanisms", in Proceedings of the 10th International Congress of Pharmacology (M. J. Rand and C. Raper, Eds.), Elsevier Science Publishers, Amsterdam, p. 615-618, 1987.
172. M. C. Guitton, D. Part, B. Keller, J. deGunzberg, R. T. Borchardt and M. Vernon, "S-Adenosylmethionine, S-Adenosylhomocysteine and S-Adenosylhomocysteine Hydrolase Variations During the Differentiation of Dictyostelium discordium", *Cell Differentiation*, **22**, 203-210 (1988).
173. A. Ghosh, R. T. Borchardt and A. K. Sinhababu, "Characterization of Norepinephrine Uptake in Murine Neuroblastoma Cells, Clone N-2a", *Biogenic Amines*, **5**, 25-35 (1988).
174. A. K. Sinhababu and R. T. Borchardt, "Molecular Mechanism of Biological Action of the Serotonergic Neurotoxin 5,7-Dihydroxytryptamine: A Commentary", *Neurochemistry International*, **12**, 273-284 (1988).
175. M. Hasobe, J. McKee, B. Keller, D. R. Borcharding and R. T. Borchardt, "Effects of 9-(Trans-2',Trans-3'-dihydroxycyclopent-4'-enyl)-Adenine and -3-Deazaadenine on the Metabolism of S-Adenosylhomocysteine in Mouse L-929 Cells", *Mol. Pharmacol.*, **33**, 713-720 (1988).
176. B. T. Keller, K. R. Smith and R. T. Borchardt, "Transport Barriers to Absorption of Peptides", *Netherlands Archives of Pharmaceutical Sciences, Pharmaceutisch Weekblad*, **10**, 38-39 (1988).
177. M. Kawase, A. K. Sinhababu and R. T. Borchardt, "Desilylation of tert-butyldimethylsilyl Ethers of Phenols", *Synthesis*, 710-712 (1988).
178. J.B.M.M. vanBree, K. L. Audus and R. T. Borchardt, "Carrier-Mediated Transport of Baclofen Across Monolayers of Bovine Brain Endothelial Cells in Primary Culture", *Pharmaceutical Res.*, **5**, 369-371, 1988.
179. B. T. Keller and R. T. Borchardt, "Inhibition of S-Adenosylmethionine-Dependent Transmethylation as an Approach to the Development of Antiviral Agents" in Antiviral Drug Development - A Multidisciplinary Approach (E. De Clercq and R. T. Walkers, Ed.), Plenum Press, New York, p. 123-138, 1988.

180. S. R. Narayanan and R. T. Borchardt, "An Improved Method for Purification of Bovine Liver S-Adenosylhomocysteine Hydrolase by Affinity Chromatography on Blue Dextran Agarose", *Biochem. Biophys. Acta*, **965**, 22-28 (1988).
181. K. R. Smith, A. Kato and R. T. Borchardt, "Characterization of Specific Receptors for Atrial Natriuretic Factor on Cultured Bovine Brain Capillary Endothelial Cells", *Biochim. Biophys. Res. Commun.*, **157**, 308-314 (1988).
182. D. R. Borcharding, M. Hasobe, S. R. Narayanan, J. McKee, B. Keller and R. T. Borchardt, "Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 11. Molecular Dissections of Neplanocin A as Potential Inhibitors of S-Adenosylhomocysteine Hydrolase", *J. Med. Chem.*, **31**, 1729-1738 (1988).
183. S. R. Narayanan, B. Keller, D. R. Borcharding, S. A. Scholtz, and R. T. Borchardt, 9-(Trans-2',Trans-3'-dihydroxycyclopent-4'-enyl)-Adenine and -3-Deazaadenine: Potent Inhibitors of Bovine Liver S-Adenosylhomocysteine Hydrolase", *J. Med. Chem.*, **31**, 500-503 (1988).
184. R. T. Borchardt, "S-Adenosyl-L-Methionine-Dependent Methyltransferases: Potential Targets for Drug Design" in Perspectives in Psychopharmacology: A Collection of Papers in Honor of Earl Usdin (J. D. Barchas and W. E. Bunney, Jr., Eds.), Alan R. Liss, Inc., New York, NY, p. 281-290, 1988.
185. A. K. Sinhababu and R. T. Borchardt, "Independent Synthesis of 5-hydroxytryptamine-4,7-dione - The Neurocytotoxic Product of Autoxidation of 5,7-Dihydroxytryptamine", *J. Heterocycl. Chem.*, **25**, 1155-1159 (1988).
186. G.K.E. Scriba, R. T. Borchardt, J. A. Zirrollo and P. V. Fennessey, "Selected Ion Monitoring Gas Chromatographic-Mass Spectrometric Analysis of Catecholamines: Enhancement of Sensitivity by a Single Clean-up Step on Sephadex G-10", *J. Chromatography: Biomedical Applications*, **433**, 31-40 (1988).
187. G.K.E. Scriba, J. A. Hower, N. Y. Liang, P. V. Fennessey and R. T. Borchardt, "Effects of Ibopamine and Its Active Metabolite Epinine on the Catecholamine Content of Rat Hypothalamus and Brainstem In Vitro", *J. Pharmacol. Exptl. Therap.*, **247**, 609-616 (1988).
188. I. J. Hidalgo, R. T. Borchardt and T. Raub, "Biochemical, Histological and Physicochemical Characterization of Human Adenocarcinoma Cells (Caco-2) as a Model System for Studying Mucosal Transport and Metabolism of Drugs", *Gastroenterology*, **96**, 736-749 (1989).
189. R. T. Borchardt, N. A. Mazer, J. H. Rytting, E. Shek, E. Ziv, E. Touitou and W. I. Higuchi, "The Delivery of Peptides", *J. Pharm. Sci.*, **78**, 883-892 (1989).
190. K. R. Smith and R. T. Borchardt, "Permeability and Mechanism of Albumin, Cationized Albumin and Glycosylated Albumin Transcellular Transport Across Monolayers of Cultured Brain Capillary Endothelial Cells", *Pharmaceutical Res.*, **6**, 466-473 (1989).
191. M. J. Wolfe, D. R. Borcharding and R. T. Borchardt, "A 9-Step Enantiospecific Total Synthesis of (-) Aristeromycin from D-Ribonolactone", *Tetrahedron Letters*, **30**, 1453-1456 (1989).
192. G.K.E. Scriba and R. T. Borchardt, "Metabolism of Catecholamine Esters by Cultured Bovine Brain Microvessel Endothelial Cells", *J. Neurochem.*, **53**, 610-615 (1989).
193. G.K.E. Scriba and R. T. Borchardt, "Metabolism of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) by Bovine Brain Capillary Endothelial Cell Monolayers", *Brain Res.*, **501**, 175-178 (1989).
194. J. E. Chastain, Jr. and R. T. Borchardt, "L- α -Methyldopa Transport Across Bovine Brain Microvessel Endothelial Cell Monolayers, A Model of the Blood Brain Barrier", *Neurosci. Res. Commun.*, **4**, 147-152 (1989).
195. S. D. Paisley, M. S. Wolfe and R. T. Borchardt, "Oxidation of Neplanocin A to the Corresponding 3'-Ketocyclopentenyl Derivative by S-Adenosylhomocysteine (AdoHcy) Hydrolase", *J. Med. Chem.*, **32**, 1415-1418 (1989).
196. S. D. Paisley and R. T. Borchardt, "Elucidation of the Mechanism by Which 9-(Trans-2'-Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine Inactivates S-Adenosylhomocysteine Hydrolase", *Nucleosides and Nucleotides*, **8**, 689-698 (1989).
197. A. K. Sinhababu and R. T. Borchardt, "Mechanism of Autoxidation of 5,7-Dihydroxytryptamine: ^{18}O is Incorporated on C-4 During Autoxidation with $^{18}\text{O}_2$ ", *J. Amer. Chem. Soc.*, **111**, 2230-2233 (1989).
198. M. V. Shah, K. L. Audus and R. T. Borchardt, "The Application of Bovine Brain Microvessel Endothelial Cell Monolayers Grown Onto Polycarbonate Membranes In Vitro to Estimate the Potential Permeability of Solutes Through the Blood Brain Barrier", *Pharmaceutical Res.*, **6**, 624-627 (1989).
199. M. Hasobe, J. G. McKee, H. Ishii and R. T. Borchardt, "The Relationship Between the Intracellular Concentration of S-

- Adenosylhomocysteine and Inhibition of Vaccinia Virus Replication Versus Inhibition of Murine L929 Cell Growth", *Antimicro. Agents Chemotherap.*, **33**, 828-834 (1989).
200. M. Hasobe, J. G. McKee, H. Ishii, M. Cools, R. T. Borchardt and E. De Clercq, "Elucidation of the Mechanism Responsible for the Synergistic Effects of DL-Homocysteine (Hcy) on the Anti Vaccinia Virus Effects of the S-Adenosylhomocysteine (AdoHcy) Hydrolase Inhibitor 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine", *Mol. Pharmacol.*, **36**, 490-496 (1989).
 201. I. J. Hidalgo, A. Kato and R. T. Borchardt, "Epidermal Growth Factor (EGF) Binding in a Human Colon Carcinoma Cell Line (Caco-2)", *Biochem. Biophys. Res. Commun.*, **158**, 317-324 (1989).
 202. E. De Clercq, M. Cools, V. E. Marquez, D. R. Borcharding, R. T. Borchardt, J. C. Drach, S. Kitaoka and T. Konno, "Broad Spectrum Antiviral Activity of New Neplanocin A Analogs", *Antimicrobial Agents and Chemotherapy*, **33**, 1291-1297(1989).
 203. A. Barancyk-Kuzma, K. L. Audus and R. T. Borchardt, "Substrate Specificity of Phenol Sulfotransferase from Primary Cultures of Bovine Brain Microvessel Endothelium", *Neurochem. Res.*, **14**, 689-691 (1989).
 204. M. Manning, K. Patel and R. T. Borchardt, "Protein Stability: Pharmaceutical Implications", *Pharmaceutical Res.*, **6**, 903-918 (1989).
 205. M. Cools, M. Hasobe, E. De Clercq and R. T. Borchardt, "Mechanism of the Synergistic Antiviral and Cytostatic Activity of (RS)-3-(Adenin-9-yl) 2-Hydroxypropanoic Acid Isobutyl Ester and D,L-Homocysteine", *Biochem. Pharmacol.*, **39**, 195-202 (1990).
 206. I. Votruba, M. Hasobe, A. Holy and R. T. Borchardt, "2-Methylpropyl Ester of 3-(Adenin-9-yl)-2-hydroxypropanoic Acid: Mechanism of Antiviral Action of Vaccinia Virus-Infected L929 Cells", *Biochem. Pharmacol.*, **39**, 1573-1580 (1990).
 207. I. J. Hidalgo and R. T. Borchardt, "Transport of a Large Neutral Amino Acid (Phenylalanine) in a Human Intestinal Epithelial Cell Line: Caco-2", *Biochim. Biophys. Acta*, **1028**, 25-30 (1990).
 208. I. J. Hidalgo and R. T. Borchardt, "Transport of Bile Acids in a Human Intestinal Epithelial Cell Line: Caco-2", *Biochim. Biophys. Acta.*, **1035**, 97-103 (1990).
 209. N. P. Bhatt, K. Patel and R. T. Borchardt, "Chemical Pathways of Peptide Degradation: I. Deamidation of Adrenocorticotrophic Hormone", *Pharmaceutical Res.*, **7**, 593-599 (1990).
 210. K. Patel and R. T. Borchardt, "Chemical Pathways of Peptide Degradation: II. Kinetics of Deamidation of the Asparaginyl Residue in a Model Hexapeptide", *Pharmaceutical Res.*, **7**, 703-711 (1990).
 211. K. Patel and R. T. Borchardt, "Chemical Pathways of Peptide Degradation: III. Effect of Primary Sequence on the Pathways of Deamidation of Asparaginyl Residues in Hexapeptides", *Pharmaceutical Res.*, **7**, 787-793 (1990).
 212. D. L. Kramer, C. W. Porter, R. T. Borchardt and J. R. Sufrin, "Combined Modulation of S-Adenosylmethionine Biosynthesis and S-Adenosylhomocysteine Metabolism Enhances Inhibition of Methylation Reactions and Cell Growth", *Cancer Res.*, **50**, 3838-3842 (1990).
 213. M. Kawase, A. K. Sinhababu and R. T. Borchardt, "Mechanism of Autooxidation of 5,7-Dihydroxytryptamine: Effects of Fluorine Substitution in Positions 4 and/or 6", *Chem. Pharm. Bull.*, **38**, 2939-2946 (1990).
 214. K. Audus, R. Bartel, I. Hidalgo and R. T. Borchardt, "The Use of Cultured Epithelial and Endothelial Cells for Drug Transport and Metabolism Studies", *Pharmaceutical Res.*, **7**, 435-451 (1990).
 215. M. S. Wolfe, B. Anderson, D. R. Borcharding and R. T. Borchardt, "Enantiospecific Syntheses of Aristeromycin and Neplanocin A", *J. Org. Chem.*, **55**, 4712-4717 (1990).
 216. S. M. Ali, K. Ramesh and R. T. Borchardt, "Efficient Enantioselective Syntheses of Carbocyclic Nucleosides and Prostaglandin Synthons", *Tetrahedron Letters*, **31**, 1509-1512 (1990).
 217. M. Kawase, A. K. Sinhababu, E. M. McGhee, T. D. Milby and R. T. Borchardt, "Molecular Mechanism of Neurodegenerative Effects of 5,6-Dihydroxytryptamine. Syntheses and Biological Evaluation of 4-Fluoro-, 7-Fluoro- and 4,7-Difluoro-5,6-dihydroxytryptamines", *J. Med. Chem.*, **33**, 2204-2211 (1990).
 218. J. E. Chastain, Jr. and R. T. Borchardt, "Acivicin Transport Across Bovine Brain Microvessel Endothelial Cell Monolayers, A Model of the Blood Brain Barrier", *Neurosci. Res. Commun.*, **6**, 51-55 (1990).
 219. K. L. Amsberry and R. T. Borchardt, "The Lactonization of 2'-Hydroxyhydrocinnamic Acid Amides: A Potential Prodrug for Amines", *J. Org. Chem.*, **55**, 5867-5877 (1990).

220. P. K. Shah and R. T. Borchardt, "Liquid Chromatographic Analysis of Leu-Enkephalin and Its Metabolites in Homogenates of Human Skin and Cultured Human Keratinocytes", *J. Pharm. Biomed. Anal.*, **8**, 457-462 (1990).
221. K. Patel and R. T. Borchardt, "Deamidation of Asparaginyl Residues in Proteins: A Potential Pathway for Chemical Degradation of Proteins in Lyophilized Dosage Forms", *J. Parenteral Sci. Technol.*, **44**, 300-301 (1990).
222. R. T. Borchardt, "Assessment of Transport Barriers Using Cell and Tissue Culture Systems", *Drug Devel. Indust. Pharm.*, **18**, 2595-2612 (1990).
223. P. K. Shah, I. Hidalgo and R. T. Borchardt, "A Simple Diffusion Device to Study Transport Across Cells Cultured on Microporous Membranes", *Int. J. Pharmaceutics*, **63**, 281-283 (1990).
224. M. Hu and R. T. Borchardt, "Mechanism of L- α -Methyldopa Transport Through a Monolayer of Polarized Human Intestinal Epithelial Cells (Caco-2)", *Pharmaceutical Res.*, **7**, 1313-1319 (1990).
225. K. Audus and R. T. Borchardt, "Transport of Macromolecules Across the Capillary Endothelium" in Handbook of Experimental Pharmacology (R. L. Juliano, Ed.), Springer, Berlin, p. 43-70, 1991.
226. J. B. Baker, I. Hidalgo and R. T. Borchardt, "Intestinal Epithelial and Vascular Endothelial Barriers to Peptide and Protein Delivery" in Peptide and Protein Drug Delivery (V.H.L. Lee, Ed.), Marcel Dekker, Inc., New York, p. 359-390, 1991.
227. G.K.E. Scriba and R. T. Borchardt, "Metabolism of Catecholamine Prodrugs in Cultured Brain Microvessel Endothelial Cells" in Pharmaceutical Applications of Cell and Tissue Culture to Drug Transport (G. Wilson, S. S. Davis and L. Illum, Eds.), Plenum Press, New York, p. 191-202 (1991).
228. I. J. Hidalgo and R. T. Borchardt, "Carrier-Mediated Transport of Bile Acids and Amino Acids in Caco-2 Cells", in Pharmaceutical Applications of Cell and Tissue Culture to Drug Transport (G. Wilson, S. S. Davis and L. Illum, Eds.), Plenum Press, New York, p. 77-92 (1991).
229. R. T. Borchardt, I. J. Hidalgo, K. M. Hillgren and M. Hu, "Pharmaceutical Applications of Cell Culture - An Overview", in Pharmaceutical Applications of Cell and Tissue Culture to Drug Transport (G. Wilson, S. S. Davis and L. Illum, Eds.), Plenum Press, New York, p. 1-14 (1991).
230. P. K. Shah and R. T. Borchardt, "A Comparison of Aminopeptidase Activity and Peptide Metabolism in Cultured Mouse Keratinocytes and Neonatal Mouse Epidermis", *Pharmaceutical Res.*, **8**, 70-75 (1991).
231. I. J. Hidalgo, K. M. Hillgren, G. M. Grass and R. T. Borchardt, "Characterization of the Unstirred Water Layer in Caco-2 Cells Using a Novel Diffusion Cell", *Pharmaceutical Res.*, **8**, 223-227 (1991).
232. J. C. Yeh, R. T. Borchardt and A. Vedani, "A Molecular Model of the Active Site of S-Adenosylhomocysteine Hydrolase", *J. Computer-Aided Mol. Design*, **5**, 213-234 (1991).
233. P. K. Shah, R. L. Bartel and R. T. Borchardt, "Permeability Characteristics of Cultured Mouse Keratinocytes Compared to Hairless Mouse Skin", *Int. J. Pharmaceutics*, **68**, 285-288 (1991).
234. K. L. Amsberry and R. T. Borchardt, "Prodrugs Which Utilize Hydroxy Amide Lactonization I: A Potential Redox Sensitive Prodrug for Amines", *Pharmaceutical Res.*, **8**, 323-330 (1991).
235. K. L. Amsberry, A. E. Gerstenberger and R. T. Borchardt, "Prodrugs Which Utilize Hydroxy Amide Lactonization II: A Potential Esterase Sensitive Prodrug for Amines", *Pharmaceutical Res.*, **8**, 455-461 (1991).
236. M. S. Wolfe and R. T. Borchardt, "S-Adenosyl-L-homocysteine Hydrolase as a Target for Antiviral Chemotherapy", *J. Med. Chem.*, **34**, 1521-1530 (1991).
237. J. R. Sufrin, A. J. Spiess, D. L. Kramer, P. R. Libby, J. T. Miller, R. T. Bernacki, Y. Lee, R. T. Borchardt and C. W. Porter, "Targeting 5'-Deoxy-5'-(methylthio)-adenosine Phosphorylase by 5'-Haloalkyl Analogues of 5'-Deoxy-5'-(methylthio) adenosine", *J. Med. Chem.*, **34**, 2600-2606 (1991).
238. Y. Takakura, K. Audus and R. T. Borchardt, "Blood-Brain Barrier: Transport Studies in Isolated Brain Capillaries and in Cultured Brain Endothelial Cells", in Advances in Pharmacology (J. T. August, M. W. Anders, F. Muirad, Eds.), Academic Press, San Diego, CA, Vol. 22, p. 137-165, 1991.
239. Y. Takakura, S. L. Kuentzel, T. Raub, A. Davies, S. A. Baldwin and R. T. Borchardt, "Hexose Uptake in Primary Cultures of Bovine Brain Microvessel Endothelial Cells I. Basic Characteristics and Effects of D-Glucose and Insulin", *Biochim. Biophys. Acta*, **1070**, 1-10 (1991).

240. Y. Takakura, A. Trammel, S. L. Kuentzel, T. J. Raub, A. Davies, S. A. Baldwin and R. T. Borchardt, "Hexose Uptake in Primary Cultures of Bovine Brain Microvessel Endothelial Cells. II. Effect of Conditioned Media from Astroglial and Glioma Cells", *Biochim. Biophys. Acta*, 1070, 11-19 (1991).
241. A. Baranczyk-Kuzma, J. A. Garren, I. J. Hidalgo and R. T. Borchardt, "Substrate Specificity and Some Properties of Phenol Sulfotransferase from Human Intestinal Caco-2 Cells", *Life Sci.*, 49, 1197-1206 (1991).
242. A. Baranczyk-Kuzma, K. L. Audus, F. L. Guillot and R. T. Borchardt, "Effects of Selected Vasoactive Substances on Adenylate Cyclase Activity in Brain, Isolated Brain Microvessels and Primary Cultures of Brain Microvessel Endothelial Cells", *Neurochemical Research*, 17, 209-214 (1992).
243. Y. Takakura, K. Audus and R. T. Borchardt, "Cultured Brain Microvessel Endothelial Cells as *In Vitro* Models of the Blood Brain Barrier", in "Drug Bioavailability and Blood Brain Barrier" (J. Frankenheim and R. M. Brown, Eds.), National Institute of Drug Abuse Research Monograph, #120, DHHS Pub. No. (ADM) 92-1910, Washington, DC, Supt. of Docs., U.S. Govt. Printing Office, pp. 138-152, 1992.
244. M. S. Wolfe, Y. Lee, W. K. Bartlett, D. R. Borcharding and R. T. Borchardt, "4'-Modified Analogs of Aristeromycin and Neplanocin A: Syntheses and Inhibition of S-Adenosylhomocysteine Hydrolase", *J. Med. Chem.*, 35, 1782-1791 (1992).
245. I. J. Hidalgo, K. M. Hillgren, G. M. Grass and R. T. Borchardt, "A New Side by Side Diffusion Cell Useful for Studying Transport Across Epithelial Cell Monolayers", *In Vitro-Cellular and Developmental Biology*, 28A, 578-580, 1992.
246. K. Audus, P. Chikhale, D. Miller S. E. Thompson and R. T. Borchardt, "Brain Uptake: Influence of Chemical and Biological Factors" in "Advances in Drug Research" (B. Testa, Ed.), Academic Press, London, Vol. 23, 1-64, 1992.
247. S. Liu, M. S. Wolfe and R. T. Borchardt, "Rational Approaches to the Design of Antiviral Agents Based on S-Adenosyl-L-homocysteine Hydrolase as a Molecular Target", *Antiviral Research*, 19, 247-265 (1992).
248. C. Oliyai, C. Schoneich, G. Wilson and R. T. Borchardt, "Chemical and Physical Stability of Protein Pharmaceuticals" in "Topics in Pharmaceutical Sciences - 1991", (D.J.A. Crommelin and K. K. Midha, Eds.), Medpharm Scientific Publishers, Stuttgart, 23-46 (1992).
249. M. Hu and R. T. Borchardt, "Transport of a Large Neutral Amino Acid in a Human Intestinal Epithelial Cell Line (Caco-2): Uptake and Efflux of Phenylalanine", *Biochim. Biophys. Acta*, 1135, 233-244 (1992).
250. D. Miller, K. Audus and R. T. Borchardt, "Application of Cultured Endothelial Cells of the Brain Microvasculature in the Study of the Blood Brain Barrier", *J. Tissue Cult. Meth.*, 14, 217-224 (1992).
251. M. J. Robins, V. Samano, W. Zhang, J. Balzarini, E. DeClercq, R. T. Borchardt, Y. Lee and C. S. Yuan, "Nucleic Acid Related Compounds. 74, Synthesis and Biological Activity of 2' (and 3')-Deoxy 2'(and 3')-Methylene Nucleoside Analogs that Function as Mechanism-Based Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase and/or Ribonucleotide Reductase", *J. Med. Chem.*, 35, 2283-2293 (1992).
252. K. Ramesh, M. S. Wolfe, Y. Lee., D. Vander Velde and R. T. Borchardt, "Synthesis of Hydroxylated Cyclohexenyl and Cyclohexenyl Adenines as Potential Inhibitors of S-Adenosylhomocysteine Hydrolase", *J. Org. Chem.*, 57, 5861-5868 (1992).
253. R. A. Gray, D. G. Vander Velde, R. T. Borchardt, C. J. Burke, C. R. Middaugh and M. C. Manning, "The Use of Computer-Aided Modeling to Understand Peptide Transport", *Chemical Design Automation News*, 7, 36-39, 1992.
254. R. T. Borchardt, "Rational Delivery Strategies to Circumvent Physical and Metabolic Barriers to the Oral Absorption of Peptides" in "Oral Delivery of Peptides-From Theory to Practice, 1991", Capsugel, Basel, Switzerland, pp. 11-19, 1992.
255. C. L. Stevenson, T. D. Williams, R. J. Anderegg and R. T. Borchardt, "Identification and Quantification of Tetrapeptide Deamidation Products by Mass Spectrometry", *J. Pharm. Biomed. Anal.*, 10, 567-575 (1992).
256. J. L. Wolfe, D. Vander Velde and R. T. Borchardt, "Facilitated Intramolecular Conjugate Addition of Amides of 3-(3',6'-Dioxo-2',4'-Dimethyl-1',4'-Cyclohexadiene 3,3-Dimethylpropionic Acid. I. Product Elucidation", *J. Org. Chem.*, 57, 6138-6142 (1992).
257. A. Baranczyk-Kuzma, K. L. Audus and R. T. Borchardt, "Properties of Phenol Sulfotransferase from Brain of the Monkey Rhesus Macaque" *Acta Biochim Polon.*, 39, 153-158 (1992).
258. S. Liu, S. M. Ali, M. S. Wolfe, C. S. Yuan and R. T. Borchardt, "Syntheses and Evaluation of 4',5'-Dehydro-5'-Fluoroaristeromycins as Inhibitors of S-Adenosyl-L-Homocysteine Hydrolase", *Bioorg. Med. Chem. Letters*, 2, 1741-1744 (1992).
259. H. Ishii, M. Hasobe, J. G. McKee and R. T. Borchardt, "Synergistic Antiviral Effects of Inhibitors of S-

- Adenosylhomocysteine Hydrolase and Ribavirin, *Antiviral Chem. Chemotherap*, **4**, 127-130 (1993).
260. C. Oliyai and R. T. Borchardt, "Chemical Pathways of Peptide Degradation. IV. Pathways, Kinetics and Mechanism of Degradation of an Aspartyl Residue in a Model Hexapeptide", *Pharmaceutical Res.*, **10**, 95-102 (1993).
 261. A. Baranczyk-Kuzma, K. L. Audus and R. T. Borchardt, "Sulfation of Catecholamines, Hypertensive and Hypotensive Drugs by Monkey Brain Cortex Enzymes, *Acta Biochim. Polan.*, **40**, 189-192 (1993).
 262. C. S. Yuan, J. Yeh, S. Liu and R. T. Borchardt, "Mechanism of Inactivation of S-Adenosylhomocysteine Hydrolase by (Z)-4',5'-Didehydro-5'-Deoxy-5'-Fluoroadenosine", *J. Biol. Chem.*, **268**, 17030-17037 (1993).
 263. S. Raeissi and R. T. Borchardt, "Cultured Human Adenocarcinoma Cells (Caco-2) As a Model to Study the Mechanism by Which Adjuvants Enhance Intestinal Permeability of Drugs", *S.T.P. Pharma Sciences*, **3**, 56-62 (1993).
 264. Ka-Yun Ng and R. T. Borchardt, "Biotin Transport in a Human Intestinal Epithelial Cell Line (Caco-2)", *Life Sci.*, **53**, 1121-1127 (1993).
 265. C. S. Yuan, J. Yeh, T. C. Squier, A. Rawitch and R. T. Borchardt, "Ligand-Dependent Intrinsic Fluorescence Changes of S-Adenosylhomocysteine Hydrolase: Implications About the Mechanism of Inhibitor Induced Inactivation", *Biochemistry*, **32**, 10414-10422 (1993).
 266. M. Hasobe, H. Liang, D. B. Ault-Riche, D. Borcharding, M. S. Wolfe and R. T. Borchardt, "(1'R,2'S,3'R)-9-(2',3'-dihydroxycyclopentan-1'-cyl)-Adenine and -3-Deazaadenine: Analogs of Aristeromycin Which Exhibit Potent Antiviral Activity with Reduced Cytotoxicity", *Antiviral Chemistry and Chemotherapy.*, **4**, 245-248 (1993).
 267. D. B. Ault-Riche, Y. Lee, C.-S. Yuan, M. Hasobe, M. S. Wolfe, D. R. Borcharding and R. T. Borchardt, "Effects of 4'-Modified Analogs of Aristeromycin on Metabolism of S-Adenosylhomocysteine in Mouse L929 Cells", *Mol. Pharmacol.*, **43**, 989-997 (1993).
 268. A. S. Tang, P. J. Chikhale, P. K. Shah and R. T. Borchardt, "Utilization of a Human Intestinal Epithelial Cell Culture System (Caco-2) for Evaluating Cytoprotective Agents", *Pharmaceutical Res.*, **10**, 1620-1626 (1993).
 269. C. L. Stevenson, R. J. Anderegg and R. T. Borchardt, "Probing the Helical Content of Growth Hormone Releasing Factor Analogs Using Electrospray Mass Spectrometry", *J. Amer. Soc. Mass Spectrometry*, **4**, 646-651 (1993).
 270. C. L. Stevenson, R. J. Anderegg and R. T. Borchardt, "Comparison of Separation and Detection Techniques for Human Growth Hormone Releasing Factor and the Products Derived from Deamidation", *J. Pharm. Biomed. Anal.*, **11**, 367-373 (1993).
 271. C. L. Stevenson, M. E. Donlan, A. R. Friedman and R. T. Borchardt, "Solution Conformation of Leu²⁷-hGRF (1-32) NH₂ and Its Deamidation Products by 2D NMR", *Int. J. Peptide Protein Res.*, **42**, 24-32 (1993).
 272. C. L. Stevenson, A. R. Friedman, T. M. Kubiak, M. E. Donlan, and R. T. Borchardt, "Effect of Secondary Structure on the Rate of Deamidation of Several Growth Hormone Releasing Factor Analogs", *Int. J. Peptide Protein Res.*, **42**, 497-503 (1993).
 273. Shihong Li, C. Schöneich, G. S. Wilson and R. T. Borchardt, "Chemical Pathways of Peptide Degradation. V. Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulfoxide in Small Model Peptides", *Pharmaceutical Res.*, **10**, 1572-1579 (1993).
 274. D. C. Kim, P. S. Burton and R. T. Borchardt, "The Correlation of the Permeability Coefficients for a Series of Peptides Using an In Vitro Cell Culture Model (Caco-2) and Those Using In Situ Perfused Rat Intestinal Model", *Pharmaceutical Res.*, **10**, 1710-1714 (1993).
 275. S. Liu, S. Wnuk, M. J. Robins, C. S. Yuan and R. T. Borchardt, "Adenosine 5'-Carboxaldehyde: A Potent Inhibitor of S-Adenosyl-L-homocysteine Hydrolase", *J. Med. Chem.*, **36**, 883-887 (1993).
 276. Ka-yun Ng, G. Grass, H. Lane and R. T. Borchardt, "Characterization of the Unstirred Water Layer in Cultured Brain Microvessel Endothelial Cells", *In Vitro Cell Dev. Biol.*, **29A**, 627-629 (1993).
 277. A. Baranczyk-Kuzma, D. Drobisz, K. L. Audus and R. T. Borchardt, "Sulfation of Hypertensive and Hypotensive Drugs by Monkey Brain Phenol Sulfotransferase", *Neurochem. Res.*, **18**, 783-786 (1993).
 278. C. Schöneich, F. Zhao, G. S. Wilson and R. T. Borchardt, "Iron-Thiolate Induced Oxidation of Methionine to Methionine Sulfoxide in Small and Medium Sized Model Peptides. Catalysis by Histidine", *Biochim. Biophys. Acta*, **1158**, 307-322 (1993).
 279. D. C. Kim, A. W. Harrison, M. J. Ruwart, K. F. Wilkinson, J. F. Fisher, I. J. Hidalgo and R. T. Borchardt, "Evaluation of

- the Bile Acid Transporter for the Enhancement of Renin-Inhibitory Peptide Intestinal Permeability", *J. Drug Targeting*, **1**, 347-359 (1993).
280. M. J. Robins, S. F. Wnuk, K. B. Mullah, N. K. Dalley, R. T. Borchardt, Y. Lee and C. S. Yuan, "Adenosine-Derived 5'- α -Fluoro Thioether, Sulfoxide, Sulfone and (5'-Halo) Methylene Analogous. Inhibition of S-Adenosyl-L-homocysteine Hydrolase" in *Nucleosides and Nucleotides as Antitumor and Antiviral Agents* (C. K. Shu and D. C. Baker, Eds.), Plenum Press, New York, NY, pp. 115-126, 1993.
 281. C. Oliyai and R. T. Borchardt, "Chemical Instability of Proteins in Solution and Lyophilized Formulations" in "Protein Formulations and Delivery" (J. Cleland and R. Langer, Eds.), ACS Symposium Series, Washington, DC, p. 46-58, 1994.
 282. E. Brunt Chikhale, Ka-yun Ng, P. S. Burton and R. T. Borchardt, "Hydrogen Bond Potential as a Determinant of the In Vitro and In Situ Blood Brain Barrier Permeability of Peptides", *Pharmaceutical Res.*, **11**, 412-419 (1994).
 283. M. J. Robins, S. F. Wnuk, K. B. Mullah, N. K. Dulley, C. S. Yuan, Y. Lee and R. T. Borchardt, "Nucleic Acid Related Compounds. 80. Synthesis of 5'-S-(Alkyl and Aryl)-5'-Fluoro-5'-Thioadenosines with Xenon Difluoride or (Diethylamino) Sulfur Trifluoride, Hydrolysis in Aqueous Buffer and Inhibition of S-Adenosyl-L-homocysteine Hydrolase by Adenosine 5'-Aldehyde-Derived Species", *J. Org. Chem.*, **59**, 544-555 (1994).
 284. R. Gray, D. Vander Velde, C. J. Burke, M. Manning, C. R. Middaugh and R. T. Borchardt, "Delta-Sleep Inducing Peptide: Investigation of Its Solution Structure(s) and Its Potential Relationship to Permeability", *Biochemistry*, **33**, 1323-1331 (1994).
 285. X. Guan and R. T. Borchardt, "A Convenient Method for the Syntheses of Indole-3-Acetic Acids", *Tetrahedron Letters*, **35**, 3013-3016 (1994).
 286. C. Oliyai and R. T. Borchardt, "Chemical Pathways of Peptide Degradation. VI. Effects of Primary Sequence on the Pathways and Kinetics of Degradation of an Aspartyl Residue in a Model Hexapeptide", *Pharmaceutical Res.*, **11**, 751-758 (1994).
 287. C. Oliyai, J. Patel, L. Carr and R. T. Borchardt, "Solid State Stability of Lyophilized Formulations of an Asparaginyl Residue in a Model Hexapeptide", *J. Parenteral Sci. Tech.*, **48**, 167-173 (1994).
 288. C. Oliyai, J. P. Patel, L. Carr and R. T. Borchardt, "Chemical Pathways of Peptide Degradation. VII. Kinetics and Mechanism of Degradation of Lyophilized Formulations of an Aspartyl Residue in a Model Hexapeptide", *Pharmaceutical Res.*, **11**, 901-908 (1994).
 289. R. J. Anderegg, D. Wagner, C. Stevenson and R. T. Borchardt, "The Mass Spectrometry of Helical Unfolding in Peptides", *J. Amer. Chem. Soc. Mass Spectrom.*, **5**, 425-433 (1994).
 290. I. Islam, K. Y. Ng, K. T. Chang, T. J. McQuade, J. O. Hui, K. F. Wilkinson, B. D. Rush, M. J. Ruwart, R. T. Borchardt and J. F. Fisher, "Evaluation of a Vitamin Clocking Strategy for Improving the Availability of Oligopeptide Therapeutics: Biotinylated HIV Protease Inhibitors", *J. Med. Chem.*, **37**, 293-304 (1994).
 291. D. Miller, B. T. Keller and R. T. Borchardt, "Identification and Distribution of Insulin Receptors in Cultured Bovine Brain Microvessel Endothelial Cells: Possible Function in Insulin Processing in the Blood Brain Barrier", *J. Cellular Physiol.*, **161**, 333-341 (1994).
 292. C. S. Yuan, S. Liu, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "Mechanism of Inactivation of S-Adenosylhomocysteine Hydrolase by (E)-5',6'-Didehydro-6'-Deoxy-6'-Halo-Homoadenosine", *Biochemistry*, **33**, 3758-3765 (1994).
 293. R. T. Borchardt, "Rational Strategies to Enhance the Intestinal Permeability of Peptides" in *Peptides: Chemistry, Structure and Biology-Proceedings of the 13th American Peptide Symposium* (R. S. Hodges and J. A. Smith, Eds.), Escom Science Publishers, B.V., Leiden, The Netherlands, pp. 827-829, 1994.
 294. R. T. Borchardt, "Rational Strategies for the Design of Peptides with Enhanced Oral Delivery", *Drug Devel. Indust. Pharm.*, **20**, 469-483 (1994).
 295. C. S. Yuan, S. F. Wnuk, S. Liu, M. J. Robins and R. T. Borchardt, "(E)-5',6'-Didehydro-6'-Deoxy-6'-Fluoro-Homoadenosine: A Substrate that Measures the Hydrolytic Activity of S-Adenosylhomocysteine Hydrolase", *Biochemistry*, **33**, 12305-12311 (1994).
 296. P. J. Chikhale and R. T. Borchardt, "Metabolism of α -MethylDOPA in Cultured Intestinal Epithelial (Caco-2) Cells: Correlation with Metabolism *In Vivo*", *Drug Metab. Dispos.*, **22**, 592-601 (1994).
 297. S. F. Wnuk, C. S. Yuan, R. T. Borchardt, J. Balzarini, E. DeClercq and M. J. Robins, "Nucleic Acid Related Compounds 84. Synthesis of 6'(E and Z)-Halogenohomovinyl Derivatives of Adenosine, Inactivation of S-Adenosyl-L-

- homocysteine Hydrolase and Correlation of Anticancer and Antiviral Activities with Enzyme Inhibition", *J. Med. Chem.*, **37**, 3579-3587 (1994).
298. D. B. Ault-Riche, C. S. Yuan and R. T. Borchardt, "A Single Mutation at Lysine 426 of Human Placental S-Adenosylhomocysteine Hydrolase Inactivates the Enzyme", *J. Biol. Chem.*, **269**, 31472-31478 (1994).
 299. D. W. Miller, L. Ng, A. Kato, E. Chikhale and R. T. Borchardt, "Cell Culture Models for Examining Peptide Absorption" in "Peptide-Based Drug Design: Controlling Transport and Metabolism" (M. Taylor and G. Amidon, Eds.), ACS Books, Washington, DC, pp. 475-500, 1995.
 300. L. S. Jeong, V. E. Marquez, C. S. Yuan and R. T. Borchardt, "4,1'- α -Methanocarbocyclic Adenosine Analogues as Potential Inhibitors of S-Adenosylhomocysteine Hydrolase", *Heterocycles*, **41**, 2651-2656 (1995).
 301. S. Li, C. Schöneich and R. T. Borchardt, "Chemical Pathways of Peptide Degradation. VIII. Oxidation of Methionine in Small Model Peptides by Prooxidant/Transition Metal Ion Systems: Influence of Selective Scavengers for Reactive Oxygen Intermediates", *Pharm. Res.*, **12**, 348-355 (1995).
 302. E. G. Chikhale, P. S. Burton and R. T. Borchardt, "The Effects of P-Glycoprotein on the Transport of Peptides Across the Blood-Brain Barrier in Rats", *J. Pharmacol. Exptl. Therap.*, **273**, 298-303 (1995).
 303. E. G. Chikhale, P. J. Chikhale and R. T. Borchardt, "Carrier-Mediated Transport of the Antitumor Agent Acivicin Across the Blood-Brain Barrier", *Biochem. Pharmacol.*, **49**, 941-945 (1995).
 304. C. S. Yuan, S. Liu, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "Rational Approaches to the Design of Mechanism-Based Inhibitors of S-Adenosylhomocysteine Hydrolase", *Nucleosides and Nucleotides*, **14**, 439-447 (1995).
 305. A. Baranczyk-Kuzma, I. Barszczewska, R. T. Borchardt and K. L. Audus, "Sulfate Conjugation of Catecholamines and Their Derivatives in Monkey Brain", *Biogenic Amines*, **11**, 281-294 (1995).
 306. K. Hillgren, A. Kato and R. T. Borchardt, "In Vitro Models to Study Intestinal Drug Absorption", *Med. Res. Rev.*, **15**, 83-109 (1995).
 307. S. Li, C. Schöneich and R. T. Borchardt, "Chemical Instability of Protein Pharmaceuticals: Mechanisms of Oxidation and Strategies for Stabilization", *Biotech. Bioeng.*, **48**, 490-500 (1995).
 308. B. Wang, S. Liu and R. T. Borchardt, "The Development of a Novel Redox Sensitive Protecting Group for Amines Which Utilizes a Facilitated Lactonization Reaction", *J. Org. Chem.*, **60**, 539-543 (1995).
 309. S. Li, T. H. Nguyen, C. Schöneich and R. T. Borchardt, "Metal-Catalyzed Oxidation of Human Relaxin", *Biochemistry*, **34**, 5762-5772 (1995).
 310. Y. Takakura, T. Morita, M. Fujikawa, M. Hayashi, H. Sezaki, M. Hashida and R. T. Borchardt, "Characterization of LLC-PK1 Kidney Epithelial Cells as an In Vitro Model for Studying Renal Tubular Reabsorption of Protein Drugs", *Pharmaceutical Res.*, **12**, 1968-1972 (1995).
 311. R. Gupta, C. S. Yuan, D. B. Ault-Riche and R. T. Borchardt, "Limited Proteolysis of S-Adenosylhomocysteine Hydrolase. Implication for Three-Dimensional Structure and for Conformational Changes", *Arch. Biochem. Biophys.*, **319**, 365-371 (1995).
 312. R. T. Borchardt, "The Application of Cell Culture Systems in Drug Discovery and Development" (Editorial), *J. Drug Targeting*, **3**, 179-182 (1995).
 313. S. Li, C. Schöneich and R. T. Borchardt, "The Chemical Instability of Proteins", *Pharmaceutical News*, **2**, 12-16 (1995).
 314. P. F. Augustijns, K. Y. Ng, T. M. Williams and R. T. Borchardt, "Peptide Dipeptidase A Catalyzed Degradation of Delta Sleep-Inducing Peptide in Cultured Microvessel Endothelial Cells", *Biochem. Biophys. Res. Commun.*, **210**, 987-994 (1995).
 315. C. S. Yuan and R. T. Borchardt, "Photoaffinity Labeling of S-Adenosylhomocysteine Hydrolase by 8-Azidoadenosine Dialdehyde: Identification of Peptides in the Adenosine Binding Site", *J. Biol. Chem.*, **270**, 16140-16146 (1995).
 316. P. F. Augustijns and R. T. Borchardt, "Transport and Metabolism of Delta Sleep-Inducing Peptide (DSIP) in Cultured Human Intestinal Epithelial (Caco-2) Cell Monolayers", *Drug Metab. Dispos.*, **23**, 1372-1378 (1995).
 317. R. T. Borchardt, H. K. Lane, B. H. Hirst, P. L. Smith, K. L. Audus and A. Tsuji, "Application of Cell Culture Systems to Study Drug Transport and Metabolism" in Pharmacological Sciences' Perspective for Research and Therapy in the late 1990's, Birkhauser, Germany, 493-501 (1995).

318. C. S. Yuan, S. Liu, S. Wnuk, M. J. Robins and R. T. Borchardt, "Design and Synthesis of S-Adenosylhomocysteine Hydrolase as Broad-Spectrum Antiviral Agents" in Advances in Antiviral Drug Design (E. De Clercq, Ed.), JAI Press, Inc., Greenwich, CT, Vol. 2, 41-88, 1996.
319. I. Islam, R. R. Hinshaw, K. T. Chong, A. Kato, R. T. Borchardt and J. F. Fisher, "Synthesis and Antiviral Activity of [2-[[4-[3-[(1-Methylethyl)amino]-2-Pyridyl]-1-Piperazinyl]-1H-Indol-5-yl] (BHAP) Acylspingosine HIV Reverse Transcriptase Inhibitors", *Bioorg. Chem.*, **23**, 499-511 (1996).
320. R. T. Borchardt, "Physicochemical and Biochemical Factors that Influence the Oral Delivery of Peptide Mimetics" in Peptides: Chemistry, Structure and Biology (Kaumaya, P. T. P. and Hodges, R. S., Eds.), Escom Science Publishers, B. V. Leiden, The Netherlands, pp. 902-904, 1996.
321. B. Wang, M. Nicolaou, S. Liu and R. T. Borchardt, "Structural Analyses of a Facile Lactonization System Facilitated by a Trimethyl Lock", *Bioorg. Chem.*, **24**, 39-49 (1996).
322. G. M. Pauletti, S. Gangwar, G. T. Knipp, M. N. Nerurkar, F. W. Okumu, K. Tamura, T. J. Siahaan and R. T. Borchardt, "Structural Requirements for Intestinal Absorption of Peptide Drugs", *J. Controlled Release*, **41**, 3-17 (1996).
323. W. Wang, M. J. Merrill and R. T. Borchardt, "Vascular Endothelial Growth Factor Affects the Permeability of Brain Microvessel Endothelial Cells *In Vitro*", *Amer. J. Physiol.*, **271**, C1973-C1980 (1996).
324. M. G. Nicolaou, J. L. Wolfe, R. L. Schowen and R. T. Borchardt, "Facilitated Intramolecular Conjugate Addition of Amides of 3-(3',6'-Dioxo-2',4'-Dimethyl-1',4'-Cyclohexadiene) 3,3-Dimethylpropionic Acid. II. Kinetics of Degradation", *J. Org. Chem.*, **61**, 6633-6638 (1996).
325. K. Tamura, C. P. Lee, P. L. Smith and R. T. Borchardt, "Effect of Charge on the Oligopeptide Transporter-Mediated Permeation of Cyclic Dipeptides Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **13**, 1752-1754 (1996).
326. R. A. Conradi, P. S. Burton and R. T. Borchardt, "Physicochemical and Biological Factors that Influence a Drug's Cellular Permeability by Passive Diffusion" in Lipophilicity in Drug Action and Toxicity (V. Pliska, B. Testa and H. Vande Waterbeend, Eds.), VCH Weinheim, Weinheim, pp. 233-252, 1996.
327. S. Liu, B. Wang, M. G. Nicolaou and R. T. Borchardt, "Trimethyl Lock Facilitated Spirocyclizations: A Structural Analysis", *J. Chem. Crystallography*, **26**, 209-214 (1996).
328. R. T. Borchardt, "Rational Design of Peptides with Enhanced Membrane Permeability", in "Medicinal Chemistry Today and Tomorrow" (M. Yamazaki, Ed.), Blackwell Science, Oxford, pp. 191-196 (1996).
329. S. Li, T. Patapoff, D. Overcashier, T. H. Nguyen and R. T. Borchardt, "Effects of Reducing Sugars on the Chemical Stability of Human Relaxin in the Lyophilized State", *J. Pharm. Sci.*, **85**, 873-877 (1996).
330. S. Li, T. Patapoff, T. H. Nguyen and R. T. Borchardt, "Inhibitory Effect of Sugars and Polyols on the Metal-Catalyzed Oxidation of Human Relaxin", *J. Pharm. Sci.*, **85**, 868-872 (1996).
331. R. T. Borchardt, G. Wilson and P. Smith, "General Principles in the Characterization and Use of Model Systems for Biopharmaceutical Assessment" in Model Systems Used for Biopharmaceutical Assessment of Drug Absorption and Metabolism (R. T. Borchardt, G. Wilson, P. Smith, Eds.), Plenum Press, New York, 1-11, 1996.
332. K. Audus, L. Ng, W. Wang and R. T. Borchardt, "Brain Microvessel Endothelial Cell Culture Systems" in Model Systems Used for Biopharmaceutical Assessment of Drug Absorption and Metabolism (R. T. Borchardt, G. Wilson, P. Smith, Eds.), Plenum Press, New York, 239-258, 1996.
333. P. S. Burton, R. A. Conradi, N. F. H. Ho, A. R. Hilgers and R. T. Borchardt, "How Structural Features Influence the Permeability of Peptides", *J. Pharm. Sci.*, **85**, 1336-1340 (1996).
334. M. Xie, R. T. Borchardt, D. Vander Velde, M. Morton and R. L. Schowen, "pH-Induced Change in the Rate-Determining Step for the Hydrolysis of the Asp/Asn-Derived Cyclic Imide Intermediate in Protein Degradation", *J. Amer. Chem. Soc.*, **118**, 8955-8956 (1996).
335. M. M. Nerurkar, P. S. Burton and R. T. Borchardt, "The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System", *Pharmaceutical Res.*, **13**, 528-534 (1996).
336. S. Liu, C. S. Yuan and R. T. Borchardt, "Aristeromycin 5'-Carboxaldehyde: A Potent Inhibitor of S-Adenosyl-L-homocysteine Hydrolase", *J. Med. Chem.*, **39**, 2347-2353 (1996).
337. S. Gangwar, S. D. S. Jois, T. J. Siahaan, D. G. Vander Velde, V. J. Stella and R. T. Borchardt, "The Effect of Conformation on Membrane Permeability of an Acyloxyalkoxy-linked Cyclic Prodrug of a Model Hexapeptide",

338. S. F. Wnuk, S. Liu, C. S. Yuan, R. T. Borchardt and M. J. Robins, "Inactivation of S-Adenosyl-L-homocysteine Hydrolase by Amide and Ester Derivatives of Adenosine 5'-Carboxylic Acid", *J. Med. Chem.*, **39**, 4162-4166 (1996).
339. K. Tamura, P. K. Bhatnagar, J. S. Takata, C. P. Lee, P. L. Smith and R. T. Borchardt, "Metabolism, Uptake and Transepithelial Transport of the Diastereomers of Val-Val in the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **13**, 1213-1218 (1996).
340. K. Tamura, C. P. Lee, P. L. Smith and R. T. Borchardt, "Metabolism, Uptake and Transepithelial Transport of the Stereoisomers of Val-Val-Val in the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **13**, 1663-1667 (1996).
341. R. T. Borchardt, "Chair Report of the Research and Graduate Affairs Committee", *Amer. J. Pharm. Educ.*, **60**, 285-285 (1996).
342. M. Nicolaou and R. T. Borchardt, "Phosphate Prodrugs of Amines Which Utilize a Fast Hydroxy Amide Lactonization", *J. Org. Chem.*, **61**, 8636-8641 (1996).
343. C. S. Yuan, D. B. Ault-Riche and R. T. Borchardt, "Chemical Modification and Site-Directed Mutagenesis of Cysteine Residues in Human Placental S-Adenosylhomocysteine Hydrolase", *J. Biol. Chem.*, **271**, 28009-28016 (1996).
344. G. M. Pauletti, S. Gangwar, F. W. Okumu, T. J. Siahaan, D. G. Vander Velde, V. J. Stella and R. T. Borchardt, "Esterase-sensitive Cyclic Prodrugs of Peptides: Evaluation of an Acyloxyalkoxy Pro-moiety in a Model Hexapeptide", *Pharmaceutical Res.*, **13**, 1615-1623 (1996).
345. L. Kupczyk-Subotkowska, K. Tamura, D. Pal, T. Sakaeda, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Melfalan Analogs and Prodrugs Designed to Enhance Accumulation in Cancer Cells", *J. Drug Targeting*, **4**, 359-370 (1997).
346. G. M. Pauletti, S. Gangwar, B. Wang and R. T. Borchardt, "Esterase-sensitive Cyclic Prodrugs of Peptides: Evaluation of a Phenylpropionic Acid Promoiety in a Model Hexapeptide", *Pharmaceutical Res.*, **14**, 11-17 (1997).
347. S. Gangwar, G. M. Pauletti, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Synthesis of a Novel, Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Using an Acyloxyalkoxy Pro-moiety", *J. Org. Chem.*, **62**, 1356-1362 (1997).
348. B. Wang, S. Gangwar, G. M. Pauletti, T. J. Siahaan and R. T. Borchardt, "Synthesis of a Unique Esterase-sensitive Cyclic Prodrug System for Peptides that Utilize a "Trimethyl Lock" Facilitated Lactonization Reaction", *J. Org. Chem.*, **62**, 1363-1367 (1997).
349. F. W. Okumu, G. M. Pauletti, D. G. Vander Velde, T. J. Siahaan and R. T. Borchardt, "The Effect of Restricted Conformational Flexibility on Permeation of Model Hexapeptides Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **14**, 169-175 (1997).
350. G. M. Pauletti, F. W. Okumu and R. T. Borchardt, "Effect of Size and Charge on the Passive Diffusion of Peptides Across Caco-2 Cell Monolayers via the Paracellular Pathway", *Pharmaceutical Res.*, **14**, 164-168 (1997).
351. F. W. Okumu, J. L. Cleland and R. T. Borchardt, "The Effect of Size, Charge and Conformation of Model Peptides and a Formulation Variable on Their *In Vitro* Release from DL-PLGA Microspheres", *J. Controlled Release*, **49**, 133-140 (1997).
352. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Novel Esterase-Sensitive Cyclic Prodrugs of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability", in Proceedings of the 14th International Symposium for Medicinal Chemistry (F. Awouters, Ed.), Elsevier Science, B.V., Amsterdam, The Netherlands, pp. 27-34 (1997).
353. G. M. Pauletti, S. Gangwar, T. J. Siahaan, J. Aube and R. T. Borchardt, "Improvement of Oral Peptide Bioavailability: Peptide Mimetics and Prodrug Strategies", *Adv. Drug Del. Rev.*, **27**, 235-256 (1997).
354. M. A. Turner, K. Dole, C. S. Yuan, M. S. Hershfield, R. T. Borchardt and P. L. Howell, "Crystallization and Preliminary X-Ray Analysis of Human Placental S-Adenosylhomocysteine Hydrolase", *Acta Cryst. D.*, **D53**, 339-341, 1997.
355. R. T. Borchardt, "Are Graduate Programs Training Pharmaceutical Scientists to Function Effectively in the New, Highly Integrated and Globalized Pharmaceutical Industry?" (Editorial), *Pharmaceutical Res.*, **14**, 553-555 (1997).
356. H. Huang, C. S. Yuan and R. T. Borchardt, "Effect of Limited Proteolysis on the Stability and Enzymatic Activity of Human Placental S-Adenosylhomocysteine Hydrolase", *Protein Science*, **6**, 1482-1490 (1997).
357. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Prodrug Strategies to Enhance the Intestinal Absorption of Peptides", *Drug Discovery Today*, **2**, 148-155, 1997.

358. S. F. Wnuk, C. S. Yuan, R. T. Borchardt, J. Balzarini, E. De Clercq and M. J. Robins, "Anticancer and Antiviral Effects and Inactivation of S-Adenosyl-L-homocysteine Hydrolase with 5'-Carboxaldehydes and Oximes Synthesized from Adenosine and Sugar-Modified Analogues", *J. Med. Chem.*, **40**, 1608-1618 (1997).
359. M. M. Nerurkar, N. F. H. Ho, P. S. Burton, T. J. Vidmar and R. T. Borchardt, "Mechanistic Roles of Neutral Surfactants on Concurrent Polarized and Passive Membrane Transport of a Model Peptide in Caco-2 Cells", *J. Pharm. Sci.*, **86**, 813-821 (1997).
360. C. Schöneich, M. J. Hageman and R. T. Borchardt, "Stability of Peptides and Proteins" in Controlled Drug Delivery: The Next Generation (K. Park, Ed.), ACS Books, Washington, DC, pp. 205-228 (1997).
361. M. M. Nerurkar, M. J. Rose, J. F. Stobaugh and R. T. Borchardt, "Selective Fluorogenic Derivatization of Peptide Nucleic Acid Trimer with Naphthalene-2,3-dicarboxaldehyde", *J. Pharm. Biomed. Anal.*, **15**, 945-950 (1997).
362. H. Huang, C. S. Yuan, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "The Mechanisms of Inactivation of Human Placental S-Adenosylhomocysteine (AdoHcy) Hydrolase by (E)-4',5'-Didehydro-5'-Deoxy-5'-Methoxyadenosine (EDDMA) and Adenosine 5'-Carboxaldehyde Oxime (ACAO)", *Arch. Biochem. Biophys.*, **343**, 109-117 (1997).
363. K. Tamura, K. A. Agrios, D. Vander Velde, J. Aube and R. T. Borchardt, "Effect of Stereochemistry on the Transport of Aca-Linked β -Turn Peptidomimetics Across a Human Intestinal Cell Line", *Bioorg. Med. Chem.*, **5**, 1859-1866 (1997).
364. G. T. Knipp, N. F. H. Ho, C. L. Barsuhn and R. T. Borchardt, "Paracellular Diffusion in Caco-2 Cell Monolayers: Effect of Perturbants on the Transport of Hydrophilic Compounds Which Vary in Charge and Size", *J. Pharm. Sci.*, **86**, 1105-1110 (1997).
365. G. T. Knipp, D. Vander Velde, T. J. Siahaan and R. T. Borchardt, "The Effect of β -Turn Structure on the Permeation of Peptides Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **14**, 1332-1340 (1997).
366. M. Sorensen, B. Steenberg, G. Knipp, W. Wang, B. Steffansen, S. Frokjaer and R. T. Borchardt, "The Effect of β -Turn Structure on the Permeation of Peptides Across Monolayers of Bovine Brain Microvessel Endothelial Cells", *Pharmaceutical Res.*, **14**, 1341-1348 (1997).
367. D. Shan, M. G. Nicolaou, R. T. Borchardt and B. Wang, "Prodrug Strategies Based on Intramolecular Cyclization Reactions", *J. Pharm. Sci.*, **86**, 765-767 (1997).
368. R. T. Borchardt, "Task Force Report: Value of the Pharmaceutical Sciences", *Pharmaceutical Res.*, **14**, 958-966 (1997).
369. A. Capdevila, R. T. Borchardt and C. Wagner, "Exocrine Secretion in Pancreatic Cells is Blocked by Prenyl Inhibitors of G-Protein Methylation", *Arch. Biochem. Biophys.*, **345**, 47-55 (1997).
370. P. Artursson and R. T. Borchardt, "Intestinal Drug Absorption and Metabolism in Cell Culture: Caco-2 and Beyond", *Pharmaceutical Res.*, **14**, 1655-1658 (1997).
371. J. Li, K. Tamura, C. P. Lee, P. Smith, R. T. Borchardt and I. J. Hidalgo, "Structure-Affinity Relationships of Val-Val and Val-Val-Val Stereoisomers with the Apical Oligopeptide Transporter in the Human Intestinal Caco-2 Cells", *J. Drug Targeting*, **5**, 317-327 (1998).
372. S. F. Wnuk, C. S. Yuan, R. T. Borchardt and M. J. Robins, "Nucleic Acid Related Compounds. Synthesis of Homologated Halovinyl Derivatives from Aristeromycin and Their Inhibition of Human Placental S-Adenosyl-L-Homocysteine Hydrolase", *Nucleosides and Nucleotides*, **17**, 99-113 (1998).
373. K. L. Audus, J. Rose, W. Wang and R. T. Borchardt, "Brain Microvessel Endothelial Cell Culture Systems" in An Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology (W. M. Pardridge, Ed.), Cambridge University Press, pp. 86-93 (1998).
374. S. Gangwar, G. M. Pauletti, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability Using an Acyloxyalkoxycarbamate Promoiety", in Peptidomimetic Protocols (W. M. Kazmierski, Ed.), The Humana Press, Totowa, NJ, pp. 37-52, 1998.
375. B. Wang, S. Gangwar, G. M. Pauletti, T. J. Siahaan and R. T. Borchardt, "Synthesis of an Esterase-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane and Enzymatic Stability Using a 3-(2'-Hydroxy-4',6'-dimethylphenyl)-2,2-dimethylpropionic Acid Promoiety", in Peptidomimetic Protocols (W. M. Kazmierski, Ed.), The Humana Press, Totowa, NJ, pp. 53-69, 1998.
376. B. Wang, H. Zhang, W. Wang, D. Shan, O. Gudmundsson and R. T. Borchardt, "Synthesis of Coumarin-Based, Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides with Enhanced Membrane Permeability and Enzymatic

- Stability", in *Peptidomimetic Protocols* (W. M. Kazmierski, Ed.), The Humana Press, Totowa, NJ, pp. 71-85, 1998.
377. M. J. Robins, S. F. Wnuk, X. Yang, C. S. Yuan, R. T. Borchardt, J. Balzarini and E. DeClercq, "Inactivation of S-Adenosylhomocysteine Hydrolase and Antiviral Activity with 5',5',6',6'-Tetrahydro-6'-Deoxy-6'-Halohomoadenosine Analogues (4'-Haloacetylene Analogues Derived from Adenosine)", *J. Med. Chem.*, **41**, 3857-3864 (1998).
 378. S. F. Wnuk, Y. Mao, C. S. Yuan, R. T. Borchardt, G. Andrei, J. Balzarini, E. De Clercq and M. J. Robins, "Discovery of Type II (Covalent) Inactivation of S-Adenosyl-L-homocysteine Hydrolase. Syntheses and Evaluation of Dihalohomovinyl Nucleoside Analogues Derived from Adenosine", *J. Med. Chem.*, **41**, 3078-3083 (1998).
 379. C. S. Yuan, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "A Novel Mechanism-Based Inhibitor (6'-Bromo-5',6'-didehydro-6'-deoxy-6'-Fluorohomoadenosine) that Covalently Modifies Human Placental S-Adenosylhomocysteine Hydrolase", *J. Biol. Chem.*, **273**, 18191-18197 (1998).
 380. M. J. Robins, V. Neschadimenko, B. O. Ro, C. S. Yuan, R. T. Borchardt and S. F. Wnuk, "Nucleic Acid Related Compounds. 101 S-Adenosyl-L-homocysteine Hydrolase Does Not Hydrate (5'-Fluoro)vinyl or (6'-Halo)homovinyl Analogues Derived from 3'-Deoxyadenosine or 4'-(Chloro or Fluoro) 3'-Deoxyadenosine", *J. Org. Chem.*, **63**, 1205-1211 (1998).
 381. R. T. Borchardt, "AAPS Task Force Report. Value of the Pharmaceutical Sciences", *J. Pharm. Biomed. Anal.*, **16**, 1387-1401 (1998).
 382. C. Goolcharran and R. T. Borchardt, "Kinetics of Diketopiperazine Formation Using Model Peptides", *J. Pharm. Sci.*, **87**, 283-288 (1998).
 383. O. S. Gudmundsson, A. Bak, W. Wang, D. Shan, H. Zhang, G. J. Friis, B. Wang and R. T. Borchardt, "Prodrug Strategies to Enhance the Permeation of Opioid Peptides Through the Intestinal Mucosa" in *Peptide and Protein Drug Delivery* (S. Frokjaer, L. Christue and P. Krogsgaard-Larsen, Eds.), Munksgaard, Denmark, pp. 259-269 (1998).
 384. M. Sudoh, G. M. Pauletti, W. Yao, P. A. Sprengeler, A. B. Smith, III, R. Hirschmann and R. T. Borchardt, "Transport Characteristics of Peptidomimetics. Effect of the Pyrrolinone Bioisostere on Transport Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **15**, 719-725 (1998).
 385. M. A. Turner, C. S. Yuan, R. T. Borchardt, M. S. Hershfield, G. D. Smith and P. L. Howell, "Structure of Human Placental S-Adenosylhomocysteine Hydrolase: Determination of a 30 Selenium Atom Structure", *Nature Struct. Biol.*, **5**, 369-376 (1998).
 386. G. P. Camenisch, W. Wang, B. Wang and R. T. Borchardt, "A Comparison of the Bioconversion Rates and the Caco-2 Cell Permeation Characteristics of Coumarin-Based Cyclic Prodrugs and Methylester-Based Linear Prodrugs of RGD Peptidomimetics", *Pharmaceutical Res.*, **15**, 1174-1181 (1998).
 387. M. Khosravi and R. T. Borchardt, "Chemistry of Peptide Degradation. IX. Metal-Catalyzed Oxidation of Histidine in Model Peptides: Nature of the Reactive Oxygen Species", *Pharmaceutical Res.*, **15**, 1096-1102 (1998).
 388. O. S. Gudmundsson, G. M. Pauletti, W. Wang, D. Shen, H. Zhang, B. Wang and R. T. Borchardt, "Coumarinic Acid-based Cyclic Prodrugs of Opioid Peptides that Exhibit Increased Metabolic Stability and Enhanced Cellular Permeability", *Pharmaceutical Res.*, **16**, 7-15 (1999).
 389. O. S. Gudmundsson, K. Nimkar, S. Gangwar and R. T. Borchardt, "Phenylpropionic Acid-based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeation", *Pharmaceutical Res.*, **16**, 16-23 (1999).
 390. A. Bak, O. S. Gudmundsson, G. J. Friis and R. T. Borchardt, "Acyloxyalkoxy-based Cyclic Prodrugs of Opioid Peptides: Evaluation of Their Chemical and Enzymatic Stability as Well as Their Transport Properties Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **16**, 24-29 (1999).
 391. B. Wang, K. Nimkar, W. Wang, H. Zhang, D. Shan, O. S. Gudmundsson, S. Gangwar, T. J. Siahaan and R. T. Borchardt, "Synthesis and Evaluation of the Physicochemical Properties of Esterase-sensitive Cyclic Prodrugs of Opioid Peptides Using Phenylpropionic Acid and Coumarinic Acid Linkers", *J. Peptide Res.*, **53**, 370-382 (1999).
 392. A. Bak, O. S. Gudmundsson, T. J. Siahaan, G. J. Friis and R. T. Borchardt, "Syntheses and Physicochemical Evaluation of Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides Using an Acyloxyalkoxy Linker", *J. Peptide Res.*, **53**, 393-402 (1999).
 393. O. S. Gudmundsson, S.D. S. Jois, D. G. Vander Velde, T. J. Siahaan, B. Wang and R. T. Borchardt, "The Effect of Conformation on the Membrane Permeation of Coumarinic- and Phenylpropionic Acid-based Cyclic Prodrugs of Opioid Peptides", *J. Peptide Res.*, **53**, 383-392 (1999).

394. O. S. Gudmundsson, D. G. Vander Velde, S. D. S. Jois, A. Bak, T. J. Siahaan and R. T. Borchardt, "The Effect of Conformation of Acyloxyalkoxy-based Cyclic Prodrugs of Opioid Peptides on Their Membrane Permeation", *J. Peptide Res.*, **53**, 403-413 (1999).
395. B. Wang, W. Wang, G. P. Camenisch, J. Elmo, H. Zhang and R. T. Borchardt, "Synthesis and Evaluation of Novel Esterase-Sensitive Cyclic Prodrugs of Peptidomimetics RGD Analogs with Improved Membrane Permeability", *Chem. Pharm. Bull.*, **47**, 90-95 (1999).
396. R. T. Borchardt, "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", *J. Controlled Release*, **62**, 231-238 (1999).
397. C. Goolcharran, M. Khossravi and R. T. Borchardt, "Chemical Stability of Peptides and Proteins" in Pharmaceutical Formulation and Development of Peptides and Proteins (S. Frokjaer and L. Hovgaard, Eds.), Taylor & Francis, London, pp. 70-88, 1999.
398. N. F. Ho, T. R. Raub, P. S. Burton, C. L. Barsuhn, A. Adson, K. L. Audus and R. T. Borchardt, "Quantitative Approaches to Delineate Transport Mechanisms in Cell Culture Monolayers", in Transport Processes in Pharmaceutical Systems (K. J. Himmelstein, G. L. Amidon and P. I. Lee, Eds.), Marcel Dekker, Inc., New York, pp. 219-316, 1999.
399. R. T. Borchardt, "Prodrug Strategies to Enhance the Permeation of Peptides Through the Intestinal Mucosa", in Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium (J. P. Tam and P. T. P. Kaumaya, Eds.), Kluwer Academic Publisher, Dordrecht, The Netherlands, pp. 825-827 (1999).
400. M. C. Lai, M. J. Hageman, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Chemical Instability of Peptides in Polymers. I. Effect of Water on Peptide Deamidation in Poly (Vinyl Alcohol) and Poly (Vinyl Pyrrolidone) Matrices", *J. Pharm. Sci.*, **88**, 1073-1080 (1999).
401. M. C. Lai, M. J. Hageman, R. L. Schowen, R. T. Borchardt, and E. M. Topp, "Chemical Stability of Peptides in Polymers. II. Discriminating Between Solvent and Plasticizing Effects of Water on Peptide Deamidation in Poly (Vinyl Pyrrolidone)", *J. Pharm. Sci.*, **88**, 1081-1089 (1999).
402. E. D. Hugger, B. L. Novak and R. T. Borchardt, "The Effects of Nonionic Surfactants on the Permeation of Solutes Across Caco-2 Cell Monolayers", Bulletin Technique Gattefosse entitled Recent Advances in the Formulation and Development of Poorly-Soluble Drugs, p. 59-65 (1999).
403. G. L. Grunewald, T. M. Caldwell, Q. Li, M. Slavica, W. Wang, R. T. Borchardt and K. R. Criscione, "Synthesis and Biochemical Evaluation of 3-fluoromethyl-1,2,3,4-tetrahydroisoquinolines as Selective Inhibitors of Phenylethanolamine N-Methyltransferase vs. the α_2 -Adrenoceptor", *J. Med. Chem.*, **42**, 3588-3601 (1999).
404. C. S. Yuan, Y. Saso, E. Lazarides, R. T. Borchardt and M. J. Robins, "Recent Advances in S-Adenosyl-L-Homocysteine Hydrolase Inhibitors and Their Potential Clinical Applications", *Expert Opinions on Therapeutic Patents*, **9**, 1197-1206 (1999).
405. R. T. Borchardt, G. Camenisch, E. Hugger, W. Wang, D. Shan, G. L. Wheeler, C. P. Cheng and B. Wang, "Prodrug Strategies to Improve the Oral Absorption of Peptide Mimetics", *Polymer Preparations*, **40**, 257-258 (1999).
406. S. F. Wnuk, C. S. Yuan, R. T. Borchardt and M. Robins, "Design and Biological Evaluation of New Mechanism-based Inhibitors of S-Adenosyl-L-homocysteine Hydrolase", *Nucleoside Nucleotides*, **18**, 595-596 (1999).
407. D. Shan, A. Zheng, C. E. Ballard, W. Wang, R. T. Borchardt and B. Wang, "Facilitated Cyclic Ether Formation and Its Potential Application in Peptide and Organic Synthesis", *Chem. Pharm. Bull.*, **48**, 238-244, 2000.
408. M. C. Lai, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Deamidation of a Model Hexapeptide in Poly(Vinyl Alcohol) Hydrogels and Xerogels", *J. Peptide Res.*, **55**, 93-101 (2000).
409. W. Wang, G. Camenisch, D. C. Sane, H. Zhang, E. Hugger, G. L. Wheeler, R. T. Borchardt and B. Wang, "A Coumarin-Based Prodrug Strategy to Improve the Oral Absorption of RGD Peptidomimetics", *J. Controlled Release*, **65**, 245-251 (2000).
410. D. Yin, X. Yang, C. S. Yuan and R. T. Borchardt, "Mechanism-Based S-Adenosyl-L-Homocysteine Hydrolase Inhibitors in the Search for Broad-Spectrum Antiviral Agents", in Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease (P. F. Torrence, Ed.), John Wiley & Sons, Inc., New York, p. 41-71 (2000).
411. R. T. Borchardt and B. Wang, "Prodrug Strategies to Improve the Oral Absorption of Peptides and Peptide Mimetics", in Drug Delivery in the 21st Century, ACS Books, Washington, DC, pp. 36-45 (2000).

412. J. Gao, E. Hugger, M. Beck-Westermeyer and R. T. Borchardt, "Protocols for the Application of Caco-2 Cells in Measuring Permeability Coefficients of Drugs", *Current Protocols in Pharmacology*, 7.2.1-7.2.23 (2000).
413. W. Wang, R. T. Borchardt and B. Wang, "Orally Active Peptidomimetic RGD Analogs That Are Glycoprotein IIb/IIIa Antagonists", *Current Medicinal Chemistry*, 7, 437-453 (2000).
414. W. Wang, R. T. Borchardt, D. Sane and B. Wang, "Delivering Peptides and Peptidomimetics Across Membrane Barriers. A Prodrug Approach", in *Peptides for the New Millennium* (G. B. Fields, J. P. Tam and G. Barany, Eds.), Kluwer Academic Publisher, Netherlands, 214-216, 2000.
415. M. Khossravi and R. T. Borchardt, "Chemical Pathways of Peptide Degradation X. Effect of Metal-Catalyzed Oxidation on the Solution Structure of a Histidine-Containing Peptide Fragment of Human Relaxin", *Pharmaceutical Res.*, 17, 851-858 (2000).
416. M. Khossravi, S. J. Shire and R. T. Borchardt, "Evidence for the Involvement of Histidine A(12) in the Aggregation and Precipitation of Human Relaxin Induced by Metal Catalyzed Oxidation", *Biochemistry*, 39, 5876-5885 (2000).
417. C. Goolcharran, J. L. Cleland and R. T. Borchardt, "The Effects of a Histidine Residue on the C-Terminal Side of an Asparaginyl Residue on the Rate of Deamidation Using Model Pentapeptides", *J. Pharm. Sci.*, 89, 818-825 (2000).
418. C. Goolcharran, J. L. Cleland, R. Keck, A. J. S. Jones and R. T. Borchardt, "A Comparison of the Rate of Deamidation and Diketopiperazine Formation in Recombinant Human Vascular Endothelial Cell Growth Factor (rhVEGF) and Model Peptide Fragments of VEGF", *AAPS Pharm. Sci.*, 2, 5-12 (2000).
419. S. F. Wnuk, C. A. Valdez, J. Khan, P. Moutinho, M. J. Robins, X. Yang, R. T. Borchardt and E. DeClercq, "Doubly Homologated Dihalovinyl and Acetylene Analogues of Adenosine: Synthesis, Interaction with S-Adenosyl-L-homocysteine Hydrolase and Antiviral and Cytostatic Effects", *J. Med. Chem.*, 43, 1180-1186 (2000).
420. M. Xie, J. Aube, R. T. Borchardt, M. Morton, E. M. Topp, D. Vander Velde and R. L. Schowen, "Reactivity Toward Deamidation of Asparagine Residues in β -Turn Structures", *J. Peptide Res.*, 56, 165-171 (2000).
421. X. Yang, D. Yin, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "Mechanism of Inactivation of Human S-Adenosylhomocysteine Hydrolase by 5',5',6',6'-Tetrahydro-6'-Deoxy-6'-Halohomoadenosine Analogues", *Biochemistry*, 39, 15234-15241 (2000).
422. X. Yang and R. T. Borchardt, "Overexpression, Purification and Characterization of S-Adenosylhomocysteine Hydrolase from Leishmania Donovanii", *Arch. Biochem. Biophys.*, 383, 272-280 (2000).
423. R. T. Borchardt, "Training Grants in the Chemical and Biological Sciences" in *Graduate Education in the Chemical Sciences: Issues for the 21st Century*, National Research Council, Washington, DC, 144-158 (2000).
424. R. Li, B. B. Laird, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Solution Polarity and Viscosity on Peptide Deamidation", *J. Peptide Res.*, 56, 326-334 (2000).
425. D. Yin, X. Yang, Y. Hu, K. Kuczera, R. L. Schowen, R. T. Borchardt and T. C. Squier, "Substrate Binding Induces Global Conformational Changes Within S-Adenosylhomocysteine Hydrolase", *Biochemistry*, 39, 9811-9818 (2000).
426. W. Wang, W. L. Dentler and R. T. Borchardt, "Vascular Endothelial Growth Factor Increases the Permeability of Brain Microvessel Endothelial Cell Monolayers by Affecting Tight Junction Assembly", *Amer. J. Physiol.: Heart and Circulatory Physiology*, 280, H434-H440 (2001).
427. M. A. Turner, X. Yang, D. Yin, K. Kuczera, R. T. Borchardt and P. L. Howell, "Structure and Function of S-Adenosylhomocysteine Hydrolase", *Cell Biochem. Biophys.*, 33, 101-125 (2001).
428. Y. Song, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of pH on the Rate of Asparagine Deamidation in Polymeric Formulations: 'pH'-Rate Profile, *J. Pharm. Sci.*, 90, 141-156 (2001).
429. R. T. Borchardt, "Biological Models to Assess Drug Bioavailability", in *Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies* (B. Testa, H. vande Waterbeemd, G. Folkers and R. Guy, Eds.), Wiley-VHCA, Zurich, 117-126, 2001.
430. Y. Song, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Formaldehyde Production by Tris Buffer in Peptide Formulations at Elevated Temperatures", *J. Pharm. Sci.*, 90, 1198-1203 (2001).
431. J. Gao, O. Murase, R. L. Schowen, J. Aube and R. T. Borchardt, "A Functional Assay for Quantitation of the Apparent Affinities of Ligands of P-Glycoprotein in Caco-2 Cells", *Pharm. Res.*, 18, 171-176 (2001).

432. J. Gao, M. Sudoh, J. Aube and R. T. Borchardt, "Transport Characteristics of Peptides and Peptidomimetics: 1 N-Methylated Peptides as Substrates for the Oligopeptide Transporter and P-Glycoprotein in the Intestinal Mucosa", *J. Peptide Res.*, **57**, 316-329 (2001).
433. J. Gao, S. L. Winslow, D. Vander Velde, J. Aube and R. T. Borchardt, "Transport Characteristics of Peptides and Peptidomimetics: 2. Hydroxyethylamine Bioisostere-Containing Peptidomimetics as Substrates for the Oligopeptide Transporter and P-Glycoprotein in the Intestinal Mucosa", *J. Peptide Res.*, **57**, 361-373 (2001).
434. R. T. Borchardt, "Integrating Drug Discovery and Development: A Major Challenge for the Pharmaceutical Industry" (Invited Commentary), *The Scientist*, **15**, 43-45 (2001).
435. Y. Hu, X. Yang, D. H. Yin, J. Madadevan, K. Kuczera, R. L. Schowen and R. T. Borchardt, "Computational Characterization of the Substrate Binding and Catalysis in S-Adenosylhomocysteine Hydrolase", *Biochemistry*, **40**, 15143-15152 (2001).
436. F. Tang and R. T. Borchardt, "Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa?", *Pharm. Res.*, **19**, 765-772 (2002).
437. F. Tang, K. Horie and R. T. Borchardt, "Are MDCK Cells Transfected with the Human MRP2 Gene a Good Model of the Human Intestinal Mucosa?", *Pharm. Res.*, **19**, 773-779 (2002).
438. H. Ouyang, F. Tang, T. J. Siahaan and R. T. Borchardt, "A Modified Coumarinic Acid-based Cyclic Prodrug of an Opioid Peptide: Enzymatic and Chemical Stability and Membrane Permeation Characteristics", *Pharm. Res.*, **19**, 794-801 (2002).
439. H. Ouyang, D. Vander Velde, R. T. Borchardt and T. J. Siahaan, "Synthesis and Conformational Analysis of a Coumarinic Acid-based Cyclic Prodrug of an Opioid Peptide with Modified Sensitivity to Esterase-catalyzed Bioconversion", *J. Peptide Res.*, **59**, 183-195 (2002).
440. F. Tang and R. T. Borchardt, "Characterization of the Efflux Transporter(s) Responsible for Restricting Mucosa Intestinal Mucosa Permeation of an Acyloxyalkoxy-based Cyclic Prodrug of the Opioid Peptide DADLE", *Pharm. Res.*, **19**, 780-786 (2002).
441. F. Tang and R. T. Borchardt, "Characterization of the Efflux Transporter(s) Responsible for Restricting Intestinal Mucosa Permeation of the Coumarinic Acid-based Cyclic Prodrug of the Opioid Peptide DADLE", *Pharm. Res.*, **19**, 787-793 (2002).
442. H. Ouyang, R. T. Borchardt and T. J. Siahaan, "Steric Hindrance is a Key Factor in the Coupling Reaction of (Acyloxy)Alkyl- α -halides with Phenols", *Tetrahedron Letters*, **43**, 577-579 (2002).
443. E. D. Hugger, B. L. Novak, P. S. Burton, K. L. Audus and R. T. Borchardt, "A Comparison of Commonly Used Polyethoxylated Pharmaceutical Excipients on Their Ability to Inhibit P-Glycoprotein Activity *In Vitro*", *J. Pharm. Sci.*, **91**, 1991-2002 (2002).
444. W-Q. Chen, F. Tang, K. Horie and R. T. Borchardt, "Caco-2 Cell Monolayers as a Model for Studies of Drug Transport Across Human Intestinal Epithelium" in Cell Culture Models of Biological Barriers: In Vitro Test Systems for Drug Absorption and Delivery (C. M. Lehr, Ed.), Haarwood Academic Publishers, pp. 143-163 (2002).
445. E. D. Hugger, K. L. Audus and R. T. Borchardt, "The Effects of Polyethylene Glycol on Efflux Transporter Activity in Caco-2 Cell Monolayers", *J. Pharm. Sci.*, **91**, 1980-1990 (2002).
446. P. Elrod, J. Zhang, X. Yang, D. Yin, Y. Hu, R. L. Schowen and R. T. Borchardt, "Contribution of Active-site Residues to the Partial and Overall Catalytic Activities of Human S-Adenosylhomocysteine Hydrolase", *Biochemistry*, **41**, 8134-8142 (2002).
447. S. F. Wnuk, Bong-Oh Ro, C. A. Valdez, E. Lewandowska, N. X. Valdez, P. R. Sacasa, D. Yin, J. Zhang, R. T. Borchardt and E. DeClercq, "Sugar-Modified Conjugated Diene Analogues of Adenosine and Uridine Synthesis, Interaction with S-Adenosyl-L-homocysteine Hydrolase and Antiviral and Cytostatic Effects", *J. Med. Chem.*, **45**, 2651-2658 (2002).
448. J. Z. Yang, C. K. Bastian, R. D. Moore, J. F. Stobaugh and R. T. Borchardt, "Quantitative Analysis of a Model Opioid Peptide and Its Cyclic Prodrugs in Rat Plasma Using high Performance Liquid Chromatography and Fluorescence and Tandem Mass Spectrometric Detection", *J. Chromatography B*, **780**, 269-281 (2002).
449. J. Z. Yang, W. Chen and R. T. Borchardt, "In Vitro Stability and In Vivo Pharmacokinetic Studies of a Model Opioid Peptide (DADLE) and Its Cyclic Prodrugs", *J. Pharmacol. Exptl. Therap.*, **303**, 840-848 (2002).
450. W. Chen, J. Z. Yang, R. Anderson, L. H. Nielsen and R. T. Borchardt, "Evaluation of the Permeability Characteristics

of a Model Opioid Peptide (DADLE and Its Cyclic Prodrugs Across the Blood Brain Barrier Model", *J. Pharmacol. Exptl. Therap.*, **303**, 849-857 (2002).

451. R. W. Miles, L. P. C. Nielsen, G. J. Ewing, D. Yin, R. T. Borchardt and M. J. Robins, "S-Homoadenosyl-L-cysteine and S-Homoadenosyl-L-homocysteine. Synthesis and Binding Studies of Non-Hydrolyzed Substrate Analogues with S-Adenosyl-L-homocysteine Hydrolase", *J. Org. Chem.*, **67**, 8258-8260 (2002).
452. G. Friedrichsen, W-Q. Chen, M. Begtrup, Chao-Pin Lee, P. Smith and R. T. Borchardt, "Synthesis of Analogs of Valacyclovir and Determination of Their Substrate Activity for the Oligopeptide Transporter in Caco-2 Cells", *European J. Pharm. Sci.*, **16**, 1-13 (2002).
453. E. D. Hugger, C. J. Cole, T. J. Raub, P. S. Burton and R. T. Borchardt, "Automated Analysis of Polyethylene Glycol (PEG)-Induced Inhibition of P-Glycoprotein Activity *In Vitro*", *J. Pharm. Sci.*, **92**, 21-26 (2003).
454. M. Xie, Z. Shahrokh, M. Kadkhodayan, W. J. Henzel, M. P. Powell, R. T. Borchardt and R. L. Schowen, "Asparagine Deamidation in Recombinant Human Lymphotoxin: Hindrance by Three-Dimensional Structures", *J. Pharm. Sci.*, **92**, 869-880 (2003).
455. A.J.M. D'Souza, R. L. Schowen, R. T. Borchardt, J. S. Salisbury, E. J. Munson and E. M. Topp, "Reaction of a Peptide with Polyvinylpyrrolidone in Solid-State", *J. Pharm. Sci.*, **92**, 585-593 (2003).
456. X. Yang, Y. Hu, D. Yin, M. A. Turner, R. T. Borchardt, L. Howell, K. Kuczera and R. L. Schowen, "Catalytic Strategy of S-Adenosyl-L-homocysteine Hydrolase: Transition State Stabilization and the Avoidance of Abortive Reactions", *Biochemistry*, **42**, 1900-1909 (2003).
457. K. Horie, F. Tang and R. T. Borchardt, "Isolation and Characterization of Caco-2 Subclones Overexpressing the MDR1 Efflux Transport", *Pharm. Res.*, **20**, 159-166 (2003).
458. B. M. Johnson, W. Chen, R. T. Borchardt, W. N. Charman and C. J. H. Porter, "A Kinetic Evaluation of the Absorption, Efflux and Metabolism of Verapamil in the Autoperfused Rat Jejunum", *J. Pharm. Exptl. Therap.*, **305**, 151-158 (2003).
459. S. Wnuk, P. R. SaCasa, L. N. Crain, E. Leward, J. Zhang and R. T. Borchardt, "Stereocontrolled Synthesis of Diene and Enzyme Sugar-Modified Nucleosides and Their Interaction with S-Adenosyl-L-Homocysteine Hydrolase", *Nucleosides, Nucleotides and Nucleic Acids*, **22**, 783-785 (2003).
460. R. T. Borchardt, Foreword in Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs (R.J.Y. Ho and M. Gibaldi, Eds.), John Wiley & Sons, Inc., New York, NY, xi-xii, 2003.
461. B. Li, R. T. Borchardt, E. M. Topp, D. Vander Velde and R. L. Schowen, "Rapid, Specific Racemization of an Asparagine Residue During Peptide Deamidation", *J. Amer. Chem. Soc.*, **125**, 11486-11487 (2003).
462. N. B. Parker, D. H. Yin, K. A. Mason, J. Henke, R. L. Schowen and R. T. Borchardt, "Isolation of the Gene Encoding Trypanosoma cruzi S-Adenosylhomocysteine Hydrolase and Characterization of the Expressed Enzyme", *Experimental Parasitology*, **105**, 149-158 (2003).
463. R. T. Borchardt, "Scientific, Educational and Communication Issues Associated with Integrating and Applying Drug-like Data in Drug Discovery", in Pharmaceutical Profiling in Drug Discovery for Lead Selection, (R. T. Borchardt et al., Eds.), AAPS Press, Arlington, VA, p. 000-000 (2004).
464. J. Vabeno, T. Lejon, C. U. Nielsen, B. Steffansen, W. Chen, H. Ouyang, R. T. Borchardt and K. Luthman, "Phe-Gly Dipeptidomimetics Designed for the Di-/Tripeptide Transporters PET1 and PEPT2: Synthesis and Biological Investigations", *J. Med. Chem.*, **47**, 1060-1069 (2004).
465. F. Tang, J. Z. Yang and R. T. Borchardt, "Bi-directional Transport of Rhodamine 123 and Hoechst 3342, Fluorescence Probes of the Binding Sites on P-glycoprotein, Across MDCK-MDR1 Cell Monolayers", *J. Pharm. Sci.*, **92**, 000-000 (2004).
466. J. E. Polli et al., "Summary Workshop Report: Biopharmaceuticals Classification System – Implementation, Challenges and Extension Opportunities", (Commentary), *J. Pharm. Sci.*, **00**, 000-000 (2004).
467. C. E. Stotz, R. T. Borchardt, C. R. Middaugh, T. J. Siahaan, D. Vander Velde and E. M. Topp, "Secondary Structure of a Dynamic Type I β -Hairpin Peptide", *J. Peptide Research*, **00**, 000-000 (2004).
468. S. F. Wnuk, E. Lewandowska, P. R. Sacasa, L. N. Crain, J. Zhang, R. T. Borchardt and E. DeClercq, "Stereoselective Synthesis of Sugar-modified enzyme Analogues of Adenosine and Uridine. Interaction with S-Adenosyl-L-homocysteine Hydrolase and Antiviral and Cytostatic Effects", *J. Med. Chem.*, submitted.
469. B. Li, R. L. Schowen, E. M. Topp and R. T. Borchardt, "Effect of N-1 and N-2 Residues on Peptide Deamidation Rate

in Solution and Solid State", *J. Pharm. Sci.*, submitted.

470. B. Li, M. O'Meara, J. W. Lubach, R. L. Schowen, E. M. Topp, E. J. Munson and R. T. Borchardt, "Effect of Sucrose and Mannitol on Asparagine Deamidation Rates in Solution and in the Solid State", *J. Pharm. Sci.*, submitted.
471. R. T. Borchardt, "Educational and Communication Issues Related to Profiling Compounds for their Drug-like Properties", in *Physicochemical and Biological Profiling in Drug Research* (B. Testa, Ed.), in preparation.
472. B. Li, E. Gorman, K. Bratton, T. D. Williams, R. L. Schowen, E. M. Topp and R. T. Borchardt, "Effects of Acidic N+1 Residues on Asparagine Deamidation Rates in Solution and in the Solid State", *J. Pharm. Sci.*, submitted.
473. W. Chen, J. Z. Yang, A. Bak and R. T. Borchardt, "Evaluation of the Intestinal Mucosal Permeation of an Opioid Peptide (DADLE) and Its Cyclic Prodrugs Using an *In Situ* Perfused Rat Ileum Model", *J. Pharmacol. Exptl. Therap.*, in preparation.
474. M. M. Nerurkar, N. F. H. Ho, P. S. Burton and R. T. Borchardt, "Inhibition of an Apically Polarized Efflux System by Surfactants in Rat Intestinal Mucosa", *J. Pharm. Sci.*, in preparation.
475. J. Zhang, Y. Hu, X. H. Yu, C. S. Yuan, R. T. Borchardt and R. L. Schowen, "The Role of the C-Terminal Region of Human S-Adenosylhomocysteine Hydrolase in Quaternary Structure and Catalytic Activity", *Biochemistry*, in preparation.
476. M. M. Wang, D. Yin, X. Yang, Y. Hu, R. L. Schowen and R. T. Borchardt, "Contribution of His55 and His301 to the Partial and Overall Catalytic Activities of Human S-Adenosylhomocysteine Hydrolase", *Biochemistry*, in preparation.
477. X. Yang, D. H. Yin, J. Zhang, R. L. Schowen and R. T. Borchardt, "The Substrate Analog 3'-Deoxyadenosine Inhibits *Leishmania donovani* S-Adenosylhomocysteine Hydrolase by Slow Binding to Half of the Cofactor Binding Sites", *Biochemistry*, in preparation.
478. A. D. Wilson, M. Lai, E. M. Topp, R. T. Borchardt, B. B. Laird and R. L. Schowen, "Mechanistic Requirements for Molecular Motion as a Determinant of the Effects of Matrix Properties on Solid-State Peptide Degradation Rates", *J. Pharm. Sci.*, in preparation.

Patents

1. R. T. Borchardt and D. R. Borchering, "Nucleoside Analogs Having Antiviral Activity", United States Patent #4,859,677 (Date of issue 8/22/89).
2. B. Wang, S. Gangwar, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "The Use of 3-(2'-Hydroxy-4',6'-dimethylphenyl)-3,3-Dimethylpropionic Acid and Acyloxyalkoxy Linkers to Make Esterase-Sensitive, Cyclic Prodrugs of Peptides and Peptide-Nucleic Acids", United States Patent #5,672,584 (Date of Allowance, 9/30/97).

Books

Editor

1. E. Usdin, R. T. Borchardt and C. R. Creveling, Eds., "Transmethylations", Elsevier North Holland, New York, NY, 1979.
2. E. Usdin, R. T. Borchardt and C. R. Creveling, Eds., "The Biochemistry of S-Adenosylmethionine and Related Compounds", Macmillan Press, Ltd., London, 1982.
3. R. T. Borchardt, A. Repta and V. Stella, Eds., "Directed Drug Delivery: A Multidisciplinary Problem", Humana Press, Clifton, NJ, 1985.
4. R. T. Borchardt, C. R. Creveling and P. M. Ueland, Eds., "Biological Methylation and Drug Design - Experimental and Clinical Roles of S-Adenosylmethionine", Humana Press, Clifton, NJ, 1986.
5. R. T. Borchardt, P. Smith and G. Wilson, Eds. "Models for Assessing Drug Absorption and Metabolism", Vol. 8 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1996.
6. R. T. Borchardt, R. M. Freidinger, T. Sawyer and P. Smith (Eds.), "Integration of Pharmaceutical Discovery and Development: Case Histories", Vol. 12 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1998.
7. R. T. Borchardt, E. H. Kerns, C. A. Lipinski, D. R. Thakker and B. Wang (Eds.), "Pharmaceutical Profiling in Drug Discovery for Lead Selection", Vol. 2 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt, C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
8. V. Stella, M. Hageman, R. Oliyai, J. Tilley, H. Maag and R. T. Borchardt (Eds.), "Prodrugs: Challenges and Rewards", in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
9. V. Stella, M. Hageman, R. Oliyai, J. Tilley, H. Maag and R. T. Borchardt (Eds.), "Prodrugs: Challenges and Rewards - Part II, Vol. 5 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
10. R. T. Borchardt, E. H. Kerns, D. R. Thakker, S. Sittampalam, M. J. Hageman, J. L. Stevens (Eds.), "Optimization of the Drug-like Properties of Lead", Vol. 6 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.

Series Editor

A) Pharmaceutical Biotechnology, Plenum Press (1992-2002)

1. B. L. Ferraiolo, C. A. Gloff and M. A. Mohler (Eds.), "Protein Pharmacokinetics and Metabolism", Vol. 1 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1992.
2. T. J. Ahern and M. Manning (Eds.), "Stability of Protein Pharmaceuticals: Chemical and Physical Pathways of Protein Degradation", Vol. 2 (Part A) in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1992.
3. T. J. Ahern and M. Manning (Eds.), "Stability of Protein Pharmaceuticals: *In Vivo* Pathways of Degradation and Strategies for Protein Stabilization", Vol. 3 (Part B) in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1992.
4. K. L. Audus and T. J. Raub (Eds.), "Biological Barriers to Protein Delivery, Vol. 4 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1993.
5. J. Wang and R. Pearlman (Eds.), "Stability of Protein Pharmaceuticals: Case Histories", Vol. 5 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1993.
6. M. Powell and M. Newman (Eds.), "Vaccine Design: The Subunit Approach", Vol. 6 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1995.
7. D.J.A. Crommelin, J. Herron and W. Jiskoot (Eds.), "Structural Analysis of Proteins" Vol. 7 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1995.

8. R. T. Borchardt, P. Smith and G. Wilson (Eds.), "Models for Assessing Drug Absorption and Metabolism", Vol. 8 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1996.
9. J. Wang and R. Pearlman (Eds.), "Stability of Protein Pharmaceuticals: Case Histories II", Vol. 9 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1996.
10. L. Sanders and W. Hendren (Eds.), "Protein Delivery: Physical Systems", Vol. 10 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1997.
11. R. T. Borchardt, R. M. Freidinger, T. Sawyer and P. Smith (Eds.), "Integration of Pharmaceutical Discovery and Development: Case Histories", Vol. 11 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Plenum Press, New York, NY, 1998.
12. G. Amidon and W. Sadee (Eds.), "Membrane Transporters as Drug Targets", Vol. 12 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Kluwer Academic/Plenum Press, New York, NY, 1999.
13. M. Manning and J. Carpenter (Eds.), "Rational Design of Stable Protein Formulations: Theory and Practice", Vol. 13 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Kluwer Academic/Plenum Press, New York, NY, 2002.
14. S. L. Nail and M. J. Akers (Eds.), "Development and Manufacture of Protein Pharmaceuticals", Vol. 14 in the series entitled, "Pharmaceutical Biotechnology" (R. T. Borchardt, Series Editor), Kluwer Academic/Plenum Press, New York, NY, 2002.

B) Biotechnology: Pharmaceutical Aspects (2002-present)

1. H. R. Costantino and M. J. Pikal (Eds.), "Lyophilization of Biomaterials", Vol. 1 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
2. R. T. Borchardt, E. H. Kerns, C. A. Lipinski, D. R. Thakker and B. Wang (Eds.), "Pharmaceutical Profiling in Drug Discovery for Lead Selection", Vol. 2 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in production.
3. W. Jiskoot and D. Crommelin (Eds.), "Methods for Structural Analysis of Protein Pharmaceuticals", Vol. 3 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
4. V. Stella, M. Hageman, R. Oliyai, J. Tilley, H. Maag and R. T. Borchardt (Eds.), "Prodrugs: Challenges and Rewards – Part I", Vol. 4 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
5. V. Stella, M. Hageman, R. Oliyai, J. Tilley, H. Maag and R. T. Borchardt (Eds.), "Prodrugs: Challenges and Rewards – Part II", Vol. 5 in the series entitled, "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.
6. R. T. Borchardt, E. H. Kerns, D. R. Thakker, S. Sittampalam, M. J. Hageman, J. L. Stevens (Eds.), "Optimization of the Drug-like Properties of Leads", Vol. 6 in the series entitled "Biotechnology: Pharmaceutical Aspects" (R. T. Borchardt and C. R. Middaugh, Series Editors), AAPS Press, Arlington, VA, in preparation.

Short Courses

A) Professional Association Short Courses

1. Organized and participated in the AAPS-sponsored short course entitled, "Cell Lines and Tissue Culture in Pharmaceutical Research and Development", San Diego, CA, November, 1994.
2. Organized and participated in the AAPS/EUFEPS-sponsored short course entitled, "Cell Lines and Tissue Culture in Pharmaceutical Research and Development", Edinburgh, Scotland, September, 1996.
3. Organized and participated in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, July, 1997.
4. Organized and participated in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, July, 1998.
5. Participated in AAPS-sponsored short course entitled, "Applications of Cell Culture Systems in Academic and Industrial Pharmaceutical Research", Arlington, VA, August, 1998.
6. Co-organized and participated in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal Blood-Brain Barrier Permeability", Princeton, NJ, July, 1999.
7. Organized and participated in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, June, 2000.
8. Participant in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal Blood-Brain Barrier Permeability", Princeton, NJ, June, 2000.
9. Organized and participated in the Drew University-sponsored short course entitled, "Designing Drugs With Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, June, 2001.
10. Organizer and participant in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal *In vivo* Activity After Oral Administration", Princeton, NJ, June, 2002.
11. Participated in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal Blood Brain Barrier Permeability", Princeton, NJ, June, 2002.
12. Organizer and participant in the Drew University-sponsored short course entitled, "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, June, 2003.
13. Organizer and participant in the Drew University-sponsored short course entitled "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", Princeton, NJ, June, 2004.

B) On-site Short Courses

1. Organizer and participant in a short course entitled, "Designing Drugs with Optimal *In Vivo* Activity After Oral Administration", which was presented at the following pharmaceutical/biotechnology companies:
 - Chiron Corporation, December, 2000
 - Guilford Pharmaceuticals, April, 2001
 - Roche Bioscience (Palo Alto, CA), May, 2001
 - Eli Lilly Corporation, November, 2001
 - Albany Molecular Research Insititute, November, 2001
 - 3D Pharmaceuticals, January, 2002
 - Pfizer Corporation (Ann Arbor, MI), January, 2002
 - Gilead Corporation, February, 2002
 - Pfizer (LaJolla, CA), February, 2002
 - Aventis, April, 2002
 - Roche (Nutley, NJ), April, 2002
 - Bristol-Myers Squibb, April, 2002
 - Sero (Geneva), July, 2002
 - Aventis (Frankfurt), July, 2002
 - Genomics Institute of the Novartis Research Foundation (LaJolla, CA), June, 2003
 - Quorex/Biota/Celgene (San Diego, CA), June, 2003
 - Millennium Pharmaceuticals (Cambridge, MA), June, 2004
 - AstraZeneca Pharmaceuticals (Waltham, MA), June, 2004

2. Participant in a short course entitled, "Designing Drugs with Optimal Blood Brain Barrier Permeability" which was presented at the following pharmaceutical/biotechnology companies:
 - Albany Molecular Research Institute, April, 2001
 - Sepracor, September, 2002
 - Eli Lilly Corporation, March, 2003

Abstracts

1. R. T. Borchardt. Kinetics of Tropolone Inhibition of Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, October, 1972.
2. R. T. Borchardt. Inhibition of Catechol-O-Methyltransferase by 8-Hydroxyquinolone. Midwest Regional Meeting, American Chemical Society, October, 1972.
3. R. T. Borchardt. Mechanism of Pyridoxal 5'-Phosphate Inhibition of Catechol-O-Methyltransferase. West Central States Biochemistry Meeting, October, 1972.
4. R. T. Borchardt, J. A. Huber and Y. S. Wu. The Specificity of the S-Adenosylhomocysteine Binding Sites of Various Methyltransferases. Symposim on the Biological Role of S-Adenosylmethionine in Methyl Transfer and Polyamine Biosynthesis, Gif-sur-Yvette, France, June, 1973.
5. R. T. Borchardt and D. Thakker. Affinity Labeling of Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, October, 1973.
6. R. T. Borchardt, C. F. Cheng, P. H. Cooke and C. R. Creveling. The Purification and Kinetic Properties of Liver Microsomal Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, October, 1973.
7. R. T. Borchardt, J. A. Huber and Y. S. Wu. The Inhibition of Biological Transmethylation Reactions by Analogs of S-Adenosylhomocysteine. Midwest Regional Meeting, American Chemical Society, October, 1973.
8. R. T. Borchardt. A Rapid Spectrophotometric Assay for Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, October, 1973.
9. R. T. Borchardt. Synthesis and Biological Activity of Analogs of S-Adenosylhomocysteine as Inhibitors of Methyltransferases. Symposium on the Biochemistry of S-Adenosylmethionine, Rome, Italy, May, 1974.
10. R. T. Borchardt and D. Thakker. Purification of Catechol-O-Methyltransferase by Affinity Chromatography. Midwest Regional Meeting, American Chemical Society, November, 1974.
11. R. T. Borchardt and D. Thakker. Affinity Labeling of Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, November, 1974.
12. R. T. Borchardt. Irreversible Inhibition of Catechol-O-Methyltransferase by Various Polyphenolic Compounds. Midwest Regional Meeting, American Chemical Society, November, 1974.
13. R. T. Borchardt and Y. S. Wu. Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. Modifications of the Ribose Portion of S-Adenosylhomocysteine. Midwest Regional Meeting, American Chemical Society, November, 1974.
14. M. F. Hegazi, R. T. Borchardt and R. L. Schowen. Toward a Mechanism of COMT Action. Midwest Regional Meeting, American Chemical Society, November, 1974.
15. R. T. Borchardt. Affinity Labeling of Catechol-O-Methyltransferase by the Oxidation products of 6-Hydroxydopamine. *Fed. Proc.*, **34** (Abst. #2858), 1975.
16. R. T. Borchardt. Catechol-O-Methyltransferase: A Model to Study the Mechanism of 6-Hydroxydopamine Interaction with Proteins. Symposium on Chemical Tools in Catecholamine Research. Goteburg, Sweden, July, 1975.
17. R. T. Borchardt and D. R. Thakker. Affinity Labeling of Catechol-O-Methyltransferase. Sixth International Congress of Pharmacology, Helsinki, Finland, July, 1975.
18. R. T. Borchardt. New Approaches to Controlling the Activity of Phenylethanolamine-N-Methyltransferase in Stress. Symposium on Catecholamines and Stress, Bratislava, Czechoslovakia, July, 1975.
19. R. T. Borchardt and D. R. Thakker. Probing the Active Site of Catechol-O-Methyltransferase. Symposium on Selected Topics of Interest to the Medicinal Chemist. American Chemical Society Meetings, Chicago, IL, August, 1975.
20. R. T. Borchardt, E. E. Smissman, D. Nerland and J. R. Reid. The Mechanism of 6-Aminodopamine Inactivation of Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, November, 1975.
21. R. T. Borchardt and D. R. Thakker. Kinetics of N-Ethylmaleimide Inactivation of Catechol-O-Methyltransferase. Midwest Regional Meeting, American Chemical Society, November, 1975.

22. R. T. Borchardt, J. A. Huber and Y. S. Wu. Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. Analogs of S-Adenosylmethionine. Midwest Regional Meeting, American Chemical Society, November, 1975.
23. R. T. Borchardt, J. A. Huber and Y. S. Wu. A Convenient Preparation of S-Adenosylhomocysteine and Related Compounds. Midwest Regional Meeting, American Chemical Society, November, 1975.
24. M. F. Hegazi, R. T. Borchardt and R. L. Schowen. Structure of the Methyl-Transfer Transition State in COMT Action. Midwest Regional Meeting, American Chemical Society, November, 1975.
25. R. T. Borchardt and C. F. Cheng. Purification of Rat Heart and Brain Catechol-O-Methyltransferase by Affinity Chromatography. *Fed. Proc.*, 35 (Abst. #672) 1976.
26. R. T. Borchardt, S. K. Burgess and J. R. Reid. Synthesis and Biological Activity of 2- and/or 5-Methylated Analogs of 6-Hydroxydopamine. Midwest Regional Meeting, American Chemical Society, October, 1976.
27. R. T. Borchardt, C. Schasteen and S. E. Wu. Inhibition of Phenol-Sulfotransferase by Adenosine 3',5'-Diphosphate and Related Nucleotides. Midwest Regional Meeting, American Chemical Society, October, 1976.
28. R. T. Borchardt and C. S. Schasteen. Purification of Phenol-Sulfotransferase by Affinity Chromatography. Midwest Regional Meeting, American Chemical Society, October, 1976.
29. R. T. Borchardt, S. K. Burgess, J. R. Reid, Y. O. Liang and R. N. Adams. Effects of 2- and/or 5-Methylated Analogs of 6-Hydroxydopamine on Noradrenergic and Dopaminergic Neurons. *Fed. Proc.*, 36 (Abst. #3570), 1977.
30. R. T. Borchardt, G. L. Grunewald, C. S. Aldrich and W. C. Vincek. Aromatic Analogs of Phenylethanolamine (PEA) as Substrates and Inhibitors of Phenylethanolamine-N-Methyltransferase (PNMT), American Chemical Society Meeting, March, 1977.
31. C.S.G. Pugh, R. T. Borchardt and H. O. Stone. Inhibition of Newcastle Disease Virion: m-RNA (guanine-7-)-methyltransferase by Analogs of S-Adenosylhomocysteine. American Chemical Society for Microbiology Meeting, May, 1977.
32. R. T. Borchardt, Y. S. Wu and B. S. Wu. S-Adenosyl-L-homocysteine Dialdehyde: An Affinity Labelling Reagent for Histamine-N-Methyltransferase, Midwest Regional Meeting, American Chemical Society, November, 1977.
33. R. T. Borchardt and C. S. Schasteen. Phenol-Sulfotransferase Inactivation by 2,3-Butanedione and Phenylglyoxal: Evidence for an Active Site Arginyl Residue. Midwest Regional Meeting, American Chemical Society, November, 1977.
34. R. T. Borchardt, Y. S. Wu and B. S. Wu. Affinity Labeling of Histamine-N-Methyltransferase by 2',3'-Dialdehyde Analogs of S-Adenosylmethionine and S-Adenosylhomocysteine. *Fed. Proc.*, 37 (Abst. #1322) 1978.
35. R. T. Borchardt. Approaches to the Design of Inhibitors of SAM-Dependent Methyltransferases. Central and Great Lakes Regional Meeting of the American Chemical Society, Symposium on Methyl Group Transfer Reaction, Indianapolis, IN, May, 1978.
36. R. T. Borchardt, J. Olsen, L. Eiden, R. L. Schowen and C. Rutledge. Isolation and Characterization of the Methyl Acceptor Protein (MAP) from Adrenal Chromaffin Granules, Fourth International Catecholamine Symposium, Monterey, CA, Sept., 1978.
37. G. L. Grunewald, W. C. Vincek and R. T. Borchardt. Some New Inhibitors of Epinephrine Biosynthesis, Fourth International Catecholamine Symposium, September, 1978.
38. R. T. Borchardt and C.S.G. Pugh. Analogs of S-Adenosyl-L-Homocysteine, as Inhibitors of Viral mRNA Methyltransferase, International Symposium on Transmethylation, Bethesda, MD, October, 1978.
39. J. Olsen, Y. S. Wu, R. T. Borchardt and R. L. Schowen. Transition-State Structure and Catalytic Power in Methyl Transfer, International Symposium on Transmethylation, Bethesda, MD, October, 1978.
40. L. E. Eiden, R. T. Borchardt and C. O. Rutledge. Protein Carboxymethylation in Neurosecretory Processes, International Symposium on Transmethylation, Bethesda, MD, October, 1978.
41. R. T. Borchardt and C. S. Schasteen. Phenol-Sulfotransferase Inactivation by 2,3-Butanedione, Phenylglyoxal and N-Ethylmaleimide: Evidence for Active Site Arginyl and Sulfhydryl Residues, *Fed. Proc.*, 39 (Abst. #467), 1980.
42. G. L. Grunewald, M. F. Rafferty, R. T. Borchardt and P. Krass. Active Site Probes of Phenylethanolamine N-

Methyltransferase (PNMT), MIKI Meeting, Minneapolis, MN, 1980.

43. A. R. Moorman, R. T. Borchardt, U. G. Patel and J. Huggins. Nucleoside Dialdehydes: Structural Studies and Inhibitory Activity Toward S-Adenosylhomocysteine Hydrolase, MIKI Meeting, Minneapolis, MN, 1980.
44. G. L. Grunewald, M. F. Rafferty, R. T. Borchardt and P. Krass. Active Site Probes of Phenylethanolamine N-Methyltransferase (PNMT), American Chemical Society Meeting, San Francisco, CA, 1980.
45. G. L. Grunewald, M. F. Rafferty, R. T. Borchardt and P. Krass. An Active Site Model of Phenylethanolamine N-Methyltransferase (PNMT). Conformational and Stereochemical Requirements for the Binding of Aromatic and Nonaromatic Substrates and Inhibitors, 10th Annual Meeting of the Society for Neuroscience, Cincinnati, OH, 1980.
46. A. Baranczyk-Kuzma, R. T. Borchardt, C. S. Schasteen and C. Pinnick. Phenol Sulfotransferase: Purification and Characterization of the Rat Liver, Kidney and Brain Enzymes. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 1980.
47. R. T. Borchardt. Inhibitors of Catechol-O-Methyltransferase. Second Conference on Structure and Function of Monoamine Enzymes. Airlie House, VA, 1981.
48. N. Y. Liang, R. E. Tessel, G. Grunewald and R. T. Borchardt. Effects of 2-Cyclooctyl-2-Hydroxyethylamine, an Inhibitor of Norepinephrine-N-Methyltransferase, on Rat Brain Catecholamine Levels and Blood Pressure, *Fed. Proc.*, **40** (Abst. #2829) 1981.
49. J. Yoffe and R. T. Borchardt. Serotonin Uptake in Neuroblastoma and Pheochromocytoma Cells, *Fed. Proc.*, **40** (Abst. #175) 1981.
50. M. Frana, R. T. Borchardt and H. O. Stone. Inhibition of Rous Sarcoma Virus Mediated Cellular Transformation by Analogues of S-Adenosyl-L-homocysteine, *Fed. Proc.*, **40**, 6, 1981
51. R. T. Borchardt, C. S. Schasteen, S. E. Wu, A. B. Kuzma and C. Pinnick. Phenol Sulfotransferase: Purification and Characterization of a Rat Liver Enzyme, Workshop on Sulfate Metabolism and Sulfate Conjugation, Noordwijkerhout, The Netherlands, September, 1981.
52. R. T. Borchardt and J. E. Simmons. General Methods for the Preparation of α - and/or β -Deuterium Labelled 6-Hydroxydopamine Derivatives, Midwest Regional Meeting, American Chemical Society, November, 1981.
53. A. K. Sinhababu and R. T. Borchardt. Synthesis of Ring C-Methylated Analogs of 5,6-Dihydroxyindole and 5,7-Dihydroxyindole, Midwest Regional Meeting, American Chemical Society, November, 1981.
54. A. K. Sinhababu and R. T. Borchardt. Synthesis of 2-Methyl, 4-Methyl and 2,4-Dimethyl-3,5-Dibenzoyloxybenzaldehydes, Midwest Regional Meeting, American Chemical Society, November, 1981.
55. G. L. Grunewald, M. F. Rafferty, B. Pazhenchevsky, V. M. Paradkar and R. T. Borchardt. Positional Effects of Aromatic Substituents on the Activity of Conformationally-defined Amphetamine Analogs Toward PNMT, 31st National Meeting of the American Academy of Pharmaceutical Sciences, Orlando, Florida, November, 1981.
56. Su-Er Wu, R. T. Borchardt and R. L. Schowen, Competitive Isotope Effect Measurements with COMT, Midwest Regional Meeting, American Chemical Society, November, 1981.
57. N. Y. Liang, A. Chandra, R. E. Tessel, G. Grunewald and R. T. Borchardt. Cardiovascular Effects of Centrally Administered Phenylethanolamine N-Methyltransferase (PNMT) Inhibitors, *Fed. Proc.*, **41** (Abst. #8162), 1982.
58. A. Baranczyk-Kuzma and R. T. Borchardt. Properties of Phenol Sulfotransferase (PST) from Rat Tissues. XVIII Symposium of the Polish Biochemical Society, Warsaw, September, 1981.
59. A. Baranczyk-Kuzma, Ronald T. Borchardt and Carol L. Pinnick. The Substrate Specificity of Phenol Sulfotransferase from Different Rat Tissues: New Method of PST Activity Assay. XVIII Symposium of the Polish Biochemical Society, Warsaw, September, 1981.
60. D. M. Houston, E. K. Dolence and R. T. Borchardt, Synthesis of Carbocyclic Nucleosides and Their Acyclic Derivatives, MIKI Meeting, Lawrence, KS, May, 1982.
61. M. F. Rafferty, J. A. Monn, R. T. Borchardt and G. L. Grunewald, Stereochemical and Conformational Aspects of the Binding of Substrates and Inhibitors to the Active Site of Norepinephrine N-Methyltransferase (NMT), American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
62. A. K. Sinhababu and R. T. Borchardt, Synthesis and Biological Evaluation of 4,7- and 4,7-dimethyl-5,6-Dihydroxytryptamine, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.

63. A. K. Sinhababu and R. T. Borchardt, An Efficient Method for the Synthesis of Hydroxyphthalides and Phthalides from *o*-Bromobenzaldehydes, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
64. A. K. Sinhababu and R. T. Borchardt, Silica Gel-Assisted Reductive Cyclization of Dinitrostyrenes to Indoles, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
65. J. E. Simmons and R. T. Borchardt, Regioselective Preparation of Deuterium Labeled 6-Hydroxydopamines, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
66. Su-Er Wu, R. T. Borchardt and R. L. Schowen, Competitive Isotope Effect of Methylation Catalyzed by Catechol-O-Methyltransferase, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
67. Su-Er Wu, R. T. Borchardt and R. L. Schowen, Chiral Instability of the Methyl Donor (-) S-Adenosyl-L-Methionine Under Model Biological Conditions, American Chemical Society Annual Meeting, Kansas City, MO, September, 1982.
68. N. Y. Liang, J. A. Hower and R. T. Borchardt, Release of Endogenous Brain Epinephrine by the Ca^{++} Ionophores X537A and A23187, *Fed. Proc.*, **42** (Abst. #3440) 1983.
69. J. E. Simmons, A. M. Trammel and R. T. Borchardt, An Efficient *In Vitro* Assay for Acetylcholinesterase Regenerators Using Immobilized Enzyme, *Fed. Proc.*, **42** (Abst. #2135) 1983.
70. R. Bartel and R. T. Borchardt, Adenosine Dialdehydes: A Potent Inhibitor of S-Adenosylhomocysteine Hydrolase and S-Adenosylmethionine-Dependent Transmethylations in Mouse L-929 Cells, *Fed. Proc.*, **42** (Abst. #2926) 1983.
71. U. Patel and R. T. Borchardt, Adenine Ribonucleoside Dialdehydes: Potent Inhibitors of Bovine Liver S-Adenosylhomocysteine Hydrolase, *Fed. Proc.*, **42** (Abst. #1627) 1983.
72. Su-Er Wu, R. T. Borchardt and R. L. Schowen, Competitive Isotope Effect of Methylation Catalyzed by Catechol-O-Methyltransferase, *Fed. Proc.*, **42** (Abst. #1207) 1983.
73. B. T. Keller and R. T. Borchardt, Adenosine Dialdehyde: A Potent Inhibitor of Vaccinia Virus Multiplication in Mouse L-929 Cells, *Fed. Proc.*, **42** (Abst. #2230) 1983.
74. N. Y. Liang, C. A. Burrichter, Ronald T. Borchardt and J. L. Voogt, Role of Central Epinephrine Neurons in the Regulation of Serum Prolactin and Luteinizing Hormone Release in Female Rats, 5th International Catecholamine Symposium, Goteberg, Sweden, June, 1983.
75. N. Y. Liang, C. A. Burrichter and R. T. Borchardt, Role of Central Epinephrine Neurons in Regulation of Serum Corticosterone Levels, Third Symposium on Catecholamines and Other Neurotransmitters in Stress, Smolenice Castle, Czechoslovakia, June, 1983.
76. A. K. Sinhababu and R. T. Borchardt, Synthesis and Biological Evaluation of 4,6- and 4,6-Dimethyl 5,7-Dihydroxytryptamines, American Chemical Society Meeting, Washington, DC, September, 1983.
77. H. Gil, O.S. L. Wong, Su-Er Wu, R. T. Borchardt and R. L. Schowen, Measurement of Kinetic Isotope Effects for Enzymatic Transmethylation in a Flash-Biosynthesis System, Midwest Regional Meeting, American Chemical Society, Lawrence, KS, November, 1983.
78. R. T. Borchardt, Transport and Metabolism as Barriers to Macromolecular Drug Delivery, Academy of Pharmaceutical Sciences Annual Meeting, November, 1983.
79. I. Osiecka, R. T. Borchardt, J. A. Fix, C. R. Gardner and P. A. Poster, A Comparison of Intestinal Rings, Isolated Mucosal Cells and Brush Border Membrane Vesicles as Models for *In Vivo* Drug Absorption, *Fed. Proc.*, **43** (Abst. #2122) 1984.
80. B. T. Keller and R. T. Borchardt, Metabolic Conversion of Neplanocin A to S-Neplanocylmethionine by Mouse L-929 Cells, *Fed. Proc.*, **43** (Abst. #332) 1984.
81. U. Patel-Thombre, R. T. Borchardt, D. M. Houston and T. Itoh, Nucleosides, Carbocyclic Nucleosides and Carbocyclic Nucleoside Dialdehydes as Potent Inhibitors of Bovine Liver S-Adenosylhomocysteine Hydrolase, *Fed. Proc.*, **43** (Abst. #749) 1984.
82. B. Matuszewska and R. T. Borchardt, Affinity Labeling of Histamine N-Methyltransferase by S-Adenosylhomocysteine 2',3'-Dialdehyde, *Fed. Proc.*, **43** (Abst. #750) 1984.
83. R. T. Borchardt, B. T. Keller and U. Patel-Thombre, Inhibition of S-Adenosylhomocysteine Hydrolase and Vaccinia Virus Multiplication by Neplanocin A, *Fed. Proc.*, **43** (Abst. #3682) 1984.

84. Su-Er Wu, R. T. Borchardt and R. L. Schowen, Competitive Isotope Effect of Methylation Catalyzed by Catechol-O-Methyltransferase, *Fed. Proc.*, **43** (Abst. #1712) 1984.
85. V. Ramakrishnan and R. T. Borchardt, Adneosine Dialdehyde and Neplanocin A: Potent Inhibitors of S-Adenosylhomocysteine Hydrolase and S-Adenosylmethionine-Dependent Transmethylations in Mouse Neuroblastoma N2a Cells, *Fed. Proc.*, **43** (Abst. #814) 1984.
86. A. Sinhababu, N. Pochopin, R. L. Bartel and R. T. Borchardt, Investigation of the Molecular Mechanism of S-Adenosylhomocysteine Hydrolase, *Fed. Proc.*, **43** (Abst. #1713) 1984.
87. R. T. Borchardt, In Vitro Biological Methods for Assessment of Oral Absorption, Land O'Lakes Conference, June, 1984.
88. R. T. Borchardt and B. Matuszewska, S-Adenosylmethionine-Dependent Transmethylation of Histamine: Purification and Partial Characterization of Guinea Pig Brain and Rat Kidney Histamine N-Methyltransferase, *Frontiers in Histamine Research, An International Symposium, Jouy-En-Josas, France, July, 1984*.
89. R. T. Borchardt, Endogenous Macromolecules as Potential Targets for Site Directed Delivery, *Academy of Pharmaceutical Sciences Annual Meeting, Nov., 1984*.
90. R. L. Bartel and R. T. Borchardt, Quantitation of S-Adenosylhomocysteine Hydrolase in Mouse L-929 Cells Using the Inhibitor Neplanocin A, *Fed. Proc.*, **44** (Abst. #2656) 1985.
91. J. Hower, N. Y. Liang and R. T. Borchardt, Epinine-Induced Synthesis of Epinephrine in Chopped Rat Hypothalamus, *Fed. Proc.*, **44** (Abst. #7141) 1985.
92. R. T. Borchardt and A. K. Ghosh, Protein Carboxymethyltransferase Catalyzed Methylation and Demethylation of Methyl Acceptor Proteins, *Fed. Proc.*, **44** (Abst. #347) 1985.
93. O. Osiecka, R. T. Borchardt, P. Porter, M. Cortese, J. Fix and C. R. Gardner, Intestinal Uptake of α -Methyldopa: A Saturable, Energy Dependent Amino Acid Transport System, *Fed. Proc.*, **44** (Abst. #4135) 1985.
94. B. Matuszewska and R. T. Borchardt, Rat Kidney Histamine N-Methyltransferase: Purification and Properties, *Fed. Proc.*, **44** (Abst. #358) 1985.
95. A. K. Ghosh and R. T. Borchardt, Characterization of Norepinephrine Uptake in Cultured Neuroblastoma Cells, *Fed. Proc.*, **44** (Abst. #3831) 1985.
96. B. T. Keller, R. S. Clark, A. E. Pegg and R. T. Borchardt, Purification and Characterization of Some Metabolic Effects of S-Neplanocylmethionine, *Fed. Proc.*, **44** (Abst. #6950) 1985.
97. V. Ramakrishnan, R. Bartel and R. T. Borchardt, Turnover of S-Adenosylhomocysteine Hydrolase in Murine L-929 Cells and Neuroblastoma N2a Cells, *Fed. Proc.*, **44** (Abst. #3982) 1985.
98. A. M. Trammel, J. E. Simmons and R. T. Borchardt, Analysis of Acetylcholinesterase Reactivators in Biological Tissues by High Performance Liquid Chromatography, *Fifth Annual Chemical Defense Bioscience Review, Applied Physics Laboratory of Johns Hopkins University, Columbia, MD, May, 1985*.
99. R. T. Borchardt and B. T. Keller, Metabolism and Mechanism of Action of Neplanocin A: A Potent Inhibitor of S-Adenosyl-L-homocysteine Hydrolase. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.
100. R. L. Bartel and R. T. Borchardt. Quantitation of S-Adenosylhomocysteine Hydrolase in Mouse L-929 Cells Using the Inhibitor Neplanocin A. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.
101. B. Matuszewska and R. T. Borchardt. The Role of NAD⁺ in the Inhibition of S-Adenosylhomocysteine Hydrolase by Neplanocin A. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.
102. V. Ramakrishnan and R. T. Borchardt. Regulation of S-Adenosylhomocysteine Hydrolase Activity in Neuroblastoma N2a Cells. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.
103. A. K. Ghosh and R. T. Borchardt. Protein Carboxymethylation in Neuroblastoma N2a Cells: Characterization of Endogenous Protein Carboxymethyltransferase and Methyl Accepting Proteins. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.

104. Su-Er Wu, R. T. Borchardt and R. L. Schowen. Rate Limiting Events and Transition-State Structure in the Enzymic Methylation of Small Molecules. Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design", Bergen, Norway, July, 1985.
105. A. Baranczyk-Kuzma, K. L. Audus and R. T. Borchardt. Activity of Marker and Catecholamine-Metabolizing Enzymes Associated with Primary Cultures of Brain Microvessel Endothelial Cells, *Fed. Proc.*, **45**, (Abst. #4536) 1986.
106. K. L. Audus and R. T. Borchardt. Neutral Amino Acid Transport Across Brain Microvessel Endothelial Cell Monolayers, *Fed. Proc.*, **45** (Abt. #1505) 1986.
107. S. Rim, K. L. Audus and R. T. Borchardt. Relationship Between Octanol/Buffer Partition Coefficient and Transcellular Diffusion Across Bovine Brain Microvessel Endothelial Cell Monolayers, *Fed. Proc.*, **45** (Abst. #1504) 1986.
108. D. R. Borcharding and R. T. Borchardt. Molecular Dissections of Neplanocin A: Potential Inhibitors of S-Adenosylhomocysteine Hydrolase, MIKI Meeting, Chicago, IL, April, 1986.
109. J. Dean-Garren and R. T. Borchardt. Sulfation by Isolated Intestinal Epithelial Cells. American Association of Pharmaceutical Scientists Meeting, Washington, DC, November, 1986.
110. R. T. Borchardt and K. Audus. Bovine Brain Microvessel Endothelial Cell Monolayers as a Model for the Blood Brain Barrier. New York Academy of Science Meeting entitled, "Controlled Delivery of Drugs: Barriers, Technologies and Therapeutic Approaches", January, 1987.
111. B. T. Keller and R. T. Borchardt. Cultured Bovine Brain Capillary Endothelial Cells (BBCEC) - A Blood-Brain Barrier Model for Studying the Binding and Internalization of Insulin and Insulin-like Growth Factors 1, *Fed. Proc.*, **46** (Abst. #416) 1987.
112. M. Hasobe, J. McKee, D. Borcharding, B. Keller and R. T. Borchardt. Effects of 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-adenine (1) and -3-Deazaadenine (2) on the Metabolism of S-Adenosylhomocysteine (AdoHcy) in Mouse L-929 Cells, *Fed. Proc.*, **46** (Abst. #93) 1987.
113. S. D. Paisley and R. T. Borchardt. Is Adenine Releasing Involved in the Inactivation of Bovine Liver S-Adenosylhomocysteine Hydrolase (AdoHcy) by Neplanocin A?, *Fed. Proc.*, **46** (Abst. #859) 1987.
114. S. R. Narayanan and R. T. Borchardt. An Improved Method for Purification of Bovine Liver S-Adenosylhomocysteine Hydrolase by Affinity Chromatography on Blue Dextran Agarose, *Fed. Proc.*, **46** (Abst. #858) 1987.
115. D. R. Borcharding, S. A. Scholtz, S. R. Narayanan, M. Hasobe, B. Keller and R. T. Borchardt. 9-(Trans-2'-trans-3'-Dihydroxycyclopent-4-enyl)-Adenine (1) and -3-Deazaadenine (2): Potent Inhibitors of Bovine Liver S-Adenosylhomocysteine (AdoHcy) Hydrolase and Vaccinia Virus Multiplication in Mouse L929 Cells, *Fed. Proc.*, **46** (Abst. #860) 1987.
116. A. M. Trammel and R. T. Borchardt. Choline Transport in Cultured Brain Microvessel Endothelial Cells, *Pharmaceutical Res.*, **4**, 541 (Abst. #PD428) 1987.
117. K. R. Smith and R. T. Borchardt. Permeability and Mechanism of Albumin Transport Across Blood-Brain Capillary Endothelial Cells, *Pharmaceutical Res.*, **4**, 541 (Abst. #PD427) 1987.
118. M. Hasbe, J. McKee, D. Borcharding and R. T. Borchardt. Antiviral Effects of 9-(trans-2'-trans-3'-dihydroxycyclopent-4'-enyl)-Adenine (1) and -3-Deazaadenosine (2). VIIth International Congress of Virology, Edmonton, Canada, Sept., 1987.
119. R. T. Borchardt. Endothelial Cells of the Vasculature: A Significant Barrier to Effective Drug Delivery, Controlled Release Society, Inc. Meeting, Abst. #3, Toronto, Canada, August, 1987.
120. R. T. Borchardt. The Use of Isolated Epithelial and Cultured Endothelial Cells in the Design of Novel Drug Delivery Systems, Xth International Congress of Pharmacology, Sydney, Australia, August, 1987.
121. R. T. Borchardt. Transport Barriers in the Absorption of Peptide Drugs, 47th International Congress of Pharmaceutical Sciences of F.I.P., Amsterdam, The Netherlands, September, 1987.
122. B. T. Keller, K. R. Smith and R. T. Borchardt. Transport Barriers to Absorption of Peptides, International FIP Satellite Symposium entitled, "Disposition and Delivery of Peptide Drugs", Leiden, The Netherlands, September, 1987.
123. D. R. Borcharding, S. A. Scholtz and R. T. Borchardt. The Synthesis of Optically Active Dihydroxycyclopentenones from Carbohydrates. American Chemical Society Meeting, New Orleans, LA, September, 1987.

124. J. E. Chastain and R. T. Borchardt. Potential Substrates for the Large Neutral Amino Acid Transport System of Bovine Brain Microvessel Endothelial Cell Monolayers. *Fed. Proc.*, 20 (Abst. #1852) 1987.
125. R. Bartel and R. T. Borchardt. Morphological and Biochemical Characterization of Epidermal Keratinocytes in Culture. Symposium entitled, "Biological Transport Mechanisms as a Basis for Rational Drug Delivery", Kalamazoo, Michigan, November, 1987.
126. I. J. Hidalgo, T. J. Raub, N. F. Ho and R. T. Borchardt. Characterization and Validation of the Caco-2 Cell Line as a Useful Model System for Intestinal Epithelial Transport. Symposium entitled, "Biological Transport Mechanisms as a Basis for Rational Drug Delivery", Kalamazoo, Michigan, November, 1987.
127. M. Hasobe, J. G. McKee, D. R. Borcharding and R. T. Borchardt. Effects of 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine (1) and -3-Deazaadenine (2) on the Metabolism of S-Adenosylhomocysteine (AdoHcy) and Vaccinia Virus Replication in Mouse L929 Cells. JUC Pharm. Sci. '87 Meeting, Hawaii, December, 1987.
128. M. Kawase, A. K. Sinhababu and R. T. Borchardt. Mechanism of Autoxidation of 5,7-Dihydroxytryptamine: Effects of Fluorine Substitution in Positions 4 and/or 6. American Chemical Society Annual Meeting, Toronto, Canada, May, 1988.
129. M. Hasobe, H. Ishii, J. G. McKee and R. T. Borchardt. The Effects of 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine (1) in Combination with DL Homocysteine (Hcy) on the Metabolism of S-Adenosylhomocysteine (AdoHcy) and on Vaccinia Virus Replication in Murine L929 Cells, *FASEB Journal*, 2, A1752 (Abst. #8458) 1988.
130. I. J. Hidalgo, T. J. Raub, S. L. Kuentzel and R. T. Borchardt. Characterization of the Caco-2 Cell Line as an Intestinal Epithelial Model System, *FASEB Journal*, 2, A734 (Abst. #2539) 1988.
131. I. J. Hidalgo, T. J. Raub and R. T. Borchardt. Permeability Properties of an Intestinal Epithelial Model System (Caco-2 Cell), *FASEB Journal*, 2, A733 (Abst. #2538) 1988.
132. J. C. Yeh, A. Vedani and R. T. Borchardt. The Generation of the Three Dimensional Structure of S-Adenosyl-L-Homocysteine Hydrolase from the Primary Sequence of the Rat Liver Enzyme and the Tertiary Structure of Lactate Dehydrogenase Using Molecular Modeling, *FASEB Journal*, 2, A1766 (Abst. #8540) 1988.
133. S. D. Paisley, M. S. Wolfe and R. T. Borchardt. Oxidation of Neplanocin A and 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine (1) to the Corresponding 3'-Ketocyclopentenyl Derivatives by S-Adenosylhomocysteine (AdoHcy) Hydrolase, *FASEB Journal*, 2, A119 (Abst. #4783) 1988.
134. B. Keller, K. Hillgren, C. Tseng, V. Marquez and R. Borchardt. Effects of S-Adenosylhomocysteine (AdoHcy) Hydrolase Inhibitors on Human Colon Carcinoma Cells, *FASEB Journal*, 2, A1348 (Abst. #6116) 1988.
135. M. Hasobe, J. G. McKee, H. Ishii and R. T. Borchardt. Elucidation of the Mechanism Responsible for the Synergistic Effects of DL-Homocysteine (Hcy) on the Anti Vaccinia Virus Effect of the S-Adenosylhomocysteine (AdoHcy) Hydrolase Inhibitor 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine 1, Second International Conference on Antiviral Research, Williamsburg, Virginia, April, 1988.
136. M. Kawase, R. T. Borchardt and A. K. Sinhababu. One Step Conversion of Tert-Butyldimethylsilyl Ethers of Phenols to Benzyl or Methyl Ethers. The 108th Annual Meeting of the Pharmaceutical Society of Japan, Hiroshima, Japan, April, 1988.
137. R. T. Borchardt. Cultured Bovine Brain Microvessel Endothelial Cells: A Model System Useful in Studying the Transport and Metabolism of Peptides and Proteins Across the Blood Brain Barrier. International Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, June, 1988.
138. R. T. Borchardt. Epithelial and Endothelial Barriers to the Effective Delivery of Protein. Symposium entitled, "The Biology and Pharmacology of Hemopoietic Growth Factors", Newport, Rhode Island, June, 1988.
139. R. T. Borchardt. Cultured Bovine Brain Capillary Endothelial Cells: A Model System for Blood-Brain Barrier Transport and Metabolism. 4th Japanese-American Conference on Pharmacokinetics and Biopharmaceutics, San Francisco, California, July, 1988.
140. S. D. Paisley, M. Hasobe, M. S. Wolfe and R. T. Borchardt. Elucidation of the Mechanism by Which Neplanocin A and 9-(Trans-2',Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine Inactivate S-Adenosylhomocysteine (AdoHcy) Hydrolase and Elevated Cellular Levels of AdoHcy. 8th International Round Table on Nucleosides and Nucleotides, Pensacola, Florida, October, 1988.
141. R. T. Borchardt. The Application of Cell Culture Models to Study Drug Transport Processes: An Overview, 3rd Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October, 1988.

142. J. A. Garren and R. T. Borchardt. Cultured Human Colon Carcinoma Cells (Caco-2) as a Model System for Studying Drug Sulfate Conjugation in the Intestinal Epithelium, *Pharmaceutical Res.*, 5, S-199 (Abst. #PP1404) 1988.
143. G.K.E. Scriba and R. T. Borchardt. Metabolism of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) by Bovine Brain Capillary Endothelial Cell Monolayers, *Pharmaceutical Res.*, 5, S-206 (Abst. #PP1429) 1988.
144. G.K.E. Scriba and R. T. Borchardt. Metabolism of Ibopamine and Related Esters of Epinine by Bovine Brain Capillary Endothelial Cell Monolayers, *Pharmaceutical Res.*, 5, S-204 (Abst. #1421) 1988.
145. M. V. Shah, G.K.E. Scriba, K. L. Audus and R. T. Borchardt. The Use of Polycarbonate Membrane Supports in Studying the Permeability of Bovine Brain Capillary Endothelial Cell (BBCEC) Monolayers, *Pharmaceutical Res.*, 5, S-111 (Abst. #953) 1988.
146. N. P. Bhatt, K. Patel and R. T. Borchardt. Kinetics of Non-enzymatic Deamidation of Adrenocorticotropin Hormone (ACTH), *Pharmaceutical Res.*, 5, S-72 (Abst. #PD797) 1988.
147. P. K. Shah and R. T. Borchardt. Peptidase Activity in Cultured Mouse Keratinocytes and Neonatal Mouse Epidermis, *Pharmaceutical Res.*, 5, S-188 (Abst. #PP1357) 1988.
148. J. L. Wolfe and R. T. Borchardt. Relationship Between Molecular Weight and Transport Through Bovine Brain Capillary Endothelial Cells (BCEC's) and Pulmonary Artery Endothelial Cells (PAEC's), *Pharmaceutical Res.*, 5, S-110 (Abst. #952) 1988.
149. C. L. Pryor and R. T. Borchardt. Fluorescent Lipid Analogue Metabolism and Transport in Cultured Human Colon Carcinoma Cells (Caco-2), *Pharmaceutical Res.*, 5, S198 (Abst. #PP1400) 1988.
150. I. J. Hidalgo and R. T. Borchardt. Transport of Taurocholic Acid in An Intestinal Epithelial Model System (Caco-2 Cell), *Pharmaceutical Res.*, 5, S-110 (Abst. #949) 1988.
151. I. J. Hidalgo and R. T. Borchardt. Amino Acid Transport in a Novel Model System of the Intestinal Epithelium (Caco-2 Cell), *Pharmaceutical Res.*, 5, S-110 (Abst. #PD950) 1988.
152. K. Patel and R. T. Borchardt. Kinetics of Deamidation of Asparaginy-Glyciny Sequence in Peptides, *Pharmaceutical Res.*, 5, S-72 (Abst. #PD798) 1988.
153. K. L. Amsberry and R. T. Borchardt. Lactonization of o-Hydroxyhydrocinnamic Acid Amides and Their Potential as Drug Carriers, *Pharmaceutical Res.*, 5, S-61 (Abst. #PD756) 1988.
154. R. L. Bartel and R. T. Borchardt. Characterization of Epidermal Keratinocyte Cultures as a Potential Model for Skin Transport and Metabolism, *Pharmaceutical Res.*, 5, S-79 (Abst. #PD828) 1988.
155. G.K.E. Scriba and R. T. Borchardt. Metabolism of Catecholamine Esters in Cell Cultures of Cerebral Microvessels as an *In Vitro* Model of the Blood-Brain Barrier. German Pharmaceutical Association, Erlangen, FRG, September, 1988.
156. R. T. Borchardt. Cultured Epithelial Cells. An *In Vitro* Model System for Studying Protein Transport and Metabolism. The Second Annual University of California-San Francisco Biotechnology Symposium, San Francisco, CA, October, 1988.
157. J. C. Yeh, A. Vedani and R. T. Borchardt. A Potential Model of the Active Site of S-Adenosyl-L-Homocysteine Hydrolase Derived by Molecular Modeling. *J. Cell Biol.*, 107, 833a (Abst. #4740), 1989.
158. R. T. Borchardt. Endothelial Cells of the Brain Vasculature: A Significant Barrier to CNS Drug Delivery. Frontiers of the Life Sciences Symposium, 1988 AAAS Annual Meeting, San Francisco, CA, January, 1989.
159. C. L. Stevenson, M. C. Manning and R. T. Borchardt. Influence of α -Helical Structure on Deamidation of Asparagine Residues. *Biophysical Journal*, 55, 357a (Abst. #Tu-Pos280), 1989.
160. C. L. Pryor and R. T. Borchardt. Metabolism and Transport of Fluorescently-Labelled Phospholipids in Cultured Human Colon Carcinoma Cells (Caco-2), *Biophysical Journal*, 55, 158 (Abst. #M-Pos251), 1989.
161. K. Patel, C. Oliyai, R. T. Borchardt and M. C. Manning. Structural Control of Protein Degradation. Peptide Models of Deamidation Sites on Proteins. 1989 UCLA Symposium entitled, "Protein and Pharmaceutical Engineering", Park City, UT, January, 1989.
162. I. J. Hidalgo, K. Hillgren, G. M. Grass and R. T. Borchardt. Permeability of Caco-2 Cell Monolayers in a Novel Diffusion Cell, Western Regional Meeting of the American Association of Pharmaceutical Scientists, Reno, NV, February, 1989.

163. R. L. Bartel and R. T. Borchardt. Characterization of Epidermal Keratinocyte Cultures as a Potential Model for Skin Transport and Metabolism. *J. Invest. Dermatol.*, 92:: 400, 1989.
164. I. J. Hidalgo, A. Kato and R. T. Borchardt. Epidermal Growth Factor (EGF) Binding in a Human Colon Carcinoma Cell-Line (Caco-2), *FASEB Journal*, 3, A899 (Abst. #3906), 1989.
165. M. V. Shah and R. T. Borchardt. Characterization of the Nucleoside Transport System in Bovine Brain Microvessel Endothelial Cell (BBMEC) Monolayers, *Pharmaceutical Res.*, 6, S-77 (Abst. #PD801), 1989.
166. K. Patel and R. T. Borchardt. The Effect of Primary Sequence on the Deamidation of a Model Hexapeptide, *Pharmaceutical Res.*, 6, S-129 (Abst. #PD1011), 1989.
167. I. J. Hidalgo, K. M. Hillgren, G. M. Grass and R. T. Borchardt. Characterization of the Aqueous Boundary Layer in Caco-2 Cells Using a Novel Diffusion Cell, *Pharmaceutical Res.*, 6, S-114 (Abst. #PD950), 1989.
168. A. M. Trammel and R. T. Borchardt. The Effects of Astrocytes and Glioma Cells on the Permeability of Cultured Brain Microvessel Endothelial Cells, *Pharmaceutical Res.*, 6, S-88 (Abst. #PD847), 1989.
169. M. Hu and R. T. Borchardt. Effects of pH and Glucose on L-Phenylalanine Transport Across an Intestinal Epithelial Cell Model System (Caco-2), *Pharmaceutical Res.*, 6, S-89 (Abst. #PD851), 1989.
170. I. J. Hidalgo and R. T. Borchardt. Polarity of Bile Acid Uptake and Efflux in an Intestinal Epithelial Cell Line, *Pharmaceutical Res.*, 6, S-115 (Abst. #PD953), 1989.
171. P. K. Shah and R. T. Borchardt. Cultured Human Keratinocytes as an *In Vitro* Model to Study Peptide Metabolism in Human Skin, *Pharmaceutical Res.*, 6, S-148 (Abst. #PD1085), 1989.
172. R. T. Borchardt. The Use of Cultured Epithelial and Endothelial Cells to Study Drug Transport and Metabolism, Drug Delivery Systems Conference, Tokyo, Japan, July, 1989.
173. R. T. Borchardt, K. Patel, N. Bhatt, C. Stevenson and M. Manning. Deamidation: A Major Pathway for Chemical Degradation of Proteins and Peptides, The Academy of Pharmaceutical Sciences and Technology Conference, Shirakaabako, Japan, July, 1989.
174. R. T. Borchardt. Pharmaceutical Applications of Cell Culture: An Overview. NATO Advanced Research Workshop on Drug Transport in Cell Culture, Bandol, France, September, 1989.
175. M. Cools, M. Hasobe, E. De Clercq and R. T. Borchardt. Mechanism of Synergy Between (RS)-3-(Adenin-9-yl)-2-Hydroxypropanoic Acid [(RS)-AHPA] and Homocysteine, International Symposium on Antiviral Chemotherapy, Porto Cervo, Sardinia, Italy, October, 1989.
176. G.K.E. Scriba and R. T. Borchardt. Metabolism of Catecholamine Prodrugs in Cultured Brain Microvessel Endothelial Cells. NATO Advanced Workshop on Drug Transport in Cell Culture. Bandol, France, September, 1989.
177. R. L. Bartel and R. T. Borchardt. Characterization of Epidermal Keratinocyte Cultures as a Model for Skin Transport and Metabolism. NATO Advanced Workshop on Drug Transport in Cell Culture. Bandol, France, September, 1989.
178. I. J. Hidalgo and R. T. Borchardt. Nutrient Transport in Caco-2 Cell Monolayers. NATO Advanced Workshop on Drug Transport in Cell Culture. Bandol, France, September, 1989.
179. D. L. Kramer, J. R. Sufrin, R. T. Borchardt and C. W. Porter, Consequence of Concomitant Inhibition of S-Adenosylmethionine (AdoMet) Biosynthesis and Polyamine Biosynthesis on Cellular Methylation, UCLA Symposium, 1990.
180. M. W. Wolfe, B. L. Anderson, D. R. Borcharding and R. T. Borchardt, Enantiospecific Syntheses of Aristeromycin and Neplanocin A, American Chemical Society National Meeting, Boston, MA, April, 1990.
181. M. S. Wolfe, Y. Lee, W. J. Bartlett and R. T. Borchardt, 4'-Modified Analogs of Aristeromycin and Neplanocin A: Synthesis and AdoHcy Hydrolase Inhibition, American Chemical Society National Meeting, Boston, MA, April, 1990.
182. J. C. Yeh, R. T. Borchardt and A. Vedani, Predicting Inhibitory Potency Using a Molecular Model of the Active Site of S-Adenosylhomocysteine Hydrolase, *FASEB Journal*, 4, A2316 (Abst. #3599) 1990.
183. M. Hasobe, Y. Lee, J. G. McKee, D. B. Ault-Riche and R. T. Borchardt, The Role of S-Adenosylhomocysteine Hydrolase in the Formation of S-Adenosylhomocysteine in Murine L-929 Cells, *FASEB Journal*, 4, A2049 (Abst. #2058) 1990.
184. M. Hasobe, S. Liang, D. B. Ault-Riche, D. Borcharding, M. S. Wolfe and R. T. Borchardt, 9-(Trans-2',Trans-3'-dihydroxycyclopentenyl)-Adenine and 3-Deazaadenine: Analogs of Aristeromycin Which Exhibit Potent Antiviral

- Activity with Reduced Cytotoxicity", *FASEB Journal*, 4, A1771 (Abst. #455) 1990.
185. Y. Lee, M. Hasobe, D. B. Ault-Riche, M. S. Wolfe, W. J. Bartlett, D. R. Borcharding and R. T. Borchardt, Effects of 4'-Modified Analogs of Aristeromycin and Neplanocin A on Metabolism of S-Adenosylhomocysteine in Mouse L-929 Cells, *FASEB Journal*, 4, 2050 (Abst. #2064) 1990.
 186. R. T. Borchardt, Protein Transport Through Cultured Brain Microvessel Endothelial Cells: A Model of the Blood Brain Barrier. XIth International Congress of Pharmacology, Amsterdam, The Netherlands, July, 1990.
 187. M. Hu and R. T. Borchardt, Mechanism of Transcellular Transport of L-Phenylalanine in an Intestinal Epithelial Model System (Caco-2) I: Apical Uptake of Phenylalanine, *Pharmaceutical Res.*, 7, S-156 (Abst. #PDD 7177), 1990.
 188. J. L. Wolfe and R. T. Borchardt, Kinetics and Mechanism of Degradation of Quinone Propionic Acid Amides, *Pharmaceutical Res.*, 7, S-126 (Abst. #PDD 7060), 1990.
 189. M. V. Shah, K. C. Pullaiah, C. C. Chu and R. T. Borchardt, Implications of Phosphorylation of Nucleosides on Their Transport Across the Blood-Brain Barrier (BBB). *Pharmaceutical Res.*, 7, S-132 (Abst. #PDD 7084), 1990.
 190. I. J. Hidalgo and R. T. Borchardt, Mechanism of Bile Acid Transport in a Cell Culture Model System of the Intestinal Epithelium. *Pharmaceutical Res.*, 7, S-155 (Abst. #PDD 7175), 1990.
 191. K. L. Amsberry and R. T. Borchardt, Redox and Esterase-Sensitive Pro-Prodrug Systems for Amines. *Pharmaceutical Res.*, 7, S-151 (Abst. #PDD 7160), 1990.
 192. Y. Takakura and R. T. Borchardt, Characterization of Glucose Uptake and Transport in Primary Cultures of Bovine Brain Microvessel Endothelial Cells. *Pharmaceutical Res.*, 7, S-113 (Abst. #PDD 7008), 1990.
 193. Y. Takakura, A. M. Trammel and R. T. Borchardt, Regulation of Glucose Uptake by Astroglial Cells in Primary Cultures of Bovine Brain Microvessel Endothelial Cells. *Pharmaceutical Res.*, 7, S-133 (Abst. #PDD 7085), 1990.
 194. P. K. Shah, K. L. Amsberry and R. T. Borchardt, Novel N-Terminal Modified Double Prodrugs of Leu-Enkephalin to Prevent Aminopeptidase-Catalyzed Metabolism in Cultured Keratinocytes and Skin. *Pharmaceutical Res.*, 7, S-174 (Abst. #PDD 7252), 1990.
 195. C. Oliyai, M. C. Manning and R. T. Borchardt, Kinetics of Aspartate Degradation in VAL-TYR-PRO-ASP-GLY-ALA. *Pharmaceutical Res.*, 7, S-129 (Abst. #PDD 7071), 1990.
 196. R. T. Borchardt, Cultured Brain Microvessel Endothelial Cells: An *In Vitro* Model of the Blood-Brain Barrier. 1991 World Congress on Cell and Tissue Culture, June, 1991.
 197. A. Baranczyk-Kuzma, K. L. Audus, R. T. Borchardt, Characterization of Phenol Sulfotransferase from Rhesus Macaque Monkey Brain. XXVII Meeting of the Polish Biochemical Society, Lublin, Poland, Sept. 18-21, 1991.
 198. R. T. Borchardt, Chemical and Physical Stability of Protein Pharmaceuticals. Pharmacy World Congress '91, Washington, DC, Sept., 1991.
 199. R. T. Borchardt, Computer-Aided Drug Delivery - An Overview, International Society of Quantum Biology and Pharmacology President's Meeting, Stanford University, Sept., 1991.
 200. R. Gray, D. Vander Velde, M. Manning and R. T. Borchardt, Determination of the Solution Structure of Delta-Sleep-Inducing Peptide (DSIP). *Pharmaceutical Res.*, 8, S-58, (Abst. #BIOTEC 2051), 1991.
 201. C. L. Stevenson, T. D. Williams and R. T. Borchardt, Differentiation of Asparagine, Aspartate and Iso-Aspartate Residues by Mass Spectrometry, *Pharmaceutical Res.*, 8, S-38 (Abst. #APQ1136), 1991.
 202. J. Wolfe and R. T. Borchardt, Degradation Kinetics of Quinone Propionic Acid Amides, *Pharmaceutical Res.*, 8, S-211 (Abst. #PDD7339), 1991.
 203. C. Oliyai and R. T. Borchardt, Kinetics of Aspartate Degradation in a Model Hexapeptide, *Pharmaceutical Res.*, 8, S-198 (Abst. #PDD7285), 1991.
 204. S. Raeissi and R. T. Borchardt, Cultured Human Adenocarcinoma Cells (Caco-2) as a Model to Study the Mechanism by Which Adjuvants Enhance Intestinal Permeability of Drugs, *Pharmaceutical Res.*, 8, S-217 (Abst. #PDD7364), 1991.
 205. D. W. Miller and R. T. Borchardt, Distribution of Binding Sites on Cultured Bovine Brain Endothelial Cells and Their Possible Role in the Transport of Insulin Across the Blood-Brain Barrier, *J. Cell Biol.*, 115, (3), 261a, 1991.
 206. P. J. Chikhale and R. T. Borchardt, "Metabolism of α -Methyl Dopa in Cultured Intestinal Epithelial (Caco-2) Cells",

Pharmaceutical Res., 9, S-288 (Abst. PPDM 8125), 1992.

207. A. S. Tang, P. J. Chikhale, P. K. Shah and R. T. Borchardt, "Utilization of an Intestinal Epithelial Cell Culture System (Caco-2) for Evaluating Cytoprotective Agents", *Pharmaceutical Res.*, 9, S-172 (Abst. PDD 705), 1992.
208. C. L. Stevenson, M. E. Donlan, A. R. Friedman and R. T. Borchardt, "Solution Conformation of Leu²⁷hGRF (1-32) NH₂ and Its Deamidation Product by 2D NMR and CD", *Pharmaceutical Res.*, 9, S-79 (Abst. BIOTEC 2052), 1992.
209. C. L. Stevenson, M. E. Donlan, T. M. Kubiak, A. R. Friedman and R. T. Borchardt, "Deamidation Rates and Solution Conformation of Growth Hormone Releasing Factor Analogs", *Pharmaceutical Res.*, 9, S-80 (Abst. BIOTEC 2053), 1992.
210. Shihong Li, S. Schoneich, G. S. Wilson and R. T. Borchardt, "Ascorbic Acid Promotes Rather than Inhibits the Oxidation of Methionine to Methionine Sulfoxide in Small Model Peptides", *Pharmaceutical Res.*, 9, S-81 (Abst. BIOTEC 2058), 1992.
211. Ka-Yun Ng and R. T. Borchardt, "Biotin Transport in a Human Intestinal Epithelial Cell Line, Caco-2", *Pharmaceutical Res.*, 9, S-246 (Abst. PPDM 8358), 1992.
212. D. C. Kim, R. T. Borchardt, M. J. Ruwart, K. F. Wilkinson, A. W. Harrison and J. Fisher, "Can the Bile Acid Transporter be Used to Enhance the Intestinal Permeability of Renin Inhibitory Peptides?", *Pharmaceutical Res.*, 9, S-246 (Abst. PPDM 8359), 1992.
213. E. G. Brunt, P. S. Burton and R. T. Borchardt, "The Influence of Peptide Structure on Transport Across the Blood-Brain Barrier", *Pharmaceutical Res.*, 9, S-75 (Abst. BIOTEC 2033), 1992.
214. C. Oliyai, J. P. Patel, L. Carr and R. T. Borchardt, "Stability of Lyophilized Formulations of a Model Asp-Containing Hexapeptide", *Pharmaceutical Res.*, 9, S-81 (Abst. BIOTEC 2057), 1992.
215. C. Oliyai and R. T. Borchardt, "The Effect of Primary Structure on the Degradation of Aspartic Acid Residues in Model Hexapeptides", *Pharmaceutical Res.*, 9, S-70 (Abst. BIOTEC 2015), 1992.
216. C. Schoneich, Shihong Li, G. S. Wilson and R. T. Borchardt, "Iron-Thiol Induced Oxidation of Methionine in Small Model Peptides. Intramolecular Catalysis by Histidine", *Pharmaceutical Res.*, 9, S-69 (Abst. BIOTEC 2012), 1992.
217. R. Gray, D. Vander Velde, C. Burke, G. Sanya, M. Manning, C. R. Middaugh and R. T. Borchardt, "The Effect of Primary Sequence on the Conformation of Delta-Sleep Inducing Peptide (DSIP)", *Pharmaceutical Res.*, 9, S-70 (Abst. BIOTEC 2016), 1992.
218. R. J. Anderegg, C. L. Stevenson and R. T. Borchardt, "Probing Helical Content of Peptides by Deuterium Exchange Electrospray Mass Spectrometry", 40th ASMS Conference on Mass Spectrometry and Allied Topics, June, 1992, Washington, DC.
219. R. T. Borchardt, "Designing Peptides with Enhanced Blood Brain Barrier Permeability", Symposium entitled, "Drug Transport to the Brain", Leiden University, Leiden, The Netherlands, October, 1992.
220. E. G. Brunt, P. S. Burton and R. T. Borchardt, "The Influence of Peptide Structure on Transport Across the Blood Brain Barrier", Symposium entitled, "Drug Transport to the Brain", Leiden University, Leiden, The Netherlands, October, 1992.
221. D. G. Vander Velde, P. R. Burton and R. T. Borchardt, "The Effect of Conformation Isomerism on Membrane Permeability of Model Peptides", Keystone Symposium on "Prospects and Progress in Drug Design Based on Peptides and Proteins", Taos, New Mexico, March, 1993.
222. R. T. Borchardt, "Rational Design of Peptides with Enhanced Membrane Permeability", Keystone Symposium on "Prospects and Progress in Drug Design Based on Peptides and Proteins", Taos, New Mexico, March, 1993.
223. C. S. Yuan, J. Yeh, S. Liu and R. T. Borchardt, "Mechanism of Inactivation of S-Adenosylhomocysteine Hydrolase by (Z)-4',5'-Didehydro-5'-Deoxy-5'-Fluoroadenosine", *FASEB Journal*, 7, A1175 (1993).
224. R. T. Borchardt, "Chemical Instability of Proteins in Solution and in Lyophilized Formulations", American Chemical Society Meeting, Spring, 1993.
225. R. T. Borchardt, "The Use of Cultured Intestinal Epithelial Cells (Caco-2) to Study the Vectorial Transport of Bile Acids", Physiology Society of Great Britain Meeting, Spring, 1993.
226. R. T. Borchardt, "S-Adenosylhomocysteine Hydrolase as a Target for the Design of Antiviral Agents", 1993 CIC Conference, Sherbrooke, Quebec, Canada, May, 1993.

227. R. T. Borchardt, "Biopharmaceutical Assessment", 35th Annual International Industrial Research Conference, Merrimac, Wisconsin, June, 1993.
228. Ka-yun Ng, D. W. Miller, A. Kato and R. T. Borchardt, "An Improved In Vitro Model of the Blood Brain Barrier for Estimating Macromolecule Transport", Pharmaceutical Res., 10, S-180 (Abst. PDD 7022), 1993.
229. Ka-yun Ng, H. Lane, G. Grass and R. T. Borchardt, "Characterization of the Unstirred Water Layer in Cultured Brain Microvessel Endothelial Cells", Pharmaceutical Res., 10, S-180 (Abst. PDD 7021), 1993.
230. Ka-yun Ng, E. G. Chikhale, P. S. Burton and R. T. Borchardt, "In Vitro-In Situ Correlations of Peptide Transport Across the Blood-Brain Barrier", Pharmaceutical Res., 10, S-206 (Abst. PDD 7128), 1993.
231. K. M. Hillgren, P. F. Augustijns and R. T. Borchardt, "Carnosine as a Substrate for the Peptide Carrier in Caco-2 Cells", Pharmaceutical Res., 10, S-181 (Abst. PDD 7027), 1993.
232. J. F. Fisher, I. Isslam, K. Y. Ng, K. T. Chang, T. J. McQuade, J. O. Hui, K. F. Wilkinson, B. D. Rush, M. J. Ruwart and R. T. Borchardt, "A Vitamin Cloaking Strategy for Oligopeptide Therapeutics: Biotinylated HIV-1 Protease Inhibitors", American Chemical Society Meeting, September, 1993.
233. S. Li, C. Schöneich and R. T. Borchardt, "Mechanistic Study on the Oxidation of Methionine in Small Model Peptides by Ascorbic Acid/Fe III System", Pharmaceutical Res., 10, S-76 (Abst. BIOTEC 2014), 1993.
234. S. Liu, C. S. Yuan and R. T. Borchardt, "Design and Synthesis of Aristeromycin 5'-Carboxaldehyde as a Potential Inhibitor of S-Adenosyl-L-Homocysteine Hydrolase", American Chemical Society Meeting, September, 1993.
235. B. Wang and R. T. Borchardt, "The Development of a Novel Redox Sensitive Protecting Group for Amines and Alcohols", American Chemical Society Meeting, Fall, 1993.
236. R. T. Borchardt, "Key Problems in Peroral Drug Delivery", International Symposium entitled, "Methods to Overcome Biological Barriers to Drug Delivery", Controlled Release Society Meeting, Kuopio, Finland, August, 1993.
237. R. T. Borchardt, "Strategies to Deliver Peptides Across the Blood-Brain Barrier", International Symposium entitled, "Methods to Overcome Biological Barriers to Drug Delivery", Controlled Release Society Meeting, Kuopio, Finland, August, 1993.
238. R. T. Borchardt, "Rational Strategies for the Design of Peptides with Enhanced Oral Delivery", International Symposium entitled, "Recent Development of Transdermal and Advanced Drug Delivery", FIP Post Congress Satellite Symposium, Taipei, Taiwan, September, 1993.
239. R. T. Borchardt, "The Unique Challenge of Formulation of Protein Drugs: Physical and Chemical Stability", 3rd Interlaken Conference on Advances in Production of Recombinant Proteins, Interlaken, Switzerland, March, 1994.
240. X. Guan, A. K. Sinhababu and R. T. Borchardt, "Mechanistic Study of the Oxidation of the Serotonergic Neurotoxin 5,7-Dihydroxytryptamine", American Chemical Society Meeting, Spring, 1994.
241. C. S. Yuan, S. F. Wnuk, S. Liu, M. J. Robins and R. T. Borchardt, "(E)-5',6'-Didehydro-6'-Deoxy-6'-Fluoro-Homo-adenosine: A Substrate that Measures the Hydrolytic Activity of S-Adenosyl-L-homocysteine Hydrolase", FASEB Journal, 8, A1412 (Abst. #891) (1994).
242. D. B. Ault-Riche, C. S. Yuan and R. T. Borchardt, "A Single Mutation at Lysine 426 of S-Adenosylhomocysteine (AdoHcy) Hydrolase Inactivates the Enzyme by Destabilizing the Enzyme's Quaternary Structure", FASEB Journal, 8, A1412 (Abst. #892) (1994).
243. R. T. Borchardt, "Storage Stability of Protein Drugs", BioPharm '94 Conference, San Francisco, CA, June, 1994.
244. R. T. Borchardt, "Special Bioavailability Problems with Biotechnology Derived Drugs", Bio-International '94 Conference, Munich, Germany, June, 1994.
245. R. T. Borchardt, "Chemical Instability of Proteins in Solution and in Lyophilized Formulations", 1994 Colorado Protein Stability Conference, Breckenridge, CO, July, 1994.
246. R. T. Borchardt, "Application of Cell Culture Systems to Study Drug Transport and Metabolism" (XIIth International Congress of Pharmacology, Montreal, Canada, July, 1994) Canadian J. Physiol. Pharmacol., 72, 46 (S361), 1994.
247. R. T. Borchardt, "Technologies, Processes and Problems Associated with Oral Delivery of Peptides", Symposium entitled, "Progress Towards Drug Delivery of Peptides and Peptidomimetics", American Chemical Society Meeting, Washington, DC, August, 1994.

248. B. Wang, M. Nicolaou, S. Liu, K. Kuczera and R. T. Borchardt, "Structural Analysis of a Facile Lactonization System", American Chemical Society Meeting, Washington, DC, August, 1994.
249. R. T. Borchardt, "Rational Approaches to the Design of Mechanism-Based Inhibitors of S-Adenosylhomocysteine Hydrolase", Eleventh International Round Table of Nucleosides and Nucleotides, Leuven, Belgium, September, 1994.
250. S. Liu, C. S. Yuan and R. T. Borchardt, "Aristeromycin 5'-Carboxaldehyde: A Novel Potent Inhibitor of S-Adenosyl-L-Homocysteine Hydrolase", Eleventh International Round Table of Nucleosides and Nucleotides, Leuven, Belgium, September, 1994.
251. R. T. Borchardt, "Predicting Chemical Instability of Proteins in Solution and in Lyophilized Formulations", Recovery of Biological Products VII Symposium, San Diego, CA, September, 1994.
252. R. T. Borchardt, "The Application of Cultured Epithelial Cells (Caco-2) to Evaluate Rational Strategies to Enhance the Intestinal Permeability of Peptides", Workshop entitled, "Physiological Barriers to Drug Delivery", Paris, France, October, 1994.
253. R. T. Borchardt, "Rational Design to Enhance Membrane Permeability of Peptides", 6th North American Meeting of the International Society for the Study of Xenobiotics, Raleigh, NC, October, 1994.
254. R. T. Borchardt, "Physical and Chemical Instability of Proteins - An Overview", Symposium entitled, "Formulation and Process Challenges with Protein Pharmaceuticals", American Association of Pharmaceutical Scientists, 9th Annual Meeting, San Diego, CA.
255. S. H. Li, T. H. Nguyen, C. Schöneich and R. T. Borchardt, "Metal-Catalyzed Oxidation of Human Relaxin", *Pharmaceutical Res.*, **11**, S-82 (Abst. BIOTEC 2048), 1994.
256. E. G. Chikhale and R. T. Borchardt, "The Influence of Physicochemical Properties and Affinity for P-Glycoprotein on the Transport of Cyclosporin A Across the Blood-Brain Barrier (BBB)", *Pharmaceutical Res.*, **11**, S-260 (Abst. PDD 7343), 1994.
257. E. G. Chikhale, P. J. Chikhale and R. T. Borchardt, "Carrier-Mediated Transport of the Antitumor Agent Acivicin Across the Blood-Brain Barrier", *Pharmaceutical Res.*, **11**, S-250 (Abst. PDD 7304), 1994.
258. M. Nicolaou and R. T. Borchardt, "Phosphate Prodrugs of Amines Which Utilize a Fast Hydroxy-Amide Lactonization", *Pharmaceutical Res.*, **11**, S-232 (Abst. PD 7230), 1994.
259. M. M. Nerurkar, P. S. Burton and R. T. Borchardt, "Use of Surfactants to Enhance the Intestinal Permeability of Peptides by Inhibition of P-Glycoprotein", *Pharmaceutical Res.*, **11**, S-251 (Abst. PDD 7306), 1994.
260. E. G. Chikhale, P. S. Burton and R. T. Borchardt, "The Effect of P-Glycoprotein on the Transport of Peptides Across the Blood-Brain Barrier (BBB) in Rats", *Pharmaceutical Res.*, **11**, S-251 (Abst. PDD 7305), 1994.
261. R. T. Borchardt, "The Role of P-Glycoprotein in Regulating the BBB Permeability of Peptide Mimetics", 2nd International Symposium on Drug Transport to the Brain, Amsterdam, The Netherlands, February, 1995.
262. R. T. Borchardt, "Developing *In Vitro* Models to Predict Human Drug Transport and Metabolism", Keystone Symposia entitled, "Discovery of Therapeutic Agents", Lake Tahoe, CA, March, 1995.
263. R. T. Borchardt, "Physicochemical and Biological Factors that Influence a Drug's Cellular Permeability by Passive Diffusion", Symposium entitled, "Lipophilicity in Drug Research and Toxicology", Lausanne, Switzerland, March, 1995.
264. R. T. Borchardt, "Structural Requirements for Intestinal Absorption of Peptide Drugs", Fifth International Symposium on Delivery and Targeting of Peptides, Proteins and Genes, Leiden, The Netherlands, June, 1995.
265. C. S. Yuan and R. T. Borchardt, "Photoaffinity Labeling of Human Placental S-Adenosylhomocysteine Hydrolase with [2-3H]-8-Azido-Adenosine", *FASEB Journal*, **9**, A1476 (Abst. #1272), 1995.
266. M. C. Lai, E. M. Topp, R. Schowen and R. T. Borchardt, "Peptide Stability in Polymer Matrices", *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.*, **22**, 532-533, Abst. #2125 (1995).
267. M. C. Lai, E. M. Topp, R. L. Schowen and R. T. Borchardt, "The Stability of a Model Hexapeptide in Poly(Vinyl Alcohol) Matrices", Midwest Regional AAPS Meeting, June, 1995.
268. R. T. Borchardt, "Physicochemical and Biochemical Factors that Influence the Oral Bioavailability of Peptide Mimetics", Fourteenth American Peptide Symposium, Columbus, Ohio, June, 1995.

269. R. T. Borchardt, "The Structure and Catalytic Mechanism of S-Adenosylhomocysteine Hydrolase", FASEB Summer Research Conference on Biological Methylation, Sextons River, Vermont, July, 1995.
270. R. T. Borchardt, "Affecting Drug Absorption", 55th World Congress of Pharmacy and Pharmaceutical Sciences, Stockholm, Sweden, August, 1995.
271. B. Wang, S. Gangwar, G. Pauletti, T. J. Siahaan and R. T. Borchardt, "A New Strategy for the Preparation of Peptide Prodrugs that Utilizes a Facile Cyclization Reaction", 1995 Conference on Pharmaceutical Science and Technology, Chicago, IL, August, 1995.
272. R. T. Borchardt, "Rational Design of Peptides with Enhanced Membrane Permeability", AFMC International Medicinal Chemistry Symposium, Tokyo, Japan, September, 1995.
273. B. Wang, S. Gangwar, G. Pauletti, T. J. Siahaan and R. T. Borchardt, "Synthesis of a Novel, Enzyme-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability. II. 3-(2'-Hydroxy-4',6'-Dimethylphenyl)-2,2-Dimethyl Propionic Acid Pro-Moiety", American Chemical Society Meeting, Chicago, IL, August, 1995.
274. S. Gangwar, G. Pauletti, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Synthesis of a Novel, Enzyme-Sensitive Cyclic Prodrug of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability. I. Acyloxyalkoxycarbamate Pro-Moiety", American Chemical Society Meeting, Chicago, IL, August, 1995.
275. B. Wang, W. Wang, S. Liu and R. T. Borchardt, "Development of a Redox-Sensitive Protecting Group Using a Facilitated Lactonization Reaction: Protection of Hydroxyl Groups", American Chemical Society Meeting, Chicago, IL, August, 1995.
276. M. M. Nerurkar, P. S. Burton, N. F. H. Ho and R. T. Borchardt, "Use of Surfactants to Enhance the Intestinal Permeability of Peptides by Inhibition of an Apically Polarized Efflux System", *Pharmaceutical Res.*, **12**, S-302 (Abst. PDD 7443), 1995.
277. M. M. Nerurkar, M. J. Rose, J. F. Stobaugh and R. T. Borchardt, "Selective Fluorogenic Derivatization of Peptide Nucleic Acids (PNA) Trimer Using NDA/CN⁻ Reagent System", *Pharmaceutical Res.*, **12**, S-69 (Abst. APQ 1233), 1995.
278. K. Tamura, P. K. Bhatnagar, J. S. Takata, C-P. Lee, P. L. Smith and R. T. Borchardt, "Inhibition of Uptake by the Oligopeptide Transporter Does Not Correlate With Transepithelial Transport", *Pharmaceutical Res.*, **12**, S-302 (Abst. PDD 7439), 1995.
279. G. T. Knipp, N. F. H. Ho, C. L. Barsuhn and R. T. Borchardt, "Delineation of Paracellular Diffusion in Caco-2 Monolayers: Effect of Perturbants on the Transport of Model Compounds Which Vary in Charge and Size", *Pharmaceutical Res.*, **12**, S-302 (Abst. PDD 7440), 1995.
280. G. T. Knipp, D. Vander Velde, T. J. Siahaan and R. T. Borchardt, "The Effect of Solution Conformation and Charge on the Paracellular Permeability of Model Pentapeptides Across Caco-2 Monolayers", *Pharmaceutical Res.*, **12**, S-303 (Abst. PDD 7441), 1995.
281. F. W. Okumu, G. M. Pauletti, D. G. Vander Velde, T. J. Siahaan and R. T. Borchardt, "The Effect of Charge and Conformation on the Permeability of a Hexapeptide Across Monolayers of a Cultured Human Intestinal Epithelial Cell (Caco-2 Cells)", *Pharmaceutical Res.*, **12**, S-302 (Abst. PDD 7438), 1995.
282. F. W. Okumu, G. M. Pauletti, D. G. Vander Velde, T. J. Siahaan and R. T. Borchardt, "The Effect of Conformational Flexibility on the Permeability of a Hexapeptide Across Monolayers of a Cultured Human Intestinal Epithelial Cell (Caco-2 Cells)", *Pharmaceutical Res.*, **12**, S-302 (Abst. PDD 7437), 1995.
283. G. M. Pauletti, S. Gangwar, B. Wang, T. J. Siahaan, D. G. Vander Velde and R. T. Borchardt, "Novel Prodrug Approaches to Prepare Cyclic Peptides with Enhanced Membrane Permeability and Enzymatic Stability. II. 3-(2'-Hydroxy-4',6'-Dimethylphenyl)-2,2-Dimethyl Propionic Acid Pro-Moiety", *Pharmaceutical Res.*, **12**, S-208 (Abst. PDD 7064), 1995.
284. S. Gangwar, G. M. Pauletti, T. J. Siahaan, D. G. Vander Velde, V. J. Stella and R. T. Borchardt, "Novel Prodrug Approaches to Prepare Cyclic Peptides with Enhanced Membrane Permeability and Enzymatic Stability. I. Acyloxyalkoxycarbamate Pro-Moiety", *Pharmaceutical Res.*, **12**, S-208 (Abst. PDD 7063), 1995.
285. S. Li, T. Patapoff, T. H. Nguyen and R. T. Borchardt, "Inhibitory Effect of Sugars and Polyols on the Metal-Catalyzed Oxidation of Human Relaxin", *Pharmaceutical Res.*, **12**, S-208 (Abst. BIOTECH 2067), 1995.
286. S. Li, T. Patapoff, D. Overchashier, C. Hsu, T. H. Nguyen and R. T. Borchardt, "Effects of Reducing Sugars on the Chemical Stability of Human Relaxin in the Lyophilized State", *Pharmaceutical Res.*, **12**, S-81 (Abst. BIOTECH 2010), 1995.

287. M. Xie, R. T. Borchardt and R. L. Schowen, "Origin of the Degradative Product Distribution in Cyclic Imide Hydrolysis", *Pharmaceutical Res.*, **12**, S-317 (Abst. PDD 7498), 1995.
288. P. J. Chikhale, H. Nakagami and R. T. Borchardt, "A Novel Esterase-Sensitive Polymeric Prodrug System for Amine-Containing Drugs", *Pharmaceutical Res.*, **12**, S-245 (Abst. PDD 7209), 1995.
289. P. J. Chikhale, Y. Kawamura, M. Nerurkar, P. K. Shah, K. L. Amsberry and R. T. Borchardt, "Intestinal Transport and Metabolism of Novel Enkephalin Prodrugs", *Pharmaceutical Res.*, **12**, S-305 (Abst. PDD 7452), 1995.
290. M. Nicolaou, C-S. Yuan and R. T. Borchardt, "Phosphate Prodrugs of Amines Which Utilize a Fast Hydroxy-Amide Lactonization. Structural Specificity for Alkaline Phosphatase", *Pharmaceutical Res.*, **12**, S-204 (Abst. PDD 7065), 1995.
291. R. T. Borchardt, "Rational Strategies to Enhance the Oral Delivery of Peptides", Western Biotech Conference, San Diego, CA, October, 1995.
292. R. T. Borchardt, "Physical and Chemical Instability of Peptides in Formulations and Drug Delivery Systems", American Chemical Society Conference entitled, "Formulations and Drug Delivery", Boston, MA, October, 1995.
293. P. S. Burton, R. A. Conradi, A. R. Hilgers, N. F. H. Ho and R. T. Borchardt, "How Structural Features Influence the Permeability of Peptides", American Chemical Society Conference entitled, "Formulations and Drug Delivery", Boston, MA, October, 1995.
294. W. Wang and R. T. Borchardt, "Characterization of the Effect of Vascular Endothelial Growth Factor on the Permeability of Brain Microvessel Endothelial Cells In Vitro", American Society for Cell Biology Annual Meeting, Washington, DC, December, 1995.
295. G. Pauletti, S. Gangwar, B. Wang, T. J. Siahaan, V. J. Stella, D. G. Vander Velde and R. T. Borchardt, "Novel, Enzyme Sensitive Cyclic Prodrugs of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability", American Chemical Society Meeting, New Orleans, LA, March, 1996.
296. R. T. Borchardt, "Use of Intestinal Tissue for Assessing Oral Bioavailability", Western Regional American Association of Pharmaceutical Scientists Meeting, South San Francisco, CA, March, 1996.
297. R. T. Borchardt, "The Application of Cell Culture Systems to Facilitate the Identification of Drugs with Enhanced Oral Bioavailability", Strategic Research Institute Conference on Lead Generation and Optimization, New Orleans, LA, March, 1996.
298. R. T. Borchardt, "Chemical Strategies to Overcome Biological Barriers: An Overview", Swedish Academy of Pharmaceutical Science Mini Symposium on Drug Delivery by Means of Chemical Modification: Prodrugs-Soft Drugs, Stockholm, Sweden, March, 1996.
299. X. H. Yu, C. S. Yuan and R. T. Borchardt, "Effects of C-Terminal Deletion of the Quaternary Structure and Activity of Human Placental S-Adenosylhomocysteine Hydrolase", *FASEB Journal*, **10**, A1244 (Abst. #1414) 1996.
300. C. S. Yuan, D. B. Ault-Riche and R. T. Borchardt, "Chemical Modification and Site-Directed Mutagenesis of Cysteine Residues in Human Placental S-Adenosylhomocysteine Hydrolase", *FASEB Journal*, **10**, A1099 (Abst. #581), 1996.
301. H. Huang, C. S. Yuan and R. T. Borchardt, "The Mechanisms of Inactivation of human Placental S-Adenosylhomocysteine (AdoHcy) Hydrolase by (E)-4',5'-Didehydro-5'-Deoxy-5'-Methoxyadenosine (EDDMA) and Adenosine 5'-Carboxaldehyde Oxime (ACAO)", *FASEB Journal*, **10**, A1244 (Abst. #1415) 1996.
302. R. T. Borchardt, "Rational Design of Peptidomimetics with Enhanced Intestinal Mucosal Permeability Properties", Cambridge Healthcare Institute Conference on Development of Small Molecule Mimetic Drugs, Washington, DC, May, 1996.
303. R. T. Borchardt, "Structural Requirements for Intestinal Absorption of Peptide Drugs", Third Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, September, 1996.
304. R. T. Borchardt, "Novel Esterase-Sensitive Cyclic Prodrugs for Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability", XIVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, September, 1996.
305. K. Tamura, K. A. Agrios, D. Vander Velde, J. Aube and R. T. Borchardt, "Transepithelial Transport of β -Turn Mimics Across the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **13**, S-238 (Abst. PDD 7023), 1996.
306. K. Tamura, C. P. Lee, P. L. Smith and R. T. Borchardt, "Effect of Charge on Permeability of Cyclic Dipeptides in the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **13**, S-238 (Abst. PDD7022), 1996.

307. K. Tamura, C. P. Lee, P. L. Smith and R. T. Borchardt, "Metabolism, Uptake and Transepithelial Transport of the Stereoisomers of Val-Val-Val in the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **13**, S-238 (Abst. PDD7021), 1996.
308. L. Kupczyk-Kubotkowska, K. Tamura, D. Pal, T. Sakaeda, T. J. Siahaan, V. J. Stella and R. T. Borchardt, "Derivatives of Melphalan Designed to Enhance Drug Accumulation in Cancer Cells", *Pharmaceutical Res.*, **13**, S-238 (Abst. PDD7024), 1996.
309. M. Xie, R. T. Borchardt and R. L. Schowen, "Effects of β -Turn Secondary Structures on the Kinetics of Deamidation in Peptides", *Pharmaceutical Res.*, **13**, S-97 (Abst. BIOTECH2081), 1996.
310. S. Gangwar, T. J. Siahaan, D. V. Vander Velde, V. J. Stella and R. T. Borchardt, "The Effect of Conformation on the Membrane Permeability of an Acyoxalkoxy Linked Cyclic Prodrug of a Model Hexapeptide", *Pharmaceutical Res.*, **13**, S-80 (Abst. BIOTECH2015), 1996.
311. G. M. Pauletti, F. W. Okumu, D. G. Vander Velde and R. T. Borchardt, "The Effect of Charge and Conformational Flexibility on the Pathway of Permeation of Model Hexapeptides Across Caco-2 Cell Monolayers in Unperturbed and Perturbed States", *Pharmaceutical Res.*, **13**, S-235 (Abst. PDD7012), 1996.
312. F. W. Okumu, J. L. Cleland and R. T. Borchardt, "The Effect of Size, Charge and Conformation on the Release Kinetics of Peptides from Biodegradable Microspheres", *Pharmaceutical Res.*, **13**, S-84 (Abst. BIOTECH2030), 1996.
313. J. Li, K. Tamura, C. P. Lee, P. Smith, R. T. Borchardt and I. J. Hidalgo, "Structure-Affinity Relationship for the Oligopeptide Transporter in Caco-2 Cells", *Pharmaceutical Res.*, **13**, S-241 (Abst. PDD7034), 1996.
314. S. Gangwar, B. Wang, G. M. Pauletti, T. J. Siahaan, D. G. Vander Velde, V. J. Stella and R. T. Borchardt, "Novel Prodrug Strategies for the Synthesis of Cyclic Peptides with Increased Metabolic Stability and Enhanced Cellular Permeability", *Pharmaceutical Res.*, **13**, S-148 (Abst. MNP5038), 1996.
315. R. T. Borchardt, "Use of Cell Culture Models for Understanding and Predicting Oral Drug Absorption", Sixteenth Annual Northeastern Regional Pharmaceutics Association Meeting, Rocky Hill, Connecticut, April, 1997.
316. R. T. Borchardt, "Prodrug Strategies to Enhance the Permeation of Peptides in the Intestinal Mucosa", The Impact of Pharmacokinetics in Modern Drug Development Symposium, San Francisco, CA, May, 1997.
317. R. T. Borchardt, "Chemical Instability of Proteins", Biochemical Engineering X Meeting, Kananaskis, Alberta, Canada, May, 1997.
318. R. T. Borchardt, "Application of the Prodrug Principle to Overcoming Oral Absorption Problems of Peptides", Fourth International Conference on Drug Absorption, Edinburgh, Scotland, June, 1997.
319. R. T. Borchardt, "Prodrug Strategies to Enhance the Intestinal Mucosa and Blood-Brain Barrier Permeation of Peptides", American Peptide Symposium, Nashville, Tennessee, June, 1997.
320. R. T. Borchardt, "Prodrug Strategies to Enhance the Intestinal Mucosa and Blood-Brain Barrier Permeation of Peptides", The Alfred Benzon Symposium entitled Peptide and Protein Drug Delivery, Copenhagen, Denmark, August, 1997.
321. C. S. Yuan, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "A Novel Mechanism-Based Inhibitor (6'-Bromo-5',6'-Didehydro-6'-Deoxy-6'-Fluorohomoadenosine) that Covalently Modifies Human Placental S-Adenosylhomocysteine Hydrolase", *FASEB Journal*, **11**, (Abst. #1020), 1997.
322. L. Gharat, P. Visser, M. Brummelhuis, R. Guiles, R. T. Borchardt and P. Chikhale, "Redox-Activation of Conformationally-Constrained Bio-reductive Melphalan Delivery Systems Designed for Solid Tumor Targeting", AAPS Southeast Regional Meeting, Raleigh, North Carolina, June, 1997.
323. M. C. Lai, R. L. Schowen, R. T. Borchardt, M. J. Hageman and E. M. Topp, "The Effect of Water and Glass Transition Temperature on the Solid State Stability of a Model Peptide in Polymers", Colorado Biopharmaceutical Delivery Conference, Breckenridge, CO, July, 1997.
324. W. Wang, G. Camenisch, H. Zhang, R. T. Borchardt and B. Wang, "Synthesis of Coumarin-based Cyclic Prodrugs of Peptidomimetic Fibrinogen Antagonists", American Chemical Society Meeting, Las Vegas, NV, September, 1997.
325. M. C. Lai, R. L. Schowen, R. T. Borchardt, E. M. Topp and M. J. Hageman, "Effect of Processing Conditions on the Water Vapor Sorption Behavior of Poly (vinyl alcohol) and Poly (vinyl pyrrolidone)", *Pharmaceutical Res.*, **14**, S-199 (Abst. 1595), 1997.

326. M. C. Lai, R. L. Schowen, R. T. Borchardt, M. J. Hageman, B. B. Laird and E. M. Topp, "The Effect of Glass Transition Temperature and Plasticizer on the Stability of a Hexapeptide in Polymeric Formulations", *Pharmaceutical Res.*, **14**, S-485 (Abst. 3067), 1997.
327. G. P. Camenisch, W. Wang, H. Zhang, B. Wang and R. T. Borchardt, "Esterase-Sensitive Coumarin-Based Prodrugs of RGD-Mimetics Having Enhanced Membrane Permeability", *Pharmaceutical Res.*, **14**, S-19 (Abst. 1055), 1997.
328. M. Khosravi and R. T. Borchardt, "Elucidation of the Reactive Oxygen Species Involved in the Oxidation of Histidine Residues in Model Peptides Using an Ascorbic Acid/Cupric Chloride Oxidative System", *Pharmaceutical Res.*, **14**, S-227 (Abst. 2034), 1997.
329. O. S. Gudmundsson, G. M. Pauletti, W. Wang, D. Shan, H. Zhang, B. Wang and R. T. Borchardt, "Novel Cyclic Prodrugs of Opioid Peptides That Exhibit Increased Metabolic Stability and Enhanced Cellular Permeability", *Pharmaceutical Res.*, **14**, S-22 (Abst. 1066), 1997.
330. A. Bak, O. Gudmundsson, G. Juel Friis, T. J. Siahaan and R. T. Borchardt, "Acyloxyalkoxy Cyclic Prodrugs of Opioid Peptides", *Pharmaceutical Res.*, **14**, S-655 (Abst. 4057), 1997.
331. O. S. Gudmundsson, S. D. S. Jois, D. G. Vander Velde, T. J. Siahaan, D. Shan, W. Wang, H. Zhang, B. Wang and R. T. Borchardt, "The Effect of Conformation on the Membrane Permeabilities of Coumarin-Based Cyclic Prodrugs of Opioid Peptides", *Pharmaceutical Res.*, **14**, S-392 (Abst. 2550), 1997.
332. C. Goolcharran and R. T. Borchardt, "Kinetics of Diketopiperazine Formation Using Model Peptides", *Pharmaceutical Res.*, **14**, S-349 (Abst. 2401), 1997.
333. M. Sudoh, G. M. Pauletti, K. Akimoto, W. Yau, P. Sprenger, A. B. Smith, III, R. Hirschmann and R. T. Borchardt, "Should the Permeation Characteristics of Solutes That are Substrates for the Apically Polarized Efflux Systems in Caco-2 Cells be Determined as Single Entities or as Mixtures (Libraries)?", *Pharmaceutical Res.*, **14**, S-26 (Abst. 1081), 1997.
334. G. M. Pauletti, M. Sudoh, K. Akimoto and R. T. Borchardt, "Effect of Experimental Conditions on the Permeation Characteristics of Paracellularly and Transcellularly Routed Peptides Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **14**, S-24 (Abst. 1074), 1997.
335. K. Akimoto, L. Kupczyk-Subotkowska, G. M. Pauletti, J. Aube and R. T. Borchardt, "Effect of the Alkene Bioisostere on the Transport of Peptidomimetics Across the Human Intestinal Cell Line, Caco-2", *Pharmaceutical Res.*, **14**, S-19 (Abst. 1053), 1997.
336. M. Sudoh, G. M. Pauletti, W. Yao, P. Sprengler, A. B. Smith, III, R. Hirschmann and R. T. Borchardt, "Effect of the Pyrrolinone Bioisostere on the Transport of Peptidomimetics Across Caco-2 Cell Monolayers", *Pharmaceutical Res.*, **14**, S-26 (Abst. 1080), 1997.
337. G. M. Pauletti, M. E. Perlman, L. Zhang and R. T. Borchardt, "Can Counterions Affect the Transport of a Lipophilic Diarylguanidine (CNS1237) Across Caco-2 Cell Monolayers *In Vitro*?", *Pharmaceutical Res.*, **14**, S-24 (Abst. 1075), 1997.
338. L. Gharat, R. Taneja, J. Polli, R. Guiles, R. T. Borchardt and P. Chikhale, "Bioreductive Activation of Conformationally-Constrained Tumor Targeted Melphalan Delivery Systems", *Pharmaceutical Res.*, **14**, 293 (Abst. 2212), 1997.
339. M. C. Lai, M. J. Hageman, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Water on Peptide Deamidation in Solid Polymeric Formulations", *Pharmaceutical Res.*, **14**, S-493 (Abst. 3095), 1997.
340. E. M. Topp, M. C. Lai, M. J. Hageman, R. L. Schowen and R. T. Borchardt, "Chemical Instability of Proteins and Peptides in Formulations in Drug Delivery Devices", Colorado Biopharmaceutical Delivery Conference, Breckenridge, CO, July, 1997.
341. R. T. Borchardt, "Use of Cell Culture Models as High Throughput Screens for Estimating Oral Drug Absorption", Society for Biomolecular Screening Annual Meeting, San Diego, CA, September, 1997.
342. R. T. Borchardt, "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", Conference on Formulations and Drug Delivery II, LaJolla, CA, October, 1997.
343. R. T. Borchardt, "Factors that Determine the Disposition and Activity of Biotechnology Products *In Vivo*: An Overview", 8th International Society for the Study of Xenobiotics Meeting, Hilton Head, SC, October, 1997.
344. P. Berglund, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Temperature on Peptide Deamidation in Polymer Matrices", AAPS Midwest Regional Meeting, Chicago, IL, May, 1998.
345. R. Li, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Dielectric Constant and Viscosity Changes on the

- Deamidation Rate of Asn-hexapeptide in PVP and Glycerol Solutions", AAPS Midwest Regional Meeting, Chicago, IL, May, 1998.
346. R. T. Borchardt, "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", Conference on Challenges for Drug Delivery and Pharmaceutical Technology, Tokyo, Japan, June, 1998.
 347. R. T. Borchardt, "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", 26th National Medicinal Chemistry Symposium, Richmond, VA, June, 1998.
 348. R. T. Borchardt, "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", 1998 American Association of Colleges of Pharmacy Meeting, Aspen, CO, July, 1998.
 349. R. T. Borchardt, "Permeability Determination and Applications: Industry/Academic Perspective", AAPS Workshop on Permeability Definitions and Regulatory Standards for Bioequivalence, Arlington, VA, August, 1998.
 350. W. Wang, D. C. Sane, S. A. Bai, C. P. Chang, R. T. Borchardt, and B. Wang, "Synthesis and Biological Evaluations of a Coumarin-based Esterase-sensitive Cyclic Prodrug of an Antithrombotic RGD Analog, MK-383", American Chemical Society Meeting, Boston, MA, September, 1998.
 351. A. Zheng, D. Shan, W. Wang, R. T. Borchardt and B. Wang, "A Trimethyl Lock-Facilitated Cyclic Ether Formation", American Chemical Society Meeting, Boston, MA, September, 1998.
 352. R. T. Borchardt, "The Unique Challenges of Stabilizing Therapeutic Peptides and Proteins to Chemical Degradation", Novo Nordisk 2nd Protein Stability Symposium, Hvidovre, Denmark, August, 1998.
 353. R. T. Borchardt, "Bridging the Gaps in Academia in Order to Properly Train Pharmaceutical Scientists for the 21st Century", *AAPS PharmSci*, 1, S-1, 1998.
 354. M. Khosravi and R. T. Borchardt, "Metal-catalyzed Oxidation of a Cyclic Histidine-containing Peptide: Characterization of the Degradation Product and Effect of Oxidation on Solution Structure", *AAPS PharmSci*, 1, S-106 (Abst. 1361), 1998.
 355. M. Khosravi, S. J. Shire and R. T. Borchardt, "Involvement of the Histidine Residue in the Aggregation and Precipitation of Human Relaxin Under Metal-catalyzed Oxidation", *AAPS PharmSci*, 1, S-106 (Abst. 1362), 1998.
 356. O. S. Gudmundsson, K. Nimkar, S. Gangwar and R. T. Borchardt, "Phenylpropionic Acid-based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeation", *AAPS PharmSci*, 1, S-63 (Abst. 1208), 1998.
 357. O. S. Gudmundsson, D. G. Vander Velde, S. D. S. Jois, A. Bak, T. J. Siahaan and R. T. Borchardt, "The Effect of Conformation of the Acyloxyalkoxy-based Cyclic Prodrugs of Opioid Peptides on Their Membrane Permeation", *AAPS PharmSci*, 1, S-62 (Abst. 1207), 1998.
 358. J. Gao, M. Sudoh, J. Aube and R. T. Borchardt, "Transport Characteristics of N-Methylated Tripeptides Across Caco-2 Cell Monolayers", *AAPS PharmSci*, 1, S-450 (Abst. 3306), 1998.
 359. C. Goolcharran, J. L. Cleland and R. T. Borchardt, "The Effect of Histidine (His) on the Rate of Deamidation of Model Asparagine (Asn)-containing Peptides", *AAPS PharmSci*, 1, S-542 (Abst. 3640), 1998.
 360. C. Goolcharran, R. T. Borchardt, R. Keck and J. L. Cleland, "Comparison of the Rate of Deamidation and Diketopiperazine Formation in rhVEGF and Model Peptides", *AAPS PharmSci*, 1, S-535 (Abst. 3612), 1998.
 361. P. Berglund, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Temperature Effects on Peptide Deamidation in Polymer Matrices", *AAPS PharmSci*, 1, S-116 (Abst. 1369), 1998.
 362. R. Li, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Polarity [$E_T(30)$] and Viscosity Changes on the Deamidation Rate of Asn-Hexapeptide in PVP and Glycerol Solutions", *AAPS PharmSci*, 1, S-545 (Abst. 3650), 1998.
 363. R. T. Borchardt, "Profiling Compounds for Biopharmaceutical Properties: Overview", 217th American Chemical Society Meeting, Anaheim, CA, March 21-25, 1999.
 364. R. T. Borchardt, G. Camenisch, E. Hugger, B. Wang, W. Wang, D. C. Sane, G. L. Wheeler and C. P. Cheng, "Prodrug Strategies to Improve the Oral Absorption of Peptide Mimetics", 217th American Chemical Society Meeting, Anaheim, CA, March 21-25, 1999.
 365. G. Camenisch, E. Hugger, B. Wang, W. Wang, D. C. Sane, G. L. Wheeler and C. P. Cheng, "The Use of Prodrug Strategies to Optimize the Oral Bioavailability of RGD Peptide Mimetics", 9th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February 22-25, 1999.

366. D. Yin, X. Yang, T. C. Squier, R. L. Schowen and R. T. Borchardt, "Decreased Hydrodynamic Volume Accompanies Substrate Oxidation During the Reaction Cycle of Adenosylhomocysteine Hydrolase", *Biophysical Society*, 76, A169, 1999.
367. B. Wang and R. T. Borchardt, "Delivering Peptides and Peptidomimetics Across Membrane Barriers. A Prodrug Approach", 16th American Peptide Symposium, Minneapolis, MN, June 20-24, 1999.
368. A. Wilson, J. Dehdashti, R. T. Borchardt, E. M. Topp and R. L. Schowen, "The Effects of Water Content and Glass Transition Temperature (T_g) on the Degradation Rate of a Cyclicimide (Asu) Containing Model Peptide in the Presence of Poly (Vinyl) Pyrrolidone (PVP) in the Solid State", Midwest Regional AAPS Meeting, Rosemont, IL, May 17, 1999.
369. S. Soenderkaer, J. Ostergaard, B. Steffansen, R. T. Borchardt, R. L. Schowen and E. M. Topp, "Peptide Deamidation in Solution State Analogs of Polymeric Media", Midwest Regional AAPS Meeting, Rosemont, IL, May 17, 1999.
370. R. T. Borchardt, "Lipids, Lipidic Excipients and Enterocyte-Based P-Glycoprotein and Cytochrome P-450-3A4 Mediated Processes", Symposium entitled, "Recent Advances in the Formulation and Development of Poorly-Soluble Drugs", St. Remy, France, June, 1999.
371. R. T. Borchardt, "Is the Intestinal Mucosa a Physical or a Biological Barrier to Oral Drug Delivery?", Symposium entitled, "Strategies for Oral Delivery of Challenging Molecules", Merrimac, WI, June, 1999.
372. Y. Song, R. Schowen, R. T. Borchardt and E. Topp, "Effect of pH on Peptide Deamidation in Polymeric Matrices", AAPS Midwest Regional Meeting, Chicago, IL, May, 1999.
373. D. Yin, X. Yang, T. C. Squier, K. Kuczera and R. T. Borchardt, "Substrate Oxidation Induces the Interdomain Conformational Changes in Human S-Adenosyl-L-Homocysteine Hydrolase", FASEB Summer Conference entitled, "Biological Methylation", Saxton River, VT, July, 1999.
374. X. Yang, D. Yin, C. S. Yuan and R. T. Borchardt, "Expression and Characterization of *Leishmania donovani* S-Adenosyl-L-Homocysteine Hydrolase", FASEB Summer Conference entitled, "Biological Methylation", Saxton River, VT, July, 1999.
375. J. Gao, S. Winslow, J. Aube and R. T. Borchardt, "Effects of the Hydroxylethylamine Peptide Bond Bioisostere on the Transport of Peptidomimetics Across Caco-2 Cell Monolayers", *AAPS PharmSci.*, 1, (Abst. 4200), 1999.
376. J. Gao, R. L. Schowen, J. Aube and R. T. Borchardt, "Functional Assay for Quantitative Determination of the Binding of Ligands to P-Glycoprotein in Caco-2 Cells", *AAPS PharmSci.*, 1, (Abst. 4180), 1999.
377. J. Yang, K. C. Bastian, R. D. Moore, A. Bak, J. F. Stobaugh and R. T. Borchardt, "A Comparison of HPLC with Fluorescence Detection and LC/MS/MS for Quantitative Analysis of a Model Opioid Peptide and Its Cyclic Prodrug in Plasma", *AAPS PharmSci.*, 1, (Abst. 2822), 1999.
378. E. Hugger and R. T. Borchardt, "The Effect of Polyethylene Glycol on Efflux Transporters in Caco-2 Cell Monolayers", *AAPS PharmSci.*, 1, (Abst. 4187), 1999.
379. A. D. Wilson, J. Dehdashti, R. T. Borchardt, E. M. Topp and R. L. Schowen, "The Effect of Water Content and Glass Transition Temperature (T_g) on the Degradation Rate of a Cyclic Imide (ASU) Containing Model Peptide in the Presence of Poly (Vinyl Pyrrolidone) (PVP) in the Solid State", *AAPS PharmSci.*, 1, (Abst. 4097), 1999.
380. J. Ostergaard, S. Soenderkaer, B. Steffansen, R. T. Borchardt, R. L. Schowen and E. M. Topp, "Deamidation of a Model Hexapeptide in Solution State Analogs of Polymeric Media", *AAPS PharmSci.*, 1, (Abst. 3741), 1999.
381. Y. Song, R. L. Schowen, R. T. Borchardt and E. Topp, "Asparagine Deamidation in Polymeric Matrices: Effect of pH", *AAPS PharmSci.*, 1, (Abst. 3715), 1999.
382. R. T. Borchardt, "How Structure Influences the Oral Absorption of Peptidemimetics", 218th American Chemical Society Meeting, Anaheim, CA, August 22-26, 1999, New Orleans, LA.
383. S. Wnuk, C. S. Yuan, R. T. Borchardt and M. J. Robins, "Design and Biological Evaluation of New Mechanism-Based Inhibitors of S-Adenosyl-L-homocysteine Hydrolase", *Nucleosides & Nucleotides*, 18, 595-596 (1999).
384. R. Li, B. Laird, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Viscosity and Solvent Polarity on Peptide Deamidation: Comparison of Experimental and Theoretical Results", *AAPS PharmSci.*, 2, (Abst. 3701), 1999.
385. A.J.N. D'Souza, C. R. Middaugh, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Effect of Polyvinylpyrrolidone on Peptide Deamidation in Solid State: Evidence for Complexation", *AAPS PharmSci.*, 2, (Abst. 3736), 1999.

386. C.A.S. Johansson, O. S. Gudmundsson, G. P. Camenisch, D. G. Vander Velde and R. T. Borchardt, "Correlation of Physicochemical Properties of Peptide Based Drugs with Their Permeation Through Caco-2 Cell Monolayer", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
387. E. D. Hugger, B. L. Novak, K. L. Audus, P. S. Burton and R. T. Borchardt, "The Effects of Nonionic Surfactants on P-Glycoprotein Activity in Caco-2 and MDR1-MDCK Cells", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
388. J. Gao, R. L. Schowen, J. Aube and R. T. Borchardt, "A Functional Assay for Quantitation of the Inhibitory Activities of Ligands of P-Glycoprotein in Caco-2 Cells", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
389. J. Yang, K. C. Bastian, R. D. Moore, A. Bak, J. F. Stobaugh and R. T. Borchardt, "A Comparison of HPLC with Fluorescence Detection and LC/MS/MS for Quantitative Analysis of a Model Opioid Peptide and Its Cyclic Prodrug in Plasma", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
390. W. Chen, J. Gao, S. Grinde, M. Brisander, K. Luthman and R. T. Borchardt, "Effect of Peptide Bond Bioisosteres on the Uptake and Transport of the Phe-Gly Dipeptidomimetics in Caco-2 Cells", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
391. D. Yin, X. Yang, T. C. Squier, P. L. Howell, Y. Hu, K. Kuczera, R. L. Schowen and R. T. Borchardt, "Conformational Changes Associated with the Reactions Catalyzed by Human Placental S-Adenosylhomocysteine Hydrolase", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
392. D. Yin, Y. Hu, X. Yang and R. T. Borchardt, "Site-Directed Mutagenesis of Residues Involved in Binding Homocysteine at the Active Site of Human Placental S-Adenosylhomocysteine Hydrolase", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
393. X. Yang and R. T. Borchardt, "Characterization of Recombinant L.donovani S-Adenosylhomocysteine Hydrolase", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
394. X. Yang, D. Yin, S. F. Wnuk, M. J. Robins and R. T. Borchardt, "Mechanism-Based Inactivation of Human Placental S-Adenosylhomocysteine Hydrolase by 5',5',6',6'-Tetrahydro-6'-Deoxy-6'-Halohomoadenosine Analogs", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
395. P. Elrod, X. Yang, D. Yin, R. L. Schowen and R. T. Borchardt, "Site-Directed Mutagenesis of Residues Involved in the 3'-Oxidative Activity of S-Adenosylhomocysteine Hydrolase", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
396. Y. Hu, D. Yin, K. Kuczera and R. T. Borchardt, "Computational Docking of Adenosine and Adenosine Analogs into the Active Site of Human Placental S-Adenosylhomocysteine Hydrolase", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
397. R. T. Borchardt, "How Structure Influences the Cell Permeation of Peptides and Peptidemimetics", Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
398. R. T. Borchardt, "Biological Models to Assess Drug Bioavailability", Symposium entitled "Lipophilicity in Drug Disposition", Lausanne, Switzerland, March, 2000.
399. E. D. Hugger, B. L. Novak and R. T. Borchardt, "Effect of Lipidic Excipients on Efflux Transporters in the Intestinal Mucosa", British Pharmaceutical Conference, Birmingham, England, *Journal of Pharmacy and Pharmacology*, **52**, 192 (2000).
400. E. Hugger, B. Novak, P. Burton, K. Audus and R. T. Borchardt, "The Effects of Nonionic Surfactants on P-Glycoprotein Activity in Caco-2 and MDR1-MDCK Cells", GPEN2000, University of Uppsala, Uppsala, Sweden, September 13-15, 2000.
401. V. -P. Ranta, A. Bak, R. T. Borchardt, S. Auriola and A. Urtti, "Corneal Permeation of Peptides and Peptide Prodrugs *In Vitro*", GPEN2000, University of Uppsala, Uppsala, Sweden, September 13-15, 2000.
402. G. Freidrichsen, W. Chen, C.-P. Lee, P. L. Smith and R. T. Borchardt, "Synthesis and Uptake/Transport Studies of Valacyclovir Derivatives by the Oligopeptide Transporter", GPEN2000, University of Uppsala, Uppsala, Sweden, September 13-15, 2000.
403. J. Z. Yang, C. K. Bastian, R. D. Moore, A. Bak, J. F. Stobaugh and R. T. Borchardt, "A Comparison of HPLC with Fluorescence Detection and LC/MS/MS for Quantitative Analysis of a Model Opioid Peptide and Its Cyclic Prodrugs in Rat Plasma", GPEN2000, University of Uppsala, Uppsala, Sweden, September 13-15, 2000.

404. Y. Song, M. Houchin, R. Schowen, R. T. Borchardt and E. Topp, "Mechanistic Interpretation of pH Effects on Asparagine Deamidation in Polymeric Formulations", *AAPS PharmSci*, 3 (Abst. 3076), 2000.
405. C. P. Lee, P. L. Smith, G. M. Friedrichsen, W. Q. Chen and R. T. Borchardt, "Synthesis and Uptake/Transport Studies of Valacyclovir Derivatives by the Oligopeptide Transporter", *AAPS PharmSci*, 3 (Abst. 2153), 2000.
406. C. R. Xu, E. D. Hugger, X. Song, R. T. Borchardt and T. J. Siahaan, "Cyclic Prodrugs of RGD Peptidomimetics with Various Macrocyclic Ring Sizes. III. The Effect of Physicochemical Properties on Permeation Through Cell Membranes", *AAPS PharmSci*, 3 (Abst. 2177), 2000.
407. W. Chen, J. Z. Yang, A. Bak and R. T. Borchardt, "Evaluation of the Intestinal Mucosal Permeation of an Opioid Peptide and Its Cyclic Prodrugs Using an *In Situ* Perfused Rat Ileum Model", *AAPS PharmSci*, 3 (Abst. 2179), 2000.
408. R. Li, M. J. Hageman, R. L. Schowen, R. T. Borchardt and E.M. Topp, "Effect of Viscosity on the Deamidation Rate of Asn-hexapeptide", *AAPS PharmSci*, 3 (Abst. 3069), 2000.
409. A.J.M. D'Souza, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Reaction of Polyvinylpyrrolidone with Asn Hexapeptide (VYPNGA) During Stability Studies", *AAPS PharmSci*, 3 (Abst. 3074), 2000.
410. C. E. Stotz, Y. Song, E. M. Topp, R. T. Borchardt and R. L. Schowen, "Development of an Assay for Deamidation in a Type I Beta Hairpin Peptide", *AAPS PharmSci*, 3 (Abst. 3075), 2000.
411. R. T. Borchardt, "How Structure Influences the Intestinal Mucosa Permeation of Peptides and Peptidomimetic Drugs", Pharmaceutical Congress of the Americas, March, 2001.
412. E. D. Hugger, C. J. Cole, J. S. Bourdage, T. J. Raub, P. S. Burton and R. T. Borchardt, "Automated Analysis of Polyethylene Glycol (PEG)-induced Inhibition of P-Glycoprotein Activity", *AAPS PharmSci*, 4 (Abst. 5069), 2001.
413. E. D. Hugger, R. A. Poorman, F. J. Kezdy, T. J. Raub, P. S. Burton and R. T. Borchardt, "A Novel Model to Describe P-Glycoprotein Inhibition Kinetics *In Vitro*", *AAPS PharmSci*, 4 (Abst. R5143), 2001.
414. J. Z. Yang, W. Chen and R. T. Borchardt, "In Vitro Stability and In Vivo Pharmacokinetic Studies of a Model Opioid Peptide and Its Cyclic Prodrugs", *AAPS PharmSci*, 4 (Abst. T3266), 2001.
415. R. Anderson, L. H. Nielsen, W. Chen, J. Z. Yang and R. T. Borchardt, "Evaluation of the Permeability Characteristics of a Model Opioid Peptide and Its Cyclic Prodrugs Across the Blood-Brain Barrier Using an *In Situ* Perfused Rat Brain Model", *AAPS PharmSci*, 4 (Abst. R5139), 2001.
416. F. Tang and R. T. Borchardt, "Characterization of the Efflux Transporter(s) Responsible for Restricting Intestinal Mucosa Permeation of the Acyloxyalkoxy-based Cyclic Prodrug of the Opioid Peptide DADLE", *AAPS PharmSci*, 4 (Abst. R5138), 2001.
417. F. Tang, K. Horie and R. T. Borchardt, "Are MDCK Cells Transfected with the Human MRP2 Gene a Good Model of the Human Intestinal Mucosa?", *AAPS PharmSci*, 4 (Abst. R5158), 2001.
418. F. Tang and R. T. Borchardt, "Characterization of the Efflux Transporter(s) Responsible for Restricting Intestinal Mucosa Permeation of the Coumarinic Acid-Based Cyclic Prodrug of the Opioid Peptide DADLE", *AAPS PharmSci*, 4 (Abst. R5280), 2001.
419. K. Horie, F. Tang and R. T. Borchardt, "Isolation and Characterization of Caco-2 Subclones that Overexpress Efflux Transporters", *AAPS PharmSci*, 4 (Abst. R5128), 2001.
420. B. Li, R. L. Schowen and R. T. Borchardt, "The Effect of a Glutamic Acid Residue on the C-Terminal Side of an Asparagine Residue on Its Rate of Deamidation", *AAPS PharmSci*, 4 (Abst. M2216), 2001.
421. H. Ouyang, F. Tang, D. R. Thakker, T. J. Siahaan and R. T. Borchardt, "A Modified Coumarinic Acid-based Cyclic Prodrug of an Opioid Peptide: Enzymatic/Chemical Stability and Cellular Transport Characteristics", *AAPS PharmSci*, 4 (Abst. R5213), 2001.
422. F. Tang and R. T. Borchardt, "Are MDCK Cells Transfected with Human MDR1 Gene a Good Model of the Human Intestinal Mucosa?", *AAPS PharmSci*, 4 (Abst. R5157), 2001.
423. S. Winslow, Q. Yu, T. Siahaan, R. T. Borchardt and E. M. Topp, "Synthesis of Model Cyclic β -Turn Peptides and Their Linear Analogs", *AAPS PharmSci*, 4 (Abst. M2336), 2001.
424. C. E. Stotz, R. T. Borchardt, C. R. Middaugh, R. L. Schowen and E.M. Topp, "Structure and Stability of a Type I Beta-Hairpin Turn", *AAPS PharmSci*, 4 (Abst. M2350), 2001.

425. A.J.M. D'Souza, R. L. Schowen, R. T. Borchardt and E. M. Topp, "Synthesis of Polyvinylpyrrolidine Based Polymeric Prodrug", *AAPS PharmSci*, 4 (Abst. W4388), 2001.
426. M. L. Houchin, R. T. Borchardt, R. L. Schowen and E. M. Topp, "The Degradation of DL-PLGA and Its Effects on the Deamidation of an Incorporated Asn Hexapeptide", *AAPS PharmSci*, 4 (Abst. W4720), 2001.
427. M. Wang, D. H. Yin, K. Kuczera, R. L. Schowen and R. T. Borchardt, "Mutations of His55 and His301 in S-Adenosylhomocysteine Hydrolase", *FASEB Journal*, A154, (Abst. 149.2), 2002.
428. B. Li, R. L. Schowen, E. M. Topp, D. Vander Velde and R. T. Borchardt, "Epimerization of Asparagine Residues in Model Peptides", *AAPS PharmSci*, 5 (Abst. T2081), 2002.
429. B. Li, R. L. Schowen, E. M. Topp, D. Vander Velde and R. T. Borchardt, "Effects of Secondary Structure and Physical State in Peptide Deamidation", *AAPS PharmSci*, 5 (Abst. T2079), 2002.
430. F. Tang and R. T. Borchardt, "Do Rhodamine 123 and Hoechst 3342 Bind to the Same or Different Sites on P-Glycoprotein?", *AAPS PharmSci*, 5 (Abst. T2101), 2002.
431. W. Chen, J. Z. Yang, A. Bak, H. Ouyang and R. T. Borchardt, "Evaluation of the Intestinal Permeation Characteristics of a Model Opioid Peptide (DADLE) and Its Cyclic Prodrugs Using an *In Situ* Perfused Rat Ileum Model", *AAPS PharmSci*, 5 (Abst. R6139), 2002.
432. S. L. Winslow, Q. Yu, R. T. Borchardt, T. Siahaan and E. Topp, "Synthesis and Deamidation of Model β -Turn Peptides in the Solution and Solid States", *AAPS PharmSci*, 5 (Abst. T2093), 2002.
433. J. Ji, C. Schöneich, R. T. Borchardt and E. M. Topp, "Glutathione Disulfide Photolytic Degradation Produces an Aldehyde", *AAPS PharmSci*, 5 (Abst. T2127), 2002.
434. M. L. Houchin, R. T. Borchardt and E. M. Topp, "Effect of PLGA Film Incorporation on Peptide Deamidation", *AAPS PharmSci*, 5 (Abst. T2101), 2002.
435. R. T. Borchardt, "Educational and Communication Issues Associated with Integrating and Applying Drug-like Data in Drug Discovery", AAPS Workshop entitled, "Pharmaceutical Profiling in Drug Discovery for Lead Selection", Whippany, NJ, May, 2003.
436. R. T. Borchardt, "Scientific, Educational and Communication Issues Related to Candidate Selection", 45th Annual Land O'Lakes Conference entitled, "Rational Drug Product Design", Merrimac, WI, June, 2003.
437. H. Ouyang and R. T. Borchardt, "Characterization of Breast Cancer Resistant Protein (MXR) in Cell Culture Models using Bi-directional Transport Assays", *AAPS PharmSci*, 6 (Abst. T2151), 2003.
438. B. Li, M. O'Meara, R. L. Schowen, E. M. Topp and R. T. Borchardt, "The Effects of Sucrose and Mannitol on the Rate of Deamidation of Asparagine Residues in Model Peptides in the Solid State", *AAPS PharmSci*, 6 (Abst. T3127), 2003.
439. B. Li, R. L. Schowen, E. M. Topp and R. T. Borchardt, "The Effects of the Residue on the N-Terminal Side of an Asparagine Residue on Its Rate of Deamidation in the Solid State", *AAPS PharmSci*, 6 (Abst. T3125), 2003.
440. B. Li, R. L. Schowen, E. M. Topp and R. T. Borchardt, "The Effects of a Carboxylate Side Chain on the C-Terminal Side of an Asparagine Residue on Its Rate of Deamidation", *AAPS PharmSci*, 6 (Abst. T3126), 2003.
441. S. L. Winslow, D. S. Reddy, R. T. Borchardt and E. M. Topp, "Characterization and Deamidation of Model Cyclic β -Turn Peptides and Their Linear Analogs in Solution and the Solid State", Colorado Protein Stability Conference, Breckenridge, CO, July, 2003.
442. M. L. Houchin, R. T. Borchardt and E. M. Topp, "Peptide Degradation and Recovery in PLGA Films", *AAPS PharmSci*, 6 (Abst. T2069), 2003.
443. S. L. Winslow, D. S. Reddy, R. T. Borchardt and E. M. Topp, "Characterization and Deamidation of Model Cyclic β -Turn Peptides and Their Linear Analogs", *AAPS PharmSci*, 6 (Abst. T2107), 2003.
444. J. Ji, C. Schöneich, R. T. Borchardt and E. M. Topp, "Products of Glutathione Disulfide Photolytic Degradation in Solution", *AAPS PharmSci*, 6 (Abst. T3120), 2003.
445. A. M. D'Souza, R. T. Borchardt, R. L. Schowen, J. S. Salisbury, E. J. Munson and E. M. Topp, "Polymer-Peptide Conjugates", *AAPS PharmSci*, 6 (Abst. M1272), 2003.
446. C. E. Stotz, D. Vander Velde, R. T. Borchardt and E. M. Topp, "Deamidation Rates Within β -Turn-containing

INVITED RESEARCH PRESENTATIONS

A. National or International Meetings

1. "The Specificity of the S-Adenosylhomocysteine Binding Sites of Various Methyltransferases", Symposium on the Biological Role of S-Adenosylmethionine in Methyl Transfer and Polyamine Biosynthesis, Gif-sur-Yvette, France, June, 1973.
2. "Synthesis and Biological Activity of Analogs of S-Adenosylhomocysteine as Inhibitors of Methyltransferases", Symposium on the Biochemistry of S-Adenosylmethionine, Rome, Italy, May, 1974.
3. "Catechol-O-Methyltransferase: A Model to Study the Mechanism of 6-Hydroxydopamine Interaction with Proteins", Symposium on Chemical Tools in Catecholamine Research, Goteburg, Sweden, July, 1975.
4. "New Approaches to Controlling the Activity of Phenylethanolamine-N-Methyltransferase in Stress", Symposium on Catecholamines and Stress, Bratislava, Czechoslovakia, July, 1975.
5. "Probing the Active Site of Catechol-O-Methyltransferase", Symposium on Selected Topics of Interest to the Medicinal Chemists, American Chemical Society Meeting, Chicago, Illinois, August, 1975.
6. "Chemical Probes of the Active Site of Catechol-O-Methyltransferase", Symposium on Biochemistry and Function of Monoamine Enzymes, Steamboat Springs, Colorado, March, 1977.
7. "Approaches to the Design of Inhibitors of SAM-Dependent Methyltransferases", Symposium on Methyl Transfer Reactions, Regional American Chemical Society Meeting, Indianapolis, Indiana, May, 1978.
8. "Isolation and Characterization of the Methyl Acceptor Protein from Adrenal Chromaffin Granules", 4th International Catecholamine Symposium, Monterey, California, September, 1978.
9. "Approaches to the Design of Inhibitors of SAM-Dependent Methyltransferases", International Conference on Transmethylation, Bethesda, Maryland, October, 1978.
10. "Biological Transmethylation Reactions", Symposium on Transmethylations at the ASBC Meeting, New Orleans, Louisiana, June, 1980.
11. "Phenol Sulfotransferase: Purification and Characterization of the Rat Liver, Kidney and Brain Enzymes", Symposium on Phenol Sulfotransferase at the American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, December, 1980.
12. "5-Substituted-3-Hydroxy-4-Methoxybenzaldehydes and Benzoic Acids as Inhibitors of Catechol-O-Methyltransferase", Conference on Monoamine Enzymes, Airlie House, Warrenton, Virginia, March, 1981.
13. "Recent Studies on Inhibitors of Biological Transmethylation Reactions", Sato Award Presentation, Annual Meeting of the Pharmaceutical Society of Japan, Kumamoto City, Japan, April, 1981.
14. "Phenol Sulfotransferase: Purification and Characterization of a Rat Liver Enzyme", Workshop on Sulfate Metabolism and Sulfate Conjugation, Noordwijkerhout, The Netherlands, September, 1981.
15. "Inhibitors of Biological Transmethylation Reaction", International Conference on Transmethylation, Lake of the Ozarks, October, 1981.
16. "Role of Central Epinephrine Neurons in Regulation of Serum Corticosterone Levels", Third Symposium on Catecholamines and Other Neurotransmitters in Stress, Smolenice Castle, Czechoslovakia, June, 1983.
17. "Role of Central Epinephrine Neurons in the Regulation of Serum Prolactin and Luteinizing Hormone Release in Female Rats" 5th International Catecholamine Symposium, Goteberg, Sweden, June, 1983.
18. "Transport and Metabolism as Barriers to Macromolecular Drug Delivery", Academy of Pharmaceutical Sciences Meeting, Miami, Florida, November, 1983.
19. "In Vitro Biological Methods for Assessment of Oral Absorption", Land O'Lakes Conference, June, 1984.

20. "S-Adenosylmethionine-Dependent Transmethylation of Histamine: Purification and Partial Characterization of Guinea Pig Brain and Rat Kidney Histamine N-Methyltransferase", *Frontiers in Histamine Research: An International Symposium*, Jouy-En-Josas, France, July, 1984.
21. "Endogenous Macromolecules as Potential Targets for Site Directed Drug Delivery", *Academy of Pharmaceutical Sciences Annual Meeting*, Philadelphia, PA, Nov., 1984.
22. "S-Adenosyl-L-homocysteine Hydrolase: A Potential Target for Drug Design", *International Symposium entitled, "The Biochemistry of S-Adenosylmethionine as a Basis for Drug Design"*, Bergen, Norway, July, 1985.
23. "Intestinal Epithelium and Vascular Endothelium as Barriers to Peptide and Protein Delivery", *Chicagoland Pharmaceutical Discussion Group*, January, 1986.
24. "Transport and Metabolism as Barriers to Absorption of Peptides and Proteins", *Land O'Lakes Conference*, June, 1986.
25. "Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood Brain Barrier", *New York Academy of Science Symposium entitled, "Controlled Delivery of Drugs: Barriers, Technologies and Therapeutic Approaches"*, New York, January, 1987.
26. "Therapeutic Aspects of rDNA Proteins - An Overview", *symposium entitled, "r-DNA-Derived Proteins: Toxicologic Considerations"*, Society of Toxicology, Washington, DC, February, 1987.
27. "Viral Requiring Methylations as a Target for the Design of Antiviral Agents", *NATO Advanced Study Institute: Antiviral Drug Development: A Multidisciplinary Approach*, Il Ciocco, Italy, May, 1987.
28. "Endothelial Cells of the Vasculature: A Significant Barrier to Effective Drug Delivery", *Controlled Release Society, Inc. Meeting*, Toronto, Canada, August, 1987.
29. "The Use of Isolated Epithelial and Cultured Endothelial Cells in the Design of Novel Drug Delivery Systems", *Xth International Congress of Pharmacology*, Sydney, Australia, August, 1987.
30. "Transport Barriers in the Absorption of Peptide Drugs", *47th International Congress of Pharmaceutical Sciences of F.I.P.*, Amsterdam, The Netherlands, September, 1987.
31. "Barriers to Absorption of Peptides", *Disposition and Delivery of Peptide Drugs-International F.I.P. Satellite Symposium*, Leiden, The Netherlands, September, 1987.
32. "S-Adenosylhomocysteine Hydrolase as a Potential Target for the Design of Antiviral Agents", *Symposium entitled, "Enzyme Inhibition". 22nd Midwest Regional ACS Meeting*, Wichita, KS, November, 1987.
33. "Protein Transport Across Cultured Brain Endothelial Cells", *Symposium entitled, "Biological Transport Mechanisms as a Basis for Rational Drug Delivery"*, Fetzer Center, Kalamazoo, Michigan, November, 1987.
34. "Cultured Bovine Brain Microvessel Endothelial Cells: A Model System Useful in Studying the Transport and Metabolism of Peptides and Proteins Across the Blood Brain Barrier", *International Conference on Pharmaceutical Sciences and Clinical Pharmacology*, Jerusalem, Israel, June, 1988.
35. "Epithelial and Endothelial Barriers to the Effective Delivery of Proteins", *Symposium entitled, "The Biology and Pharmacology of Hemopoietic Growth Factors"*, Newport, Rhode Island, June, 1988.
36. "Cultured Bovine Brain Capillary Endothelial Cells: A Model System for Blood-Brain Barrier Transport and Metabolism", *4th Japanese-American Conference on Pharmacokinetics and Biopharmaceutics*, San Francisco, California, July, 1988.
37. "Elucidation of the Mechanism by Which Neplanocin A and 9-(Trans-2'-Trans-3'-Dihydroxycyclopent-4'-enyl)-Adenine Inactivate S-Adenosylhomocysteine Hydrolase", *8th International Round Table on Nucleosides and Nucleotides*, Pensacola, Florida, October, 1988.
38. "Cultured Endothelial Cells: An *In Vitro* Model System for Studying Protein Transport and Metabolism". *The Second Annual University of California-San Francisco Biotechnology Symposium*, San Francisco, California, October, 1988.
39. "The Application of Cell Culture Models to Study Drug Transport Processes: An Overview". *Symposium entitled, "Cell Culture as a Tool to Study Drug Transport Processes"*, American Association of Pharmaceutical Scientists Meeting, Orlando, Florida, November, 1988.
40. "Endothelial Cells of the Brain Vasculature: A Significant Barrier to CNS Drug Delivery". *Frontiers of the Life Sciences Symposium, 1989 AAAS Annual Meeting*, San Francisco, California, January, 1989.

41. "Cultured Brain Microvessel Endothelial Cells: An In Vitro Model System to Evaluate Strategies for Drug Targeting to the Brain", BioScience 89, Malmo, Sweden, April, 1989.
42. "S-Adenosylhomocysteine Hydrolase: A Target for the Design of Antiviral Agents", Gordon Conference on Purines, Pyrimidines and Related Compounds, Salve Regina College, Newport, Rhode Island, July, 1989.
43. "The Use of Cultured Epithelial and Endothelial Cells to Study Drug Transport and Metabolism", Drug Delivery Systems Conference, Tokyo, Japan, July, 1989.
44. "Deamidation: A Major Pathway for Chemical Degradation of Proteins and Peptides", The Academy of Pharmaceutical Science and Technology Conference, Shirakaabako, Japan, July, 1989.
45. "Pharmaceutical Applications of Cell Culture: An Overview", NATO Advanced Research Workshop on Drug Transport in Cell Culture, Bandol, France, September, 1989.
46. "Development of In Vitro Blood-Brain Barrier Model Systems for Studying Drug Transport", The Preuss Foundation Seminar entitled, "The Role of the Blood-Brain Barrier in the Therapy of Brain Tumors", Scottsdale, Arizona, November, 1989.
47. "The Blood-Brain Barrier in Culture", The King's College Symposium entitled, "The Capillary Endothelium of the Brain", London, England, December, 1989.
48. "Rational Design of Antiviral Drugs", Indian Pharmaceutical Congress, Bombay, India, December, 1989.
49. "Biological Approaches to Rational Drug Delivery", Indian Pharmaceutical Congress, Bombay, India, December, 1989.
50. "In Vitro Models of the Blood Brain Barrier", Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, December, 1989.
51. "Cultured Bovine Brain Microvessel Endothelial Cells: An In Vitro Model System to Study the Blood-Brain Barrier Permeability of Peptides and Proteins", AAPS Western Regional Meeting, Reno, Nevada, February, 1990.
52. "Assessment of Transport Barriers Using Cell and Tissue Culture Systems", 9th annual Update Conference in Pharmaceutics entitled, "A Critical Evaluation of Future Drug Forms - Drugs for the 21st Century", Madison, Wisconsin, April, 1990.
53. "Inhibitors of S-Adenosylhomocysteine Hydrolase: A Target for the Design of Antiviral Agents", 3rd International Conference on Antiviral Research, Brussels, Belgium, April, 1990.
54. "S-Adenosylhomocysteine Hydrolase: A Target for the Design of Antiviral Agents", 31st Annual Medicinal Chemistry Symposium, State University of New York at Buffalo, Buffalo, NY, June, 1990.
55. "Protein Transport Through Cultured Brain Microvessel Endothelial Cells, A Model of the Blood Brain Barrier", XIth International Congress of Pharmacology, Amsterdam, The Netherlands, July, 1990.
56. "Cultured Brain Microvessel Endothelial Cell: An In Vitro Model System to Evaluate Strategies for Drug Targeting to the Brain", National Institute on Drug Abuse Technical Review Meeting, Washington, DC, September, 1990.
57. "S-Adenosylhomocysteine Hydrolase: A Target for Design of Antiviral Agents", Chemical Pharmacology Symposium, Purdue University, West Lafayette, IN, May, 1991.
58. "The Changing World of Drug Discovery: An Academician's Perspective", 1991 Analytical and Physical Chemistry Symposium, The Upjohn Company, Kalamazoo, MI, May, 1991.
59. "Cultured Brain Microvessel Endothelial Cells: An In Vitro Model of the Blood Brain Barrier", 1991 World Congress on Cell and Tissue Culture, Anaheim, CA, June, 1991.
60. "Physical and Chemical Stability of Protein Pharmaceuticals", Pharmacy World Congress '91, Washington, DC, September, 1991.
61. "Computer-Aided Drug Delivery - An Overview", International Society of Quantum Biology and Pharmacology Presidents Meeting, Stanford University, September, 1991.
62. "Rational Delivery Strategies to Circumvent Physical and Metabolic Barriers to the Oral Absorption of Peptides", Oral Delivery of Peptides - From Theory to Practice, 1991 Capsugel Symposium, New Brunswick, NJ, September, 1991.
63. "Cell Culture Systems for Studying Drug Absorption", Symposium entitled, "Facilitating Drug Absorption from the Gastrointestinal Tract", American Association of Pharmaceutical Scientists Meeting, Washington, DC, November,

1991.

64. "Designing Peptides and Peptide-Mimetics with Enhanced Blood Brain Barrier Permeabilities", Symposium entitled, "New Concepts in Drug Delivery to the Brain", American Society of Clinical Pharmacology and Therapeutics", Orlando, FL, March, 1992.
65. "Cultured Brain Microvessel Endothelial Cells: an *In Vitro* Model of the Blood Brain Barrier", Symposium entitled, "Blood Brain Barrier Transport", Parke-Davis Company, Ann Arbor, MI, May, 1992.
66. "The Role of the Pharmaceutical Scientist in Drug Discovery", symposium entitled, "Oral Absorption and Drug Development", Taisho Pharmaceutical Co., Ltd., Tokyo, Japan, June, 1992.
67. "The Use of Cultured Intestinal Epithelial Cells to Evaluate Rational Strategies for Enhancing Drug Permeability", Kanazawa University Symposium, Kanazawa, Japan, June, 1992.
68. "Cultured Brain Microvessel Endothelial Cells: An *In Vitro* Model of the Blood Brain Barrier", 1992 World Congress on Cell and Tissue Culture, Washington, DC, June, 1992.
69. "Rational Delivery Strategies to Circumvent Physical and Metabolic Barriers in the Oral Absorption of Peptides", 19th International Symposium on Controlled Release of Bioactive Materials, Orlando, FL, July, 1992.
70. "Designing Peptides with Enhanced BBB Permeability", Symposium entitled, "Drug Transport to the Brain", Center for Bio-Pharmaceutical Sciences, Leiden University, The Netherlands, October, 1992.
71. "Cultured Brain Microvessel Endothelial Cells: An *In Vitro* Model of the Blood Brain Barrier", Symposium entitled, "*In Vitro* Systems for Studying Epithelial and Endothelial Transport and Metabolism: Applications in Pharmacology and Toxicology", Lepetit Research Center, Gerezono, Italy, October, 1992.
72. "Unique Challenges of Formulation of Proteins: Physical and Chemical Instability", Symposium entitled, "Formulation Approaches to Challenging Intravenous Drugs", Johnson & Johnson, New Brunswick, NJ, October, 1992.
73. "The Unique Challenges of Developing Products Derived from Biotechnology", 28th Annual Arden House Conference entitled, "Sterile Biotechnology Products: The Science of Protein Characterization, Dosage Form Development and Manufacturing", Harriman, New York, February, 1993.
74. "Rational Design of Peptides with Enhanced Membrane Permeability", Symposium entitled, "Prospects and Progress in Drug Design Based on Peptides and Proteins", Keystone Symposium, Taos, New Mexico, March, 1993.
75. "Chemical Instability of Proteins in Solution and in Lyophilized Formulations", Symposium entitled, "Protein Formulations and Delivery", American Chemical Society Meeting, Denver, CO, March, 1993.
76. "The Use of Cultured Bovine Brain Microvessel Endothelial Cells to Study the Vectorial Transport of Peptides in the Blood Brain Barrier", Workshop entitled, "Vectorial Transport in Cultured Epithelial and Endothelial Cells", European Tissue Culture Society, Newcastle, England, April, 1993.
77. "The Use of Cultured Intestinal Epithelial Cells (Caco-2) to Study the Vectorial Transport of Bile Acids", Physiology Society of Great Britain, Leicester, England, April, 1993.
78. "S-Adenosylhomocysteine Hydrolase as a Target for the Design of Antiviral Agents", Symposium entitled, "New Chemotherapeutic Approaches to Cancer and Viral Diseases", 1993 CIC Conference, Sherbrooke, Quebec, Canada, May, 1993.
79. "Biopharmaceutical Assessment", 35th Annual International Industrial Research Conference, Merrimac, Wisconsin, June, 1993.
80. "Rational Strategies to Enhance the Intestinal Permeability of Peptides", 13th American Peptide Symposium, Edmonton, Alberta, Canada, June, 1993.
81. "The Use of Cultured Intestinal Epithelial (Caco-2) Cells to Study Drug Transport and Metabolism", 1993 Gordon Research Conference on Drug Metabolism, July, 1993.
82. "Rational Approaches to the Design of Inhibitors of S-Adenosylhomocysteine Hydrolase", FASEB Summer Research Conference on the "Biochemistry and Pharmacology of S-Adenosylmethionine and Methylation", Copper Mountain, Colorado, August, 1993.
83. "Key Problems in Peroral Drug Delivery" and "Strategies to Delivery Peptides Across the Blood Brain Barrier", International Symposium entitled, "Methods to Overcome Biological Barriers to Drug Delivery", Controlled Release Society Meeting, Kuopio, Finland, August, 1993.

84. "Rational Strategies for the Design of Peptides with Enhanced Oral Delivery", International Symposium entitled, "Recent Developments in Transdermal and Advanced Drug Delivery", FIP Post Congress Satellite Symposium, Taipei, Taiwan, September, 1993.
85. "The Role of the Intestinal Mucosa in Limiting Oral Drug Delivery", NIGMS Workshop entitled, "Oral Drug Delivery: Interface Between Discovery and Development", Herndon, Virginia, December, 1993.
86. "The Unique Challenge of Formulation of Protein Drugs: Physical and Chemical Stability", 3rd Interlaken Conference on Advances in Production of Recombinant Proteins, Interlaken, Switzerland, March, 1994.
87. "Storage Stability of Protein Drugs", BioPharm Conference '94, San Francisco, CA, June, 1994.
88. "Special Bioavailability Problems with Biotechnology-Derived Drugs", Bio-International '94 Conference, Munich, Germany, June, 1994.
89. "Chemical Instability of Proteins in Solution and in Lyophilized Formulations", 1994 Colorado Protein Stability Conference, Breckenridge, CO, July, 1994.
90. "Application of Cell Culture Systems to Study Drug Transport and Metabolism", XIIth International Congress of Pharmacology, Montreal, Canada, July, 1994.
91. "Technologies, Processes and Problems Associated with Oral Delivery of Peptides", Symposium entitled, "Progress Toward Drug Delivery of Peptides and Peptidomimetics", American Chemical Society Meeting, Washington, DC, August, 1994.
92. "Rational Approaches to the Design of Mechanism-Based Inhibitors of S-Adenosylhomocysteine Hydrolase", Eleventh International Round Table of Nucleosides and Nucleotides, Leuven, Belgium, September, 1994.
93. "Predicting Chemical Instability of Proteins in Solution and in Lyophilized Formulations", Recovery of Biological Products VII Symposium, San Diego, CA, September, 1994.
94. "The Application of Cultured Epithelial Cells (Caco-2) to Evaluate Rational Strategies to Enhance the Intestinal Permeability of Peptides", Workshop entitled, "Physiological Barriers to Drug Delivery", Paris, France, October, 1994.
95. "Rational Design to Enhance Membrane Permeability of Peptides", 6th North American Meeting of the International Society for the Study of Xenobiotics, Raleigh, NC, October, 1994.
96. "Physical and Chemical Instability of Proteins - An Overview", Symposium entitled, "Formulation and Process Challenges with Protein Pharmaceuticals", Ninth Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November, 1994.
97. "The Role of P-Glycoprotein in Regulating the BBB Permeability of Peptide Mimetics", 2nd International Symposium on Drug Transport to the Brain, Amsterdam, The Netherlands, February, 1995.
98. "Developing *In Vitro* Models to Predict Human Drug Transport and Metabolism", Keystone Symposia entitled, "Discovery of Therapeutic Agents", Lake Tahoe, CA, March, 1995.
99. "Physicochemical and Biological Factors that Influence a Drug's Cellular Permeability by Passive Diffusion", Symposium entitled, "Lipophilicity in Drug Research and Toxicology", Lausanne, Switzerland, March, 1995.
100. "Structural Requirements for Intestinal Absorption of Peptide Drugs", Fifth International Symposium on Delivery and Targeting of Peptides, Proteins and Genes, Leiden, The Netherlands, June, 1995.
101. "Physicochemical and Biochemical Factors that Influence the Oral Bioavailability of Peptide Mimetics", Fourteenth American Peptide Symposium, Columbus, Ohio, June, 1995.
102. "The Structure and Catalytic Mechanism of S-Adenosylhomocysteine Hydrolase", FASEB Summer Research Conference on Biological Methylations, Saxtons River, Vermont, July, 1995.
103. "Affecting Drug Absorption", 55th World Congress of Pharmacy and Pharmaceutical Sciences, Stockholm, Sweden, August, 1995.
104. "Rational Design of Peptides with Enhanced Membrane Permeability", AFMC International Medicinal Chemistry Symposium, Tokyo, Japan, September, 1995.
105. "Rational Strategies to Enhance the Oral Delivery of Peptides", Western Biotech Conference, San Diego, CA, October, 1995.

106. "Physical and Chemical Instability of Peptides in Formulations and Drug Delivery System", American Chemical Society Conference on Formulation and Drug Delivery, Boston, MA, October, 1995.
107. "Rational Design of Prodrug Strategies to Enhance Membrane Permeability of Peptides", Hoffmann-LaRoche sponsored Wildhaus Scientific Conference, Wildhaus, Switzerland, February, 1996.
108. "Use of Intestinal Tissue for Assessing Oral Bioavailability", Western Regional American Association of Pharmaceutical Scientists Meeting, South San Francisco, CA, March, 1996.
109. "The Application of Cell Culture Systems to Facilitate the Identification of Drugs with Enhanced Oral Bioavailability", Strategic Research Institute Conference on Lead Generation and Optimization, New Orleans, LA, March, 1996.
110. "Chemical Strategies to Overcome Biological Barriers: An Overview", Swedish Academy of Pharmaceutical Sciences Mini-Symposium on Drug Delivery by Means of Chemical Modification: Prodrugs-Soft Drugs, Stockholm, Sweden, March, 1996.
111. "Rational Design of Peptidomimetics with Enhanced Intestinal Mucosal Permeability Properties", Cambridge Healthcare Institute Conference on Development of Small Molecule Mimetic Drugs, Washington, DC, May, 1996.
112. "Novel Esterase-Sensitive Cyclic Prodrugs of a Model Hexapeptide Having Enhanced Membrane Permeability and Enzymatic Stability", XIVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, September, 1996.
113. "Rational Design of Peptides for Intestinal Absorption", 1996 Immobilized Artificial Membrane Meeting, Chicago, IL, September, 1996.
114. "Novel Strategies for the Synthesis of Cyclic Peptides with Increased Metabolic Stability and Enhanced Cellular Permeability", MNPC Mini-Symposium, Eleventh Annual Meeting of the American Association of Pharmaceutical Scientists, Seattle, WA, October, 1996.
115. "Use of Cultured Bovine Brain Microvessel Endothelial Cells to Elucidate the Structural Features of Peptides that Afford Optimal Permeation of the Blood-Brain Barrier Via Passive Diffusion", Table Ronde Roussel UCLAF #85 entitled, "Passage of Drugs Across Physiological Barriers", Paris, France, December, 1996.
116. "Physical and Chemical Instability of Proteins and Peptides in Formulations and Drug Delivery Systems", 1st Symposium on the Analysis of Well Characterized Biotechnology Pharmaceuticals, San Francisco, CA, January, 1997.
117. "Membrane Transport as a Barrier to Drug Delivery", 2nd Winter Conference on Bioorganic and Medicinal Chemistry, Steamboat Spring, CO, January, 1997.
118. "Use of Cell Culture Models for Understanding and Predicting Oral Drug Absorption", Sixteenth Annual Northeastern Regional Pharmaceutics Association Meeting, Rocky Hill, Connecticut, April, 1997.
119. "Prodrug Strategies to Enhance the Permeation of Peptides in the Intestinal Mucosa", The Impact of Pharmacokinetics in Modern Drug Development Symposium, San Francisco, CA, May, 1997.
120. "Chemical Instability of Proteins", Biochemical Engineering X Meeting, Kananaskis, Alberta, Canada, May, 1997.
121. "Application of the Prodrug Principle to Overcoming Oral Absorption Problems of Peptides", Fourth International Conference on Drug Absorption, Edinburgh, Scotland, June, 1997.
122. "Prodrug Strategies to Enhance the Intestinal Mucosa and Blood-Brain Barrier Permeation of Peptides", American Peptide Symposium, Nashville, Tennessee, June, 1997.
123. "The Unique Challenges of Stabilizing Therapeutic Peptides and Proteins", American Association of Colleges of Pharmacy Annual Meeting, Indianapolis, IN, July, 1997.
124. "Prodrug Strategies to Enhance the Intestinal Mucosa and Blood-Brain Barrier Permeation of Peptides", The Alfred Benzon Symposium entitled Peptide and Protein Drug Delivery, Copenhagen, Denmark, August, 1997.
125. "Use of Cell Culture Models as High Throughput Screens for Estimating Oral Drug Absorption", Society for Biomolecular Screening Annual Meeting, San Diego, CA, September, 1997.
126. "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", Conference on Formulations and Drug Delivery II, La Jolla, CA, October, 1997.
127. "Factors that Determine the Disposition and Activity of Biotechnology Products In Vivo: An Overview", 8th

International Society for the Study of Xenobiotics Meeting, Hilton Head, SC, October, 1997.

128. "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", Conference on Challenges for Drug Delivery and Pharmaceutical Technology, Tokyo, Japan, June, 1998.
129. "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", 26th National Medicinal Chemistry Symposium, Richmond, VA, June, 1998.
130. "Optimizing Oral Absorption of Peptides Using Prodrug Strategies", 1998 American Association of Colleges of Pharmacy Meeting, Aspen, CO, July, 1998.
131. "Permeability Determination and Applications: Industry/Academic Perspective", AAPS Workshop on Permeability Definitions and Regulatory Standards for Bioequivalence, Arlington, VA, August, 1998.
132. "The Unique Challenges of Stabilizing Therapeutic Peptides and Proteins to Chemical Degradation", Novo Nordisk 2nd Protein Stability Symposium, Hvidovre, Denmark, August, 1998.
133. "Bridging the Gaps in Academia in Order to Properly Train Pharmaceutical Scientists for the 21st Century", 1998 American Association of Pharmaceutical Scientists Meeting, San Francisco, CA, November, 1998.
134. "Prodrug Strategies to Optimize the Oral Bioavailability of RGD Peptide Mimetics", 9th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February, 1999.
135. "Prodrug Strategies to Improve the Oral Absorption of Peptide Mimetics", Symposium entitled, "Drug Delivery in the 21st Century", 217th American Chemical Society Meeting, Anaheim, CA, March, 1999.
136. "Profiling Compounds for Biopharmaceutical Properties: Overview", Symposium entitled, "Biopharmaceutical Profiling", 217th American Chemical Society Meeting, Anaheim, CA, March, 1999.
137. "Permeability Determination and Applications: Industry/Academic Perspective", International Symposium entitled, "Strategies for Optimizing Oral Drug Delivery: Scientific to Regulatory Approaches", Kobe, Japan, April, 1999.
138. "Lipids, Lipidic Excipients and Enterocyte-Based P-Glycoprotein and Cytochrome P-450-3A4 Mediated Processes", International Symposium entitled, "Recent Advances in the Formulation and Development of Poorly-Soluble Drugs", St. Remy, France, June, 1999.
139. "Is the Intestinal Mucosa a Physical or a Biological Barrier to Oral Delivery?", Symposium entitled, "Strategies for Oral Delivery of Challenging Molecules", Merrimac, WI, June, 1999.
140. "S-Adenosylmethionine and Methylation: The First 50 Years", FASEB Summer Research Conference on "Biological Methylation", Saxton River, VT, July, 1999.
141. "How Structure Influences the Oral Absorption of Peptidemimetics", Smissman Award Symposium, American Chemical Society Annual Meeting, New Orleans, LA, August, 1999.
142. "How Structure Influences the Oral Absorption of Peptides", Host-Madsen Award Lecture at the World Congress of Pharmacy and Pharmaceutical Sciences '99, Barcelona, Spain, September, 1999.
143. "How Structure Influences Permeation of Drugs Across the Blood-Brain Barrier", Pharma Biotec Center Symposium, Sandbjerg Castle, Denmark, October, 1999.
144. "Training Grants in the Chemical and Biological Sciences", workshop entitled "Graduate Education in the Chemical Sciences: Issues for the 21st Century", sponsored by the National Research Council, Washington, DC, December, 1999.
145. "Biological Models to Assess Drug Bioavailability", Lipophilicity in Drug Disposition Symposium, University of Lausanne, Lausanne, Switzerland, March, 2000.
146. "How Structure Influences the Cell Permeation of Peptides and Peptidemimetics", Plenary Presentation at the Millennial World Congress of Pharmaceutical Sciences, San Francisco, CA, April, 2000.
147. "Effect of Lipidic Excipients on Efflux Transporters in the Intestinal Mucosa", Birmingham 2000, British Pharmaceutical Conference, Birmingham, England, August, 2000.
148. "How to Design High Affinity Receptor Ligands that Have Drug-like Characteristics", Workshop entitled, "What Makes a Drug Attractive for Its Receptor: ADME, Affinity and Selectivity", Schloss Rauischholzhausen, Marburg, Germany, March, 2001.
149. "How Structure Influences the Intestinal Mucosal Permeation of Peptide and Peptidemimetic Drugs", Pharmaceutical

Congress of the Americas, March, 2001.

150. "The Use of Cell Culture Systems as Models of the Intestinal Mucosa in Drug Discovery and Development", World Congress of Pharmacy and Pharmaceutical Sciences 2001, Singapore, September, 2001.
151. "The Use of Cell Culture Models to Predict Oral Absorption of Drugs in Humans", International Workshop on the Biopharmaceutics Classification System, London, UK, October, 2001.
152. "Role of Cell Culture Models of Biological Barriers in Pharmaceutical R&D", Short Course entitled, "Cell Culture and *In Vitro* Models for Drug Absorption and Delivery", University of Saarland, Saarbrücken, Germany, February, 2002.
153. "Profiling Compounds for Biopharmaceutical Properties: Overview", Symposia entitled "The Role of Bioanalytical Chemists in Profiling the Biopharmaceutical Properties of Drug Candidates", PITTCON 2002, New Orleans, LA, March, 2002.
154. "Transport Across the Intestinal mucosa. Are There Lessons for the Blood-Brain Barrier?", Gordon Research Conference entitled, "Barriers of the CNS", Tilton School, Tilton, NH, June, 2002.
155. "Drug Design with Biopharmaceutics in Mind", AAPS/FIP/Chinese Pharmaceutical Society Joint Symposium on Scientific and Regulatory Challenges of Pharmaceutical Sciences, Beijing, China, July, 2002.
156. "Applications of Cell Culture Models of the Intestinal Mucosa in Drug Discovery and Development", AAPS/FIP/Chinese Pharmaceutical Society Joint Symposium on Scientific and Regulatory Challenges of Pharmaceutical Sciences, Beijing, China, July, 2002.
157. "Predictive Models for Permeability-Standard and Novel Techniques", British Pharmaceutical Conference, Manchester, England, September, 2002.
158. "Will Cell Culture Models be Predictive of Transporter-Mediated Drug Permeation in the Context of BCS?", AAPS Workshop entitled, "Biopharmaceutical Classification System", Arlington, VA, September, 2002.
159. "The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-brain Barrier", 2002 American Association of Pharmaceutical Scientists, Toronto, Canada, November, 2002.
160. "Developing Rational Strategies to Stabilize Protein Therapeutics Based on Knowledge About the Protein's Potential Pathways of Chemical Degradation", Short Course entitled, "Analytical Challenges in the Formulation of Pharmaceutical Proteins", Royal Danish School of Pharmacy, Copenhagen, Denmark, December, 2002.
161. "Educational and Communication Issues Associated with Integrating and Applying Drug-like Data in Drug Discovery", AAPS Workshop entitled, "Pharmaceutical Profiling in Drug Discovery for Lead Selection", Whippany, NJ, May, 2003.
162. "Scientific, Educational and Communication Issues Related to Candidate Selection", 45th Annual Land O'Lakes Conference entitled, "Rational Drug Product Design", Merrimac, WI, June, 2003.
163. "Educational and Communication Issues Related to Profiling Compounds for their Drug-like Properties", LogP 2004 Symposium, Zurich, Switzerland, March, 2004.
164. "Drug Design with Biopharmaceutics in Mind: A Paradigm Shift in Drug Discovery", European Drug Absorption Network Meeting, Leuven, Belgium, March, 2004.

B. University or Industry (Since 1975)

1. Department of Pharmacology, School of Pharmacy, University of Wisconsin, Madison, Wisconsin, September, 1975.
2. Department of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota, November, 1975.
3. Department of Medicinal Chemistry, School of Pharmacy, University of Minnesota, Minneapolis, Minnesota, November, 1975.
4. Department of Neurology, Mount Sinai School of Medicine, New York, December, 1975.

5. Department of Pharmacology, School of Medicine, Yale University, New Haven, Connecticut, December, 1975.
6. Burroughs-Wellcome Corporation, Research Triangle Park, North Carolina, June, 1976.
7. Department of Pharmacology, Mayo Foundation, School of Medicine, Rochester, Minnesota, July, 1976.
8. Lilly Research Laboratories, Indianapolis, Indiana, October, 1976.
9. Department of Chemistry, University of Indiana, Bloomington, Indiana, October, 1976.
10. Smith Kline & French Laboratories, Philadelphia, Pennsylvania, October, 1976.
11. Medical College of Virginia, Department of Pharmacology, Richmond, Virginia, December, 1977.
12. The John Curtin School of Medical Research, The Australian National University, Canberra City, Australia, March, 1979.
13. Department of Pharmacy, The University of Sydney, Sydney, Australia, March, 1979.
14. School of Pharmaceutical Chemistry, Victorian College of Pharmacy, Ltd., Melbourne, Australia, March, 1979.
15. School of Pharmaceutics, Victorian College of Pharmacy, Ltd., Melbourne, Australia, March, 1979.
16. School of Pharmacy, Oregon State University, Corvallis, Oregon, February, 1979.
17. Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, February, 1979.
18. Department of Pharmacology, School of Medicine, Ohio State University, November, 1979.
19. E. C. Franklin Lecture, University of Kansas April, 1980.
20. School of Pharmacy, University of Wisconsin, June, 1980.
21. Department of Pharmacology, University of Nebraska Medical Center, Omaha, Nebraska, September, 1980.
22. Department of Chemistry, University of Missouri-Rolla, October, 1980.
23. Department of Biochemistry, University of Missouri-Columbia, October, 1980.
24. Department of Chemistry, University of Missouri-Kansas City, October, 1980.
25. Department of Biochemistry, Kansas State University, Manhattan, Kansas, October, 1980.
26. University of Oklahoma, Health Sciences Center, January, 1981.
27. Department of Biochemistry, Iowa State University, January, 1981.
28. School of Pharmacy, University of Nebraska, Omaha, Nebraska, January, 1981.
29. Department of Chemistry, University of Nebraska, Lincoln, Nebraska, January, 1981.
30. Department of Biochemistry, University of Kansas Medical Center, Kansas City, Kansas, February, 1981.
31. Biology Division, National Cancer Center Research Institute, Tokyo, Japan, April, 1981.
32. Sankyo Company, Limited, Tokyo, Japan, April, 1981.
33. Department of Biochemistry, National Taiwan University Medical Center, Taipei, Taiwan, April, 1981.
34. Department of Pharmaceutical Chemistry, National Taiwan University, School of Pharmacy, Taipei, Taiwan, April, 1981.
35. Department of Biochemistry, National Yang Ming Medical College, Taipei, Taiwan, April, 1981.
36. Department of Pharmacology, University of Kansas Medical Center, Kansas City, Kansas, December, 1981.
37. Allergan Corporation, Irvine, California, January, 1982.

38. Burroughs Wellcome Corporation, Research Triangle Park, North Carolina, February, 1982.
39. University of Kansas, Summerfield Professorship Inaugural Lecture, April, 1982.
40. G. D. Searle Corporation, North Chicago, Illinois, June, 1982.
41. Department of Medicinal Chemistry, School of Pharmacy, University of Iowa, Iowa City, Iowa, October, 1982.
42. Schering Corporation, Bloomfield, New Jersey, October, 1982.
43. The Upjohn Company, Kalamazoo, Michigan, September, 1983.
44. School of Pharmacy, University of Michigan, Ann Arbor, Michigan, September, 1983.
45. Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, October, 1983.
46. Smith Kline & French Laboratories, Philadelphia, Pennsylvania, October, 1983.
47. School of Pharmacy, University of Rhode Island, Kingston, Rhode Island, November, 1983.
48. Department of Pharmacology, Medical School of New Jersey, Newark, New Jersey, February, 1984.
49. Department of Pharmacology, University of Kansas Medical School, Kansas City, Kansas, February, 1984.
50. National Center for Drugs and Biologies, Food and Drug Administration, March, 1984.
51. Pfizer Corporation, Groton, Connecticut, September, 1984.
52. Schering Corporation, Bloomfield, New Jersey, October, 1984.
53. Wichita State University, Wichita, Kansas, November, 1984.
54. Upjohn Corporation, Kalamazoo, Michigan, December, 1984.
55. Upjohn Corporation, Craveley, England, February, 1985.
56. Smith Kline & French Laboratories, Philadelphia, Pennsylvania, March, 1985.
57. Ciba-Geigy Corporation, Summit, New Jersey, May, 1985.
58. Berlex Laboratories, Cedar Knolls, New Jersey, May, 1985.
59. Upjohn Corporation, Kalamazoo, Michigan, October, 1985.
60. Walter Reed Army Institute of Research, Washington, DC, October, 1985.
61. Laboratory on Oncology Research, Mayo Clinic, Rochester, Minnesota, December, 1985.
62. Travenol Laboratories, Inc., Morton Grove, Illinois, January, 1986.
63. Bristol-Myers Corporation, Syracuse, New York, February, 1986.
64. Burroughs Wellcome, Inc., Research Triangle Park, North Carolina, February, 1986.
65. Lederle Laboratories, Pearl River, New York, July, 1986.
66. Alcon Laboratories, Fort Worth, Texas, July, 1986.
67. G. D. Searle & Co., St. Louis, Missouri, September, 1986.
68. Glaxo, Inc., Research Triangle Park, North Carolina, November, 1986.
69. Adria Laboratories, Inc., Columbus, Ohio, December, 1986.
70. Lilly Research Laboratories, Indianapolis, Indiana, February, 1987.
71. G. D. Searle & Co., Chicago, Illinois, February, 1987.

72. Northeast Section of the American Chemical Society, Boston, Massachusetts, April, 1987.
73. School of Pharmacy, University of Florida, Gainesville, Florida, April, 1987.
74. Victorian College of Pharmacy, Ltd, Melbourne, Australia, August, 1987.
75. Faulding Research & Development, Adelaide, Australia, August, 1987.
76. Syntex Corporation, Palo Alto, California, October, 1987.
77. Alza Corporation, Palo Alto, California, October, 1987.
78. Johnson & Johnson, New Brunswick, New Jersey, October, 1987.
79. Merck Sharp & Dohme, West Point, Pennsylvania, December, 1987.
80. Smith Kline & French Laboratories, Philadelphia, Pennsylvania, December, 1987.
81. Hoechst, Roussel Pharmaceutical, Inc., Somerville, New Jersey, January, 1988.
82. Merck Sharp & Dohme, Rahway, New Jersey, January, 1988.
83. Hoshi University, Tokyo, Japan, April, 1988.
84. Sankyo Co., Tokyo, Japan, April, 1988.
85. Eisai Co., Tokyo, Japan, April, 1988.
86. Tokyo University, Tokyo, Japan, April, 1988.
87. S-S Pharmaceutical Co., Ltd., Ikebukuro, Japan, April, 1988.
88. Josai University, Tokyo, Japan, April, 1988.
89. Hokkaido University, Sapporo, Japan, April, 1988.
90. Toyo Jozo Co., Ltd., Mishima, Japan, April, 1988.
91. Nagoya City University, Nagoya, Japan, April, 1988.
92. Takeda Chem. Ind., Ltd., Osaka, Japan, April, 1988.
93. Kyoto University, Kyoto, Japan, April, 1988.
94. Teikoku Company, Tokushima, Japan, April, 1988.
95. Hiroshima University, Hiroshima, Japan, April, 1988.
96. Procter & Gamble Company, Norwich, Connecticut, May, 1988.
97. Procter & Gamble Company, Cincinnati, Ohio, May, 1988.
98. University of Cincinnati, School of Pharmacy, Cincinnati, Ohio, May, 1988.
99. Emporia State University, Emporia, Kansas, September, 1988.
100. University of Oklahoma, Department of Chemistry, Norman, Oklahoma, October, 1988.
101. Rutgers University, Department of Chemistry, Newark, New Jersey, September, 1988.
102. Roche Institute of Molecular Biology, Nutley, New Jersey, September, 1988.
103. Rutgers University, School of Pharmacy, Piscataway, New Jersey, December, 1988.
104. University of Washington, School of Pharmacy, Seattle, Washington, December, 1988.
105. Ohio State University, School of Pharmacy, Columbus, Ohio, December, 1988.

106. Amgen Corporation, Thousand Oaks, California, January, 1989.
107. Brigham Young University, Department of Chemistry, Provo, Utah, January, 1989.
108. Glaxo, Inc., Research Triangle Park, North Carolina, February, 1989.
109. University of Michigan, School of Pharmacy, Ann Arbor, Michigan, February, 1989.
110. Merrell Dow Research Institute, Cincinnati, Ohio, February, 1989.
111. University of Kentucky, College of Pharmacy, Lexington, Kentucky, March, 1989.
112. University of Minnesota, College of Pharmacy, Minneapolis, Minnesota, April, 1989.
113. Hassle Corporation, Goteburg, Sweden, April, 1989.
114. Uppsala University, Uppsala, Sweden, April, 1989.
115. Alkermes, Inc., Boston, Massachusetts, May, 1989.
116. Gensia Pharmaceuticals, Inc., San Diego, California, May, 1989.
117. Drug Delivery Systems Institute, Tsukuba, Japan, July, 1989.
118. Upjohn--Japan, Tsukuba, Japan, July, 1989.
119. Daiichi Pharmaceutical Co., Tokyo, Japan, July, 1989.
120. Eisai Pharmaceutical Co., Tsukuba, Japan, July, 1989.
121. Yamanouchi Pharmaceutical Co., Tsukuba, Japan, July, 1989.
122. Taiho Pharmaceutical Co., Tokushima, Japan, July, 1989.
123. Shionogi Pharmaceutical Co., Osaka, Japan, July, 1989.
124. Takeda Chemical Industry, Osaka, Japan, July, 1989.
125. Squibb Corporation, Princeton, New Jersey, September, 1989.
126. Pfizer Corporation, Groton, Connecticut, September, 1989.
127. Univ. of Rhode Island, School of Pharmacy, Kingston, Rhode Island, September, 1989.
128. Kansas City Discussion Group of Pharmaceutical and Allied Sciences, Overland Park, Kansas, September, 1989.
129. Univ. of New York--Buffalo, School of Pharmacy, Buffalo, New York, October, 1989.
130. Grace Cancer Drug Center, Roswell Park Memorial Institute, Buffalo, New York, October, 1989.
131. Univ. of Iowa, Dept. of Chemistry, Iowa City, Iowa, October, 1989.
132. Univ. of Wisconsin, School of Pharmacy, Madison, Wisconsin, November, 1989.
133. Eastman Pharmaceuticals, Inc., Malvern, Pennsylvania, December, 1989.
134. Squibb Corporation, Princeton, New Jersey, February, 1990.
135. North Jersey Drug Metabolism Discussion Group Meeting, Clifton, NJ, April, 1990.
136. University of Toledo, Toledo, Ohio, October, 1990.
137. Department of Pharmacology, University of Kansas Medical Center, Kansas City, Kansas, November, 1990.
138. Parke-Davis Company, Ann Arbor, Michigan, December, 1990.
139. Applied Analytical Systems, Wilmington, North Carolina, January, 1991.

140. 3M Pharmaceuticals, Minneapolis, Minnesota, April, 1991.
141. The Upjohn Company, Kalamazoo, Michigan, May, 1991.
142. Procter & Gamble Company, Cincinnati, Ohio, May, 1991.
143. Purdue University, West Lafayette, Indiana, May, 1991.
144. University of Arizona, Tucson, Arizona, September, 1991.
145. Applied Analytical Systems, Wilmington, North Carolina, September, 1991.
146. Gilead Corporation, Forest City, California, September, 1991.
147. Baxter Healthcare Corporation, Lincolnshire, Illinois, October, 1991.
148. SmithKline Beecham, King of Prussia, Pennsylvania, October, 1991.
149. Wichita State University, Wichita, Kansas, November, 1991.
150. Howard University, Washington, DC, November, 1991.
151. Marion Merrell Dow, Kansas City, Missouri, December, 1991.
152. Syntex Research, Palo Alto, California, January, 1992.
153. Fisons Pharmaceuticals, Rochester, New York, March, 1992.
154. Wichita State University, Wichita, Kansas, April, 1992.
155. Abbott Laboratories, North Chicago, Illinois, May, 1992.
156. Ciba-Geigy Corporation, Summit, New Jersey, May, 1992.
157. Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, Pennsylvania, May, 1992.
158. Parke-Davis Company, Ann Arbor, Michigan, May, 1992.
159. Upjohn Pharmaceutical Ltd., Tsukuba, Japan, June, 1992.
160. Hisamitsu Pharmaceutical Co., Inc., Tsukuba, Japan, June, 1992.
161. Eisai Pharmaceutical Co., Tsukuba, Japan, June, 1992.
162. Japan Tobacco, Inc., Yokohama, Japan, June, 1992.
163. Kanazawa University, Kanazawa, Japan, June, 1992.
164. Taisho Pharmaceutical Co., Ltd., Saitama, Japan, June, 1992.
165. Shiesei Co., Ltd., Tokyo, Japan, June, 1992.
166. Kyusyu University, Fukuoka, Japan, June, 1992.
167. Kyoto University, Kyoto, Japan, June, 1992.
168. Fujisawa Pharmaceutical Co., Osaka, Japan, June, 1992.
169. Takeda Chemical Industry, Osaka, Japan, June, 1992.
170. Sandoz Pharmaceutical Corp., East Hanover, New Jersey, September, 1992.
171. Johnson and Johnson, New Brunswick, New Jersey, October, 1992.
172. DuPont Merck Pharmaceutical Corp., Wilmington, Delaware, November, 1992.
173. Merck Sharp & Dohme Research Laboratories, Rahway, NJ, November, 1992.

174. St. John's Univ., New York, New York, November, 1992.
175. Syntex Corporation, Palo Alto, California, December, 1992.
176. Alza Corporation, Palo Alto, California, December, 1992.
177. University of Tennessee, Memphis, Tennessee, January, 1993.
178. Merck Sharp & Dohme Research Laboratories, Rahway, NJ, February, 1993.
179. Merck Sharp & Dohme Research Laboratories, West Point, PA, February, 1993.
180. Schering-Plough Research Institute, Kenilworth, NJ, February, 1993.
181. University of North Carolina, Chapel Hill, NC, February, 1993.
182. Glaxo Inc., Research Triangle Park, NC, February, 1993.
183. Chiron, Inc., Emeryville, CA, February, 1993.
184. University of Colorado, Denver, CO, April, 1993.
185. Southwest Missouri State University, Springfield, MO, April, 1993.
186. Ciba-Geigy Pharmaceuticals, Horsham, England, April, 1993.
187. Glaxo Research Group, Ware, England, April, 1993.
188. SmithKline Beecham, Mundells, England, April, 1993.
189. Vertex Pharmaceuticals, Cambridge, MA, May, 1993.
190. Bristol-Myers Squibb, Wallingford, CT, May, 1993.
191. Rhone Poulenc Rorer Central Research, Collegeville, PA, May, 1993.
192. SmithKline Beecham Pharmaceuticals, King of Prussia, PA, May, 1993.
193. Abbott Laboratories, North Chicago, IL, June, 1993.
194. Wyeth Ayerst Laboratories, Rouses Point, NY, June, 1993.
195. Daiichi-Seiyaku Pharmaceutical Co., Tokyo, Japan, September, 1993.
196. Hoechst-Japan, Tokyo, Japan, September, 1993.
197. National Defense University, Taipei, Taiwan, September, 1993.
198. University of California, San Francisco, October, 1993.
199. Tanabe Research Laboratories, San Diego, CA, October, 1993.
200. Genentech, Inc., South San Francisco, CA, October, 1993.
201. University of Missouri, Columbia, MO, November, 1993.
202. Glaxo Inc., Research Triangle Park, NC, November, 1993.
203. National Institute on Drug Abuse, Rockville, MD, December, 1993.
204. University of Michigan, Ann Arbor, MI, March, 1994.
205. Sandoz Pharma Ltd., Basel, Switzerland, March, 1994.
206. Ciba-Geigy Ltd., Basel, Switzerland, March, 1994.
207. Hoffmann-LaRoche, Basel, Switzerland, March, 1994.

208. Pharmazeutisches Institute, University of Basel, Basel, Switzerland, March, 1994.
209. University of Kentucky, Lexington, KY, April, 1994.
210. Alza Corporation, Palo Alto, CA, May, 1994.
211. G. D. Searle Pharmaceutical Co., Skokie, IL, June, 1994.
212. SmithKline Beecham Pharmaceuticals, King of Prussia, PA, July, 1994.
213. Neurobiological Technologies, Richmond, CA, August, 1994.
214. SmithKline Beecham Pharmaceuticals, Harlow, England, September, 1994.
215. Pfizer Corp., Groton, CT, September, 1994.
216. Westfälische Wilhelms Universität-Münster, Münster, Germany, October, 1994.
217. University of Marburg, Marburg, Germany, October, 1994.
218. Rhone Poulenc Rorer, Collegeville, PA, October, 1994.
219. Wayne State University, Detroit, MI, December, 1994.
220. Kansas City Discussion Group of Pharmaceutical and Allied Sciences, Overland Park, KS, December, 1994.
221. The Upjohn Company, Kalamazoo, MI, December, 1994.
222. Gilead Sciences, Foster City, CA, January, 1995.
223. Alza Corporation, Palo Alto, CA, January, 1995.
224. Affymax Corporation, Palo Alto, CA, January, 1995.
225. University of Pennsylvania, Philadelphia, PA, April, 1995.
226. Katholieke University, Leuven, Belgium, May, 1995.
227. Royal Danish School of Pharmacy, Copenhagen, Denmark, May, 1995.
228. Glaxo Inc., Research Triangle Park, NC, June, 1995.
229. Astra Pharmaceuticals, Rochester, NY, June, 1995.
230. Houghten Pharmaceuticals, Inc., LaJolla, CA, June, 1995.
231. Sandoz Pharma Ltd., Basel, Switzerland, June, 1995.
232. Hoffmann-LaRoche, Ltd., Basel, Switzerland, June, 1995.
233. Cephalon, Inc., West Chester, PA, July, 1995.
234. Genentech, Inc., South San Francisco, CA, August, 1995.
235. Astra Arcus AB, Sodertalje, Sweden, August, 1995.
236. Astra Draco, Lund, Sweden, August, 1995.
237. University of Uppsala, Uppsala, Sweden, August, 1995.
238. Hoechst Pharmaceuticals Ltd., Tokyo, Japan, September, 1995.
239. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, September, 1995.
240. Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan, September, 1995.
241. University of Tokyo, Tokyo, Japan, September, 1995.

242. Sankyo Company, Ltd., Tokyo, Japan, September, 1995.
243. Upjohn Pharmaceuticals Ltd., Tsukuba, Japan, September, 1995.
244. Kyoto University, Kyoto, Japan, September, 1995.
245. Sumitomo Pharmaceutical Co., Ltd., Kyoto, Japan, September, 1995.
246. Tanabe Pharmaceutical Co., Ltd., Kyoto, Japan, September, 1995.
247. Japan Tobacco, Ltd., Kyoto, Japan, September, 1995.
248. Ono Pharmaceutical Co., Kyoto, Japan, September, 1995.
249. Cambridge Neurosciences, Cambridge, MA, October, 1995.
250. Immulogic Pharmaceutical Corp., Cambridge, MA, October, 1995.
251. University of Nebraska, Omaha, NE, October, 1995.
252. Alza Corporation, Palo Alto, CA, December, 1995.
253. Cibus Pharmaceuticals, Inc., Redwood City, CA, March, 1996.
254. Pharmacia & Upjohn, Inc., Stockholm, Sweden, March, 1996.
255. Cygnus Pharmaceuticals, Redwood City, CA, April, 1996.
256. Arris Pharmaceuticals Corp., South San Francisco, CA, April, 1996.
257. Adolar Corporation, Malvern, PA, May, 1996.
258. Oncogene Science, Uniondale, NY, May, 1996.
259. Wyeth-Ayerst Research, Pearl River, NY, October, 1996.
260. Pfizer, Inc., Sandwich, England, November, 1996.
261. Glycomed-Ligand, Alameda, CA, November, 1996.
262. University of Florida, Gainesville, FL, November, 1996.
263. Pharmacia & Upjohn, Inc., Stockholm, Sweden, December, 1996.
264. Uppsala University, Uppsala, Sweden, December, 1996.
265. Inhale Therapeutic Systems, Palo Alto, CA, February, 1997.
266. MetaXen, Palo Alto, CA, February, 1997.
267. IntraBiotics Pharmaceuticals, Sunneyvale, CA, February, 1997.
268. Isis Pharmaceuticals, Carlsbad, CA, March, 1997.
269. Hoechst Marion Roussel, Kansas City, MO, March, 1997.
270. Zeneca Pharmaceuticals, Wilmington, DE, January, 1997.
271. Vertex Pharmaceuticals, Cambridge, MA, April, 1997.
272. Biogen, Cambridge, MA, April, 1997.
273. Pfizer, Groton, CT, April, 1997.
274. Hybridon, Inc., Cambridge, MA, May, 1997.
275. Genentech, South San Francisco, CA, May, 1997.

276. Zeneca Pharmaceuticals, Manchester, England, June, 1997.
277. Sepracor, Inc., Marlborough, MA, September, 1997.
278. Tanabe Research Laboratories, San Diego, CA, September, 1997.
279. Parke-Davis Research Laboratories, Ann Arbor, MI, October, 1997.
280. University of Michigan, Ann Arbor, MI, October, 1997.
281. Vertex Pharmaceuticals, Inc., Cambridge, MA, November, 1997.
282. Genentech, South San Francisco, CA, November, 1997.
283. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, November, 1997.
284. Athena Pharmaceuticals, South San Francisco, CA, November, 1997.
285. SmithKline Beecham Pharmaceuticals, Collegeville, PA, December, 1997.
286. AnorMed Pharmaceuticals, Vancouver, BC, January, 1998.
287. Millennium Pharmaceuticals, Cambridge, MA, March, 1998.
288. GeneMedicine, Houston, TX, March, 1998.
289. ARIAD Pharmaceuticals, Cambridge, MA, March, 1998.
290. Washington State University, Pullman, WA, April, 1998.
291. Oregon State University, Corvallis, OR, April, 1998.
292. Eli Lilly Research Laboratories, Indianapolis, IN, April, 1998.
293. Hoffmann-LaRoche, Nutley, NJ, May, 1998.
294. Synaptic Pharmaceutical Corp., Paramus, NJ, May, 1998.
295. Takeda Pharmaceutical Co., Osaka, Japan, June, 1998.
296. Sumitomo Pharmaceutical Co., Osaka, Japan, June, 1998.
297. Ono Pharmaceutical Co., Kyoto, Japan, June, 1998.
298. Yamanouchi Pharmaceutical Co., Shizuoka, Japan, June, 1998.
299. Daiichi Pharmaceutical Co., Tokyo, Japan, June, 1998.
300. Banyu Pharmaceutical Co., Tsukuba, Japan, June, 1998.
301. Sankyo Pharmaceutical Co., Tokyo, Japan, June, 1998.
302. Chugai Pharmaceutical Co., Tokyo, Japan, June, 1998.
303. Taisho Pharmaceutical Co., Saitama, Japan, June, 1998.
304. Novo Nordisk A/S, Hvidovre, Denmark, August, 1998.
305. Novo Nordisk A/S, Maaloev, Denmark, August, 1998.
306. Royal Danish School of Pharmacy, Copenhagen, Denmark, August, 1998.
307. Zeneca Pharmaceuticals, Ltd., Macclesfield, England, August, 1998.
308. Glaxo-Wellcome Pharmaceuticals, Stevenage, England, September, 1998.
309. SmithKline Beecham Pharmaceuticals, Harlow, England, September, 1998.

310. Ares Advanced Technology, Randolph, MA, September, 1998.
311. Coulter Pharmaceuticals, Palo Alto, CA, November, 1998.
312. University of Mississippi, University, MI, December, 1998.
313. Praecis Pharmaceuticals, Cambridge, MA, December, 1998.
314. Agouron Pharmaceuticals, Inc., San Diego, CA, January, 1999.
315. Coelacanth, Inc., Princeton, NJ, January, 1999.
316. University of Kansas Medical Center (Physiology), Kansas City, KS, January, 1999.
317. Virginia Commonwealth University, Richmond, VA, January, 1999.
318. University of the Pacific, Stockton, CA, February, 1999.
319. Abbott Laboratories, North Chicago, IL, February, 1999.
320. Wayne State University, Detroit, MI, February, 1999.
321. University of Connecticut, Storrs, CT, March, 1999.
322. Boehringer-Ingelheim, Ridgefield, CT, March, 1999.
323. The Immune Response Corporation, Carlsbad, CA, March, 1999.
324. Hoechst Marion Roussel, Bridgewater, CT, March, 1999.
325. University of Minnesota, Minneapolis, MN, April, 1999.
326. University of Colorado, Denver, CO, April, 1999.
327. Shionogi & Co., Ltd., Osaka, Japan, April, 1999.
328. Organon Pharmaceutical Co., Osaka, Japan, April, 1999.
329. Fujisawa Pharmaceutical Co., Osaka, Japan, April, 1999.
330. Dainippon Pharmaceutical Co., Osaka, Japan, April, 1999.
331. Kumamoto University, Kumamoto, Japan, April, 1999.
332. University of Illinois-Chicago, IL, May, 1999.
333. University of Singapore, Singapore, May, 1999.
334. ViroPharm, Inc., Lionville, PA, May, 1999.
335. Scios, Inc., Sunnyvale, CA, June, 1999.
336. Hoechst Marion Roussel, Romainville, France, June, 1999.
337. Millennium Pharmaceuticals, Inc., Cambridge, MA, August, 1999.
338. University of Michigan, Ann Arbor, MI, September, 1999.
339. Guilford Pharmaceuticals, Baltimore, MD, September, 1999.
340. Biogen Corporation, Cambridge, MA, September, 1999.
341. Royal Danish School of Pharmacy, Copenhagen, Denmark, October, 1999.
342. TEVA Pharmaceutical Industries, Kfar Saba, Israel, October, 1999.
343. Bio-Mega-Boehringer Ingelheim, Montreal, Canada, October, 1999.

344. Hoffmann-LaRoche Pharmaceutical Co., Nutley, NJ, November, 1999.
345. Bristol-Myers Squibb, New Brunswick, NJ, February, 2000.
346. ARIAD Pharmaceuticals, Inc., Cambridge, MA, February, 2000.
347. University of Missouri-Kansas City, Kansas City, MO, February, 2000.
348. SeroPharmaceutical Research Institute, Geneva, Switzerland, March, 2000.
349. Rutgers University, Piscataway, NJ, March, 2000.
350. West Pharmaceutical Services, Lionville, PA, March, 2000.
351. Monsanto Company, St. Louis, MO, April, 2000.
352. Pharmacia & Upjohn, Kalamazoo, MI, April, 2000.
353. Schering Plough Corporation, Kenilworth, NJ, May, 2000.
354. Genentech Corporation, South San Francisco, CA, May, 2000.
355. Pharmacia, Skokie, IL, June, 2000.
356. Sugan Corporation, South San Francisco, CA, June, 2000.
357. Chiron Corporation, Emeryville, CA, June, 2000.
358. Vertex Corporation, Cambridge, MA, August, 2000.
359. Pfizer Corporation, Groton, CT, August, 2000.
360. Biogen Corporation, Cambridge, MA, August, 2000.
361. Wyeth-Ayerst Pharmaceutical Corporation, Princeton, NJ, October, 2000.
362. Pfizer Corporation, Ann Arbor, MI, October, 2000.
363. University of Basel, Basel, Switzerland, November, 2000.
364. Boehringer Ingelheim, Biberach, Germany, November, 2000.
365. University of Leiden, Leiden, The Netherlands, November, 2000.
366. University of Utrecht, Utrecht, The Netherlands, November, 2000.
367. University of California—San Francisco, San Francisco, CA, December, 2000.
368. Chiron Corporation, Emeryville, CA, December, 2000.
369. Hoffmann-LaRoche, Palo Alto, CA, December, 2000.
370. Genetic Institute, Cambridge, MA, December, 2000.
371. University of South Carolina, Charleston, SC, February, 2001.
372. Albany Molecular Research Institute, Albany, NY, April, 2001.
373. University of Nebraska Medical Center, Omaha, NE, April, 2001.
374. New England Drug Metabolism Discussion Group, Cambridge, MA, April, 2001.
375. Kansas City Discussion Group of the American Association of Pharmaceutical Scientists, Kansas City, MO, April, 2001.
376. Pharmacopeia, Inc., Monmouth Junction, NJ, May, 2001.
377. Ricerca, Painesville, OH, May, 2001.

378. Roche Bioscience, Inc., Palo Alto, CA, May, 2001.
379. Transform Pharmaceuticals, Inc., Boston, MA, June, 2001.
380. ArQule Pharmaceuticals, Inc., Boston, MA, June, 2001.
381. University of Southern California, Los Angeles, CA, August, 2001.
382. Inhale Therapeutics, Inc., San Carlos, CA, October, 2001.
383. Aventis, Inc., Bridgewater, NJ, October, 2001.
384. Sepracor, Inc., Marlboro, MA, October, 2001.
385. Serono, Inc., Boston, MA, October, 2001.
386. MetaPhore Pharmaceuticals, Inc., St. Louis, MO, November, 2001.
387. Indianapolis/Cincinnati Discussion Group, Indianapolis, IN, November, 2001.
388. University of Manchester, Manchester, England, December, 2001.
389. Roche Biosciences, Palo Alto, CA, December, 2001.
390. Versicor, Fremont, CA, December, 2001.
391. Lexicon Pharmaceuticals, Princeton, NJ, January, 2002.
392. Department of Pharmacology & Toxicology, The University of Kansas Medical Center, Kansas City, KS, February, 2002.
393. Saarland University, Saarland, Germany, February, 2002.
394. Immunex, Seattle, WA, March, 2002.
395. GlaxoSmithKline, Collegeville, PA, March, 2002.
396. AAPS ChicagoLand Discussion Group, May, 2002.
397. Baxter Healthcare Corporation, Round Lake, IL, May, 2002.
398. Roche Bioscience, Palo Alto, CA, May, 2002.
399. Arradial, Inc., Bedford, MA, July, 2002.
400. Alkermes, Inc., Cambridge, MA, July, 2002.
401. Peking University, Beijing, China, July, 2002.
402. Boehringer-Ingelheim, Montreal, Canada, September, 2002.
403. Enzon, Inc., Bridgewater, NJ, September, 2002.
404. Abbott Laboratories, Chicago, IL, October, 2002.
405. Infinity Pharmaceuticals, Cambridge, MA, October, 2002.
406. 3D Pharmaceuticals, Exton, PA, November, 2002.
407. Royal Danish School of Pharmacy, December, 2002.
408. Abbott Laboratories, Ludwingshafen, Germany, December, 2002.
409. University of Vienna, Vienna, Austria, December, 2002.
410. Aventis, Frankfurt, Germany, December, 2002.

411. American Chemical Society Northeastern Section Symposium, December, 2002.
412. Achillion Pharmaceuticals, New Haven, CT, December, 2002.
413. Sunesis Pharmaceuticals, Inc., South San Francisco, CA, January, 2003.
414. University of Pittsburgh, Pittsburgh, PA, February, 2003.
415. Rib-X Pharmaceuticals, New Haven, CT, February, 2003.
416. Serono, Rockland, MA, February, 2003.
417. Synaptic Pharmaceuticals, Paramus, NJ, February, 2003.
418. Enzon, Inc., Bridgewater, NJ, February, 2003.
419. AstraZeneca, Waltham, MA, March, 2003.
420. Bay Area ADME Discussion Group, South San Francisco, CA, May, 2003.
421. Purdue Pharma, Cranbury, NJ, July, 2003.
422. Rib-X Pharmaceuticals, New Haven, CT, July, 2003.
423. Abbott Laboratories, North Chicago, IL, September, 2003.
424. North Carolina Drug Metabolism Discussion Group, Chapel Hill, NC, September, 2003.
425. 3-D Pharmaceuticals, Exton, PA, October, 2003.
426. Rib-X Pharmaceuticals, New Haven, CT, October, 2003.
427. Lundbeck Pharmaceuticals, Copenhagen, Denmark, November, 2003.
428. Aventis Pharmaceuticals, Frankfurt, Germany, November, 2003.
429. Serono, Rockland, MA, December, 2003.
430. Synaptic Pharmaceuticals, Paramus, NJ, December, 2003.
431. Neurocrine Biosciences Inc., San Diego, CA, December, 2003.
432. Pfizer, Ann Arbor, MI, December, 2003.
433. Florida International University, Miami, FL, February, 2004.
434. Merck Research Laboratories, West Point, PA, February, 2004.
435. Aventis Pharmaceuticals, Paris, France, March, 2004.
436. Lilly Development Center, Mont-Saint-Guibert, Belgium, April, 2004.
437. University of New York-Buffalo, Buffalo, NY, April, 2004.
438. Pharmacopeia, Cranbury, NJ, April, 2004.